 
Document Type:  Study Protocol 
Official Title:  Sorafenib Long Term Extension Program (STEP)  
Study ID: [REMOVED] 
Document D ate: 26 MAY 2020 
 
 
Integrated Clinical Study Protocol A mendment 8
BAY 43-9006 / 12311
26 MAY2020 Version 7.0 Page: 1of 147
Cover page of the integrated protocola
Study title: Sorafenib Long Term Extension Program (STEP)
This protocol version is an integration of the following documents / sections:
Original protocol, 
Version 1.0, dated 05 JUL  2007
Amendment 02 (global amendm ent described in Section 10.2)
forming integrated p rotocol Version 3.0, dated 16 MAR 2011
Amendment 
03 (global amendment described in Section 10.3)
forming integrated protoco l Version 
4.0, dated 30 M AR 2012
Amendment 04 (global amendment described in Section 10.4)
forming integrated protocol Version 
5.0, dated 25 MAR 2014
Amendment 07 (global amendment described in Section 10.5)
forming integr a
ted protocol Version 6.0, dated 15 MAY 2018
Amendment 08 (global amendment describe din Section 10.6)
forming integrated protocol Version 7.0, dated 26 MAY 2020
This protocol has also been amended for specific countries:
Local Amendment 01, Germany, dated 07 FEB 2008
Local Amendment 
05, China ,dated 19 JAN 2016
Local Amendment 06, Taiwan, dated 25 JUL  2017
Amendments not included in the consecutive numbering of amendments are 
local amendments not forming part of this integrate d global protocol.
                                                
aCover page wasadde d by Amendment 7. See Sect ion 10.5.6 , Mo dificat ion 6.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 2of 147
Title page – amended
Title: Sorafenib Long Term Extension Program (STEP)
Test Drug: Sorafenib/Nexavar®  BAY 43-9006
Spon sor: Sponsor (Non -US): Bayer AG 
51368 Leverkusen , Germany
Sponsor (US territory): Bayer US LLC
100 Bayer Bou levard, P.O. Box 915, Whippany,
NJ 07981
-0915, USAb
Senior Clinical Development 
Leader (CDL)c:Müllerstr. 178
13353 Berlin, German y
Phone :
Study Number/Version/Date: 12311/Version 7.0/ 26 MAY 2020
EudraCT -No.: 2007-002604-17
Development Phase: 3b
The undersigned confirm that they agree to conduct the study under the conditions 
described in this protocole
Date
Date
                                                
bThe Sponsor’s address w as updated by Amendment 7. See Section 10.5.1 , Modification 1.
cThe Sponsor’s Medical Expert’s role name was updated b y Amendment 8. See Section 10.6.1 , Modific ation 1.
dThe Senior Clinical Development Leader’s address was updated by Amendment 8. See Sect ion 10.6.1 , 
Modification 1.
e:  Changes were made to the Study Manager, Statistician, an d Medical Expert under Amendment 3.  See Section
10.3,Modification 6.
fThe Study Manager changed and w as modified by Amendment 7 and 8. See Sectio n 10.5.1 , Modif ication 1 and 
Section 10.6.1 , Modification 1.
gTheStatistician changed and was modified by Amendment 7. See Section 10.5.1 , Modification 1.
PPD
PPD
PPD
PPD
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 3of 147
Date
i j
Confidentiality 
statement:The following confidential information is the property of Bayer.  As long as the information contained in 
this protocol has not been published, it may o nly be used when permission has been obtained from Bayer.  
It is not possible to make reproductions of all or sections of this protocol.  Commercial use of the 
information is only possible with the permission of the proprietor and is subject to a license f ee.
Additional Signatures
Name:kSignature: __________________
Function: Principal Investigator Date:
Address :
This document is electronically  signed. The eSignature is archived in the Trial Master File 
(TMF) and can be provided upon reques t.l
                                                
hThe signatu re of the Medical Expert w as modifi ed by Ame ndment 8. See Section 10.6.1 , Modification 1.
iTheGloba l Clinical Lead changed and was modified by Amendment 7. See Section 10.5.1 , Modification 1. The 
signature of the Global Clinical Lea dwas rem oved by Amendment 8. See Section 10.6.1 , Modificat ion 1.
jChange of responsibility for the Study Manager and Medical Expert and a line was added f or the signature of the 
Global Clinic al Lead under Amendment 4.  See Sect ion 10.4, Modi fication 1.
kThe Principal Investigator’s name and address changed by Amendment 7. See Section 10.5.1 , Modific ation 1.
lNew  eSignature text added with Amendment 8. See Section 10.6.2 , Modification 2.
PPD
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 4of 147
Table of Conte nts
Cover page of the integrated protocol ............................................................................................. 1
Title page –amended ...................................................................................................................... 2
Table of Contents ............................................................................................................................ 4
Glossary  and Abb r
eviations ............................................................................................................ 7
1. Introduction ............................................................................................................................. 8
2. Study  objectives -amended ..................................................................................................... 8
3. Investigator(s) and other study  participants ............................................................................ 9
4. Investigational plan ................................................................................................................. 9
4.1 Study  Design and Plan -
amended .................................................................................... 9
4.2 Selection of Study  Population ........................................................................................ 12
4.2.1 Inclusion Criteria
............................................................................................... 13
4.2.2 Exclusion Criteria .............................................................................................. 14
4.3 Removal of Subjects from Study .................................................................................... 15
4.4 Premature Termination of Study
/Closure of Centre ....................................................... 16
4.5 Treatments ...................................................................................................................... 17
4.5.1 Treatments to be Administered ......................................................................... 17
4.5.2 Dose Modification ................................ ................................ ............................. 18
4.5.2.1 Sorafenib monotherapy ..................................................................................... 18
4.5.2.2
Sorafenib and capecitabine combination........................................................... 22
4.5.2.3 Sorafenib and TACE co m
bination .................................................................... 22
4.5.3 Identity  of Investigational Product ................................ ................................ ....23
4.5.3.1 Sorafenib ........................................................................................................... 23
4.5.4 Method of Assigning Subjects to Treatment Groups ........................................ 25
4.5.5 Selection of Doses in the Study ................................ ................................ ......... 25
4.5.6 Selection and Timing of Dose for Each Subject -amended .............................. 25
4.5.7 Blinding............................................................................................................. 25
4.5.8 Prior and Concomitant Therap y
........................................................................ 25
4.5.9 Treatment Compliance ...................................................................................... 27
4.6 Study  Variables ............................................................................................................... 27
4.6.1 Efficacy  Variables 
-amended ........................................................................... 27
4.6.2 Safety  Variables ................................................................................................ 27
4.6.3 Assessment Periods - amended ................................ ................................ ......... 29
4.7 Data Qualit y.................................................................................................................... 31
4.8 Documentation ................................................................................................................ 31
4.9 End of Study ................................................................................................................... 32
5. Ethical and legal aspects ........................................................................................................ 32
5.1
Ethics Committee (EC) or Institutional Review Board (IRB)........................................ 32
5.2 Ethical Conduct of the Study .......................................................................................... 33
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 5of 147
5.3 Subject I nformation and Consent ................................ ................................ ................... 34
5.4 Insuranc e......................................................................................................................... 34
5.5 Confidentiality ................................................................................................................ 34
6. Statistical methods and determination of sample size ........................................................... 35
6.1 Statistical and Analy tical Plans
-amended ...................................................................... 35
6.2
Determination of Sample Size ........................................................................................ 35
7. Adverse events ...................................................................................................................... 35
7.1 Warnings/Precautions ..................................................................................................... 35
7.2 Adverse Event Monit oring ............................................................................................. 35
7.3 Adverse Event Definitio ns.............................................................................................. 36
7.3.1 Adverse Event ................................................................................................... 36
7.3.2 Serious Adverse Event ...................................................................................... 37
7.3.3 Unexpected Adverse Event ............................................................................... 38
7.3.4 Relationship of Adverse Event to I nvesti
gational Product ............................... 39
7.3.5 Severity  of the Serious Adverse Event.............................................................. 40
7.3.6
Adverse Event Documentation.......................................................................... 41
7.4 Reporting of Serious Adverse Events/Pregnancy ................................ ........................... 41
8. Use of data and publication ................................................................................................... 42
9. References ............................................................................................................................. 43
10. Protocol amendments ............................................................................................................ 43
10.1 Amendment 1 .................................................................................................................. 44
10.1.1 Overview of Change s
........................................................................................ 44
10.1.2 Changes to the Protocol Text ............................................................................ 45
10.2 Amendment 2 .................................................................................................................. 48
10.2.1 Overview of Changes ........................................................................................ 48
10.2.2
Changes to the Protocol Text ............................................................................ 48
10.3 Amendment 3 .................................................................................................................. 50
10.3.1 Overview of Changes ........................................................................................ 50
10.3.2 Changes to the Protocol Text ............................................................................ 53
10.4 Amendment 4 ................................................................................................................ 102
10.4.1
Overview of Changes ...................................................................................... 102
10.4.2 Changes to the Protocol Text .......................................................................... 105
10.5 Amendment 7 ................................................................................................................ 139
10.5.1 Modification 1: Cha nge of responsibility
 for Sponsor’s Medical Expert, Study  
Manager, Statistician, Global Clinical L ead and Principal I nvestigator .............................. 139
10.5.2 Modification 2: Overall survival (OS) evaluation removed from the study  
objectives 139
10.5.3 Modification 3: Safety  visits........................................................................... 139
10.5.4 Modification 4: L aboratory  evaluations .......................................................... 140
10.5.5
Modification 5: Follow- up period changed ..................................................... 140
10.5.6 Modificati on 6: Editorial changes, corrections an d
clarifications................... 141
10.6 Amendment 8 ................................................................................................................ 141
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 6of 147
10.6.1 Modification 1: Change of responsibility  for Sponsor’s Medical Expert, Study  
Manager, Statistician, Medical Expert, and Global Clinical L ead...................................... 141
10.6.2
Modification 2: Added new eSignature text.................................................... 141
10.6.3
Modification 3: A dded Post -Trial Access Program ........................................ 142
10.6.4
Modification 4: Removal of the instructions for dose modifications for the 
combination of sorafenib with capecitabine and TACE
...................................................... 142
10.6.5
Modification 5: Added clar ification for continuation on study  drug .............. 142
10.6.6 Modification 6: Added clarification for ending the study ............................... 143
10.6.7 Modification 7: Added clarification on last patient last visit date .................. 143
10.6.8 Modification 8: Removed reference to Study  Sites in Japan .......................... 143
10.6.9 Modification 9: Corrected timepoint ............................................................... 144
10.6.10 Modification 9 : Editorial changes, corrections and clarifications ................... 144
11. Appendices .......................................................................................................................... 145
11.1 Study  Flow Chart
.......................................................................................................... 145
11.2 New York Heart Association Criteria ........................................................................... 146
11.3 ECOG Performance Status ........................................................................................... 147
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 7of 147
Glossary and Abbr eviations
AE Adverse Event
ADR Adverse Drug Re action
ALT Alanine aminotransferase
AST Aspartate aminotransferase
Bid Bis in die (Latin), Tw ice a day
CRF Case Report Form either paper or electronic
EC Ethical Committee
ECOG Eastern Cooperative Oncology  Group
eg For Example
FU Follow -up
IB Investigator’s Brochure
GCP Good Clinical Practice
Gr Grade
HCT Hematocrit
Hgb Hemoglobin
ICH International Confere nce on Harmonisation
ie That is
IRB Institutional Review Board
MI My ocardial Infarction
NCI National Cancer Institute
NCI-CTC National Canc er Institute – C ommon T erminology Criteria Version 3.0
NCI-
CTCAENational Cancer Institute –Common Terminology Criteria Adverse 
Event
NYHA New York Heart Association
OS Overall survival
PI Principal Investigator
PMF Pregnancy  Monitoring Form
RBC RedBlood Cells
RK Raf Kinase
RKI Raf Kinase Inhibitor
SAE Serious Adverse Event
STEP Soraf enib Long Term Extension Program
TACE T ransarterial Chemoembolization
TMF Trial Master File
WBC White Blood Cell s
WHO World Health Organization 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 8of 147
1. Introduction
Experience ha sshown t hat in nearl y all clinical trials with sorafenib (Nexavar®) there are patients 
who are continuing to receive sorafenib after the study has met it s primary  endpoint. The options
to provide sorafenib to these patients who have a non-approved /reimbur sed tumor type are
through aclinical trial,through a Post -Trial Access Progr amor through an y other mechanism
(e.g. local access program) in accordance with local legal and compliance rules.mThe intention 
of this clinical s
tudy 12311 (STEP program )is toenable patients who ar estill bene fiting from 
treatment in a completed clin ical trial to continue to receive treatment .n  
Please refer to t hesorafenib I nvestigator Brochure and an y additional data supplied by  the 
Sponsor.
2. Study o bjectives -amended
Theprimary  purpose of the STEP program is to enable patients, currently  receivi ng sorafenib 
(Nexavar ) in a Bayer/Ony x sponsored clinical trial, to continue sorafenib treatment after their 
respective stud yhas met it s primary  endpoint and/or has reached the end as defined in the 
original 
protocol. Patients will be able to continue tr eatment until (i)the treating ph ysician feels 
the patient is no longe r benefiting from the treatment or (ii)the treatmentnbecomes
commerciall y available and rei mbursed for the respective indication as applic able in the country  
in which the patient lives and the patient ca
n obtain suitable amounts of drug for treatment 
through standard mechanisms of commercial availability (ie, there should be no interruptio n
in the patient ’s treatment schedule when switching to commercially available product)oor (iii)
the 
patient can join a Post-Trial-Access Program, an other stud y or can receive sorafenib through 
                                                
m:Added Post -Trial Access Program with Am endm ent 8. See Section 10.6.3 , Modification 3.
n:  Reference to sub jects receiving single -agent sorafenib was modified under Amendment 3 to allow inclusion of
subjects receiving sorafenib in combination with other drugs, specif ically, subjects from the SEARCH trial receiving 
sorafenib and erlotinib and subjects from the R ESILIENCE trial receiving sorafenib an d capecitabine.  See Section 
10.3, Modification 5.
o: Under Amendment 3, it was clarified that there should be no interruption in a patient’s treatment schedule when 
switching to commercial ly available product.  See Section 10.3, Mod ification 6.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 9of 147
any other mechanism (e.g. local access program) in accordance with local legal and complia nce 
rules ,with no cost to the patient with respect to sor afenib .p
An additional objective is the assessment of the safety of Nexavar or Nexavar combination 
treatment .qr
3. Investigator(s) and other study participants
Information regarding additional key  personnel involved in t he conduct of the study , including 
names and contact details of participating Investigators, monitors, clinical laboratories, technical 
departments and/or institutions, as well as inf ormation on members of additional study  
committees, will be found in the study  files of the Sponsor a nd on s ite if reque sted.
4. Investigational plan 
4.1 Study Design and Plan -amended
This is an open label clinical trial that will enable patient
s receiving sor afenib (Nexavar ) in a 
completed Bayer/On yx sponsored clinical trial to co ntinue treatment .A complete dstudy is one 
thathas passed the official stati stical and regulato ry endpoints and/or has reached its end , as 
outline d in that protocol.   
The patient sinthis open -label clinical trial will continue receiving single -agent sor afenib 
(Nexavar )sor sorafeni b and capecitabine combination if transferred from Study 12444 
(RESILIENCE)tat the same dose and schedule as in the iroriginal Clinical Trial.  
                                                
p:Added clarification for continuation onstudy drug with Amendment 8. See Section 10.6.5 , Modification 5.
q: These additional objectives wer e added in Amendment 3. See Section 10.3 Modification 1 and Modi fication 2.
r:Obje ctive modified by Amendmen t 7 to remove overall survival (OS). See Sec tion 10.5.2 , Modification 2.
s:Reference to erlotinib removed since none of the subjects that transferre d into this study were assigned to erlotinib
from stu dy 12917. See Section 10.4, Ame ndment 4, Modification 2.
t:  Reference to subjects receiving singl e agent sorafenib was modified under Amendment 3 to allow  inclusion of 
subjects receiving soraf enib in c om
binatio n with other drugs, specif ically, subjects from the SEARCH trial receiving 
sorafenib and erlotinib and subjects from the RESILIENCE trial recei ving sorafenib an d capecitabine.  See Section 
10.3, Amendment 3, M odificati on 5.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 10of 147
Patients will continue receiving sorafenib (Nexavar ; as single agent or combinati ontreatment ),t
as long as the treating physician feels the patient is continuing to benefit from tre atment or until 
sorafenib (as single agent or combination treatment ) becomes commercially available and 
reimbursed for the respective ind ication in the country  in which the patient lives or until being 
switched to an yother form of drug sup ply with no 
interr uption in the patient’ s treatment 
schedule .uThe patient may also continue treatmentvuntil he/she withdra ws consent ,is non -
compliant , is lost to follow up, or if an unacceptable toxicity  occurs.
Prior to being dispensed study  medication for this long term extensio
n clinical trial , patie nts will 
be required to complete their End of Treatment visit in their or iginating study .  Once the End of 
Treatme nt visi t in the o riginating study  is complete, patients will be required to provide informed 
consent 
for this long term extension clinical tri al.  Patients will continue with single agent 
sorafenib (Nexavar )worsorafenib and capecitabine if transferred from Stud y 12444 
(RES ILIENCE)x yat the same dose and schedule thepatient was receiving in their original 
clinical trial.   
Sorafenib (Nexavar ) will be provided as 200 mg tablets. zCapecitabine is available in many 
countries including generic sources and will be c ommercia lly supplied 150 mg and 500mg 
tabletsaafor patients receiving the sorafenib/capecitabine combination an d transferring from 
                                                
u: Added clarification forcontinuation onstudy drug with Amendment 8. See Sect ion 10.6.5 ,Modification 5.
v:  Refere nce to subjects receiving single agent sorafenib was modified under Amendment 3 to allow  inclusion of 
subjects receiving sorafenib in combin ation with other drugs, specifically, subjects fro m the SEARCH trial receiving 
sorafenib and erlotinib and subjects from the RESILIENCE trial receiving sorafenib and cap ecitabin e.  See Section 
10.3, Mo dification 5.
wReference toerlotinib removed since none of the subjects th at transferred into this study were as signed to erlotinib 
from stu dy 12917. See Section 10.4, Modification 2.
x:  Reference to subjects receiving single agent so r afenib was modified under Amendment 3 to allow  inclusion of 
subjects receiving sorafeni bin combination with other drugs, specifically, subjects from the SEARCH trial receiving
sorafenib and erlotinib and subjects from t he RESILI ENCE trial receiving soraf enib and capecitabine.  See Section 
10.3, Modification 5.
yReference t o capecitabine w as rem oved with Amendment 8. See Section 10.6.4 , Modification 4.
z Sen tence removed since none o fthe subjects that transferred into this study were assigned to erlotinib. See Section
10.4, Amendment 4, Modification 2.
aaText ch anged to clarify that capecitabine will be s upplied c ommercially and not by th esponsor under Amendment 
4.  See Section 10.4, Modification 3.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 11of 147
Study 12444 (RESILIENCE) .bbThe patient should be eval uated according to Good Medical
Practices as well as local thera peutic and diag nostic standard s. The p atients should be evaluated 
by a stud y physician for safet yat least once every 8 weeks and more frequen tly as needed. The 
protocol allows for a±7 day s window when scheduling a ny visit. Physicians can cho ose to 
contin ue to s ee the p atients every  8 weeks in a face to face visit. At least e very other visit must be
a mandatory  on site vi sit for examination and drug dispensing ,with the other visit being either in 
person or as a phone call. I t is at the discretion of the i nvestig ator bas ed on the patient ’scurrent 
condition and adverse event profile to determine if the next visit will be p
erformed on site or as a
phone visit . Any  scheduled phone visit is mandatory andit will be at t he discretion of the 
investigator to deci deif thatphone vi sit is sufficient. I f the patient needs a phy sical examination, 
the visit will be perform
ed on site. If the i nvestigator fe els the patient is stable with no new safety  
concerns nor new AEs in betw een visits, a phone call with labs, ECOG a nd rev iew of A Es w ould 
be enoughcc.Once every  8 weeksccsafety evaluatio ns include vital sign s
(ie,heart rate, blood 
pressure, temperature) only when the visit is on s ite, Eastern Cooperative Oncology Group 
(
ECOG ) performan ce status , laboratory  evaluations may be performed by local accredited lab
which need to have PI signoff within a week of drawingdd(hematology , ALT, AST, lipase and 
amylase, PT -INR as applicable for a nticoagulated patients) and
a review of a ny new or ongoi ng 
adverse event or concomitant medication sas well as study  medication taken during the visit 
interval .  All adverse event s,l aboratory  data , ECOG performance status and survival status 
(dead or aliv e and date of death or date of last conta
ct),eeas well a s End of Treatment 
information and study  medication taken must be clearl y and accuratel y recorded in the Case 
Report Form provi ded.  All other data, including but not limited to, vital signs, concomit ant 
                                                
bb:  Info rmation on the erlotinib and capecitabine formulations w as ad ded under Amendment 3. See Section 10.3, 
Modification 5. Reference to capecitabine w as rem oved w ith Amendment 8. See Sec tion 10.6.4 , Modification 4.
ccSafety follow -up adjusted by Ame ndment 7 to lessen the travel burden on pati ents. See Section 10.5.3 , 
Modification 3.
ddLaboratory e valuations have been adjusted by Ame ndment 7 to ensure these are n ot missed. See Section 10.5.4 , 
Modification 4.
ee:  Survival and ECOG perform ance stat us were added to the Case Report Form as of Amendment 3. See Section 
10.3 Modificat ion 1 and Modification 2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 12of 147
medications must be recorded in the p atient’ s source documents and may  be requested at the 
discretion of the Sponsor.   
Following the End of Treatment asses sments from the origina lstudy , the following information 
will be recorded in the long term exte nsion CRF:  demograph y, date of first dose of sorafenib 
(Nex avar)in originating studyffdate of first dose of capecitabine if the patient is transferred from 
RESILIENCE ( Study  12444),ggoriginating stud y number, ECOG performance status and 
survival status ( dead or alive and date of death or date o flast contact)hhand
ongoing adverse 
events .
In the event the patient experiences a treatment related Serious Adverse E vent, based on the 
definition outlined in Section 7 of this document, this event must be reporte d to Bay er Global 
Drug Safet yimmediatel y(withi n 24 hours o f awareness) using the forms provided, and recorded 
in the CRF.
In the event that another mechanism of continued drug suppl yis established, the present study  
will end when all patients have trans itioned to an y new drug suppl
y program ordiscontinued 
from this study  for another reason (e.g. consent withdrawa l, lost to follow -up, death, sponsor 
decision). Until the transition, patients will continue to follow all the procedures and visits 
required i n the current version of the protocol.ii
4.2
Selectio n of Stu dy P opulation
Patients who remain ongoing in a Bay er/Ony x sponsored Clinical Trial that has reached its 
statistical, regulatory and/or study  end and who, in the opinion of the Investigator, still bene fiting 
from treatment, will be eligible f or entr y intothis study  (STEP program ).
                                                
ffSentence removed since none of the subjects that transferred in to this study were assigned to erlotinib. Se e Section
10.4, Modification 2.
gg:  Participation of sub jects from the SEARCH trial (Study 1 2917) or from the RESILIENCE t rail (Study 2444) w as 
added un der Amendment 3 See Section 10.3, Modification 5.
hh: Th ese additional objectives were added in Amendment 3. See Section 10.3,Modification 1 and Modification 2.
iiAdded clarification for ending the study with Amendment 8. See Sec tion 10.6.6 , Mod ification 5.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 13of 147
4.2.1 Inclusion Criteria
Patients, who are participating in a previous Bay er/Ony x sponsored study  that has reached its 
endpoint (statistical and regulatory or study  end), and who a re, in the opinion of the 
Investigator, expected to cont inue to have an overall positive benefit/risk from continuing 
treatment.
Patients who have signed informed consent for this long term extension program.
Women of childbearing potential and men must a gree to use adequate contraception prior t
o 
study entr y and for the duration of study participation, including the 30 day s period after last 
study  drug dosing. The investigator should advise the patient how to achieve an adequate 
contraception .
Women of c hildbearing potential who have a n egative pregna ncy test within 7 day s of the 
first dose of sorafenib in this long term extension program.
Patient is receiving sorafenib (Ne xavar) as amonotherapy  in their originating protocol.  
Patients who were being tre
ated with sorafenib (Nexavar )in combinat ion with other 
chem otherapies in the original study , but continued on single agent sorafenib (Nexavar ) after 
discontinuation of the combinatio nagent will be eligible.
Patients who are receiving concurrent combinati on with sorafenib (Nexavar) and TACE
(transarter ial chem oemb olization) in their originating study  will be eligible.jjkk
Patients who are receiving concurrent com bination with sorafenib (Nexavar) and 
capecitabine in their originating S tudy 12444 (RESILIENCE) will be eligible.
Patients who have com pleted the End of Treatment assessments in their originating study.  
Every  effort should be made to conduct the End of Treatment visit such th at the patient does 
not have an y interruption of sorafenib dosing.
                                                
jj:  The inclusion cri terion regarding eligibility of subjects receiving combination sorafenib and TACE in th eir 
originating studies was ad ded under Amendment 2.  See Section 10.2.
kkReference to erlotinib removed s ince none of the subjects that tra nsferred into this study were assigned to erlotinib
from study 12917. See Section 10.4, Modification 2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 14of 147
4.2.2 Exclus ion Criteria
Any condition that is unstab le or that coul d jeopardize the safet y of the patient (please refer to 
the Investigator Brochure and product labeling s afety  sections) .
Histor y
of cardiac disease:  congestive heart failure>NYHA Class 2 ( Appendix 11.2) or 
uncon trolled hyperte nsion 
Myocardial infarction (MI) within the last 3 months
Symptomatic metastatic brain or meningeal tum ors 
Previous or concur rent cancer that is distinct in primary  site or histology  from the cancer
being evaluated in this study  EXCEPT cer vical c arcinoma in situ, treated basal cell 
carcinoma, superficial bladder tumors (Ta, Tis & T1) or an y cancer curative ly treated > 5 
years pr ior to study  entry.
Patients with seizure disorder requiring medication (
such as steroid  anti- epileptics)
Substanc e abus e, medic al, psychological or social conditions that may  interfere with the 
patient’s participation in the study  or evaluation of the st udy results
Any condition which could jeopardise the safet y of the patien
t and his/her compliance in the 
study
Excluded t herapies andmedications, previous and concomitant:
Concurrent anti -cancer chemotherap y, except TACE (transarter ial chemoembolization)llmm nn
and capecitabine
                                                
ll:  The exclusion criterion r egarding concurrent anti -cancer chemotherapy wasmodified under Amendment 2.  See 
Section 10.2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 15of 147
Concurrent immunotherapy  (including monoclonal antibodies) , during or within 30 day s prior 
to star t of study  drugoo
Concurrent h
ormonal therap y, except for bisph osphonates, during or with in 30 days prior to 
start of study  drugoo
Concomitant Rifampicin and St John’s Wort (Warfarin may be used only with very close 
monitoring.)
Radiotherap y during study or within 3 weeks of start of stud y drug.  [Palliative radiotherap y 
will be allowed as descr ibed in the Prior and Concomitant Therap y Section 4.5.8.]
Concomitan tuse o f potent inhibitors of CYP 3A4 including ketoconazole, itraconazole and 
ritonavir.  Consumption of grapefruit ju ice should also be avoided.
4.3 Removal of Subjects from Study
Subjects may  be withdrawn from the st udy for the following reasons:
At their o
wn requ est or a t the request of their legally  acceptable representative.
If, in the Investigator's opinion, continuatio n in the study  would be detrimental to the subject's 
well-being.
At the specific request of the Sponsor.
The patient dies.
                                                                                                                                                             
mmReference to erlotinib removed since n one of the subjects that trans ferred into this study were assigned to 
erlotinib from study 12917. See Section 10.4 , Modifica tion 2.
nn: Participation of subjects from the SEAR CH trial (Study 12917) or from the R ESILIENCE trial (Study 12444) 
was added under Amendment 3.   In Amendment 4, reference to er lotinib is removed, as no subjects was enrol led into 
this study from study 129 17 taking the combination of erlotinib and sorafeni b. Therefore, capecitabine isnot an
excluded therapy . See Sectio n 10.3, Modification 5.
oo:  The exclusion criterion regarding concurrent an ti- cancer chem otherapy was modified under Amendment 2.  See 
Section 10.2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 16of 147
Also subjects m ust di scontinue tr eatment for the following reasons: 
Substantial non- compliance. 
Patients with clinical signs or lab oratory  tests results c onsistent with pregnancy . Pregnancy  
will be reported b y the Investigator on a Pregnancy  Monitoring Form (PMF) foll owing t he 
same timelines as a Serious Adverse Event.
The patient uses illicit drugs or other substances that may , in th e opinion of the Invest
igator, 
have a reasonable chance of contributing to toxicity or otherwise interfering with results. 
Occurrence of unacce ptable t oxicity.
When Nexavar is commercially  available and reimbursed for the respective indication in the 
coun try in which the patien tlives .
The patient is lost to follow -
up. 
In all cases, the reasons for withdrawal must be recorded in the case report form and patient’s 
medical record.  All patients who discontinue due to adverse events or clinical laboratory  
abnormalities should be followed up until they  recover or stabilize, and the subsequent outcome 
recorded.
If any patient should die during the tr ial or w ithi
n 30 day s of the patient’s last dose of sorafeni b 
(Nexavar ), the Investigator should inform Bay er by completing the SAE Com plimentary  Form 
and Adverse Event page for the study .
The cause 
and date of death should also be record ed on the E nd of T reatment page, as applicable.
4.4 Premature Termination of Study/Closure of Centre
The Sponsor has the right to clos e this study , and the I nvestigator/Sponsor has the right to close a 
center , at any  time, althoug h this should occur only  after consultati on betw een invo lved parties.  
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 17of 147
The EC/I RB ppmust be informed.  Should the study/center be closed prematurely , all study  
materials (except docum entation that has to remain stored at site) must be returned to the 
Sponsor.  The Investigator will retain all oth er docu ments unt il notification given b y the Sponsor 
for destruction.
4.5 Treatments
4.5.1 Treatments to be Administered
Sorafeni bwill be supplied as 20 0mg tablets.qqrrPatients should continue on the same dose as 
they were receiving in the patient’s originating Bayer/Ony x
-sponsor ed Clinical Trial. 
The patients’ dose may  not be increased bey ond the dose they  were receiving upon en try into this 
program.
If the patient is receiving a reduced dose upon study  entry  into STEP due to an adverse event 
(AE), it is possible to re-escalate thisdose after AE resolution. Any way the maximum dose 
allowed in the STEP trial is the one the patient had received before AE induced dose reduction in 
the originating stud y.
Upon completion of the End of Treatment evaluations in the origi nating study  and registration in 
this program, the patient should be dispensed a new bottle of medication specific for this long 
term 
extensio nprogram .  Patients should be dispensed enough medication to last until their next 
scheduled visit.
                                                
pp:  As of Amendmen t3, additional text was added to include the head of the center for sites in Japan. See Se ction 
10.3 Modi fication 3.Reference to center fo rsites in Japan was removed with Amendment 8. See Section 10.6.8 , 
Modification 8.
qq:  In formation on the erlotinib and capecitabine formulations w as added under Amendment 3. See Section 10.3, 
Modifi cation 5.
rrReference to erlotinib removed since no ne of the subjects that transferred into this study were assigned to erlotinib 
and sorafenib in study 12917 and references to t he supply of capecitabine were removed since this dru g will not be 
supplied by the sponsor. See Section 10.4, Modificati ons 2 and 3.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 18of 147
Every  effort s hould be made t o collect all unused medication and empty bottles on the last visit in 
their original protocol as well at every  visit that med ication is dispensed in this long term 
extension program .
4.5.2 Dose Modificationss
4.5.2.1 Sorafenib monotherapy
If the starting dose i s 600 mg bid the modifications of sorafenib (Nexavar ) will follow the pre -
defined dose levels:
Dose level 1 600 mg (3 x 200 mg) po q 12 hr
Dose level 
-1 400 mg (2 x 200 mg) po q 12 hr
Dose level -2 400 mg (2 x 200 mg) po q 24 hr
Dose level 
-3 400 m g (2 x 200 mg ) po q 48 hr
If the starting dose is 400 mg bid the modi fications of sorafenib (Nexavar ) will follo w the pre -
defined dose l evels:
Dose level  1 400 mg (2 x 200 mg) po q 12 hr
Dose level -1 400 mg (2 x200 mg) po q 24 hr 
Dose level -
2 400 mg (2 x 200 mg) po q 48 hr
If a dose reduction b y more than two dose levels in relation to the current perta ining standard 
dose lev
el is required, the patient should be discontinued from the study  treatme nt. Also, at the 
discretion of the investi gator, the dose may be re -escalated to a higher dose level up to the present 
standard dose level after the resolution of the adverse event. R esolution of an adverse event is 
                                                
ss:  With the incl usion of subjects from the SEARCH study and The RESILIENCE st udy, this section was modified 
under Amendme nt 3 to i nclude information on sor afenib monotherapy, sorafenib/erlotinib combination therapy, and 
sorafenib/capecitabine combination therapy as separa te sub -sections.  See Section 10.3, Modification 5.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 19of 147
defined as the disappearance or the decr ease of the AE to a lo wer toxicity  grade, at lea st ≤ Grade 
2. 
Table 4–1 illustrates dose modifications and de lays for hematologic toxicities.
Table 4
–1:  Hematologic Criteria for Dose Delay and Dose Mod ification of Bay 43 -9006
Grade Dose Delay Dose Modification
Grade 0 -2 Treat on time No Change
Grade 3 Treat on time DECRE ASE one dose level b
Grade 4 DELAY auntil Grade 2 DECREASE one dose level b
aIf no recover y after 30 day delay, treatment will be di scontin ued unless patient is deriving 
clinical benefit
bIf more than 2 dose reductions are required, treatment will be d iscontinued
Table 4–2 summarizes the recommendations for dose delay s and modifications f or all non-
hematologic adverse events, except for skin toxicities, which will be detailed separatel y (Table 4–
3and Table 
4–4).
Table 4
–2:  Non -hematologic Criteria for Dose Delay and Dose Modification of Bay 43-9006 
(except skin toxicity)a
Grade Dose Delay Dose Modification
Grade 0 -2 Treat on time No Change
Grade 3 DELAYbuntil Grade 2 DECREASE one dos e levelc
Grade 4 OFF protoco l therapy OFF protocol therapy
aAlso excludes nausea/vomiting that has not been premedicated, and diarrhea
bIf no recover y after 30 day delay, treatment will be discontinued unless patient is deriving 
clinical benefit
cIf more than 2 dose reducti ons a re requ ired, treatment will be discontinued
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 20of 147
Only  for the purpose of dose modifications, patients experiencing Hand -Foot Skin Reactionstt
should have their signs and sy mptoms graded according to the following sy stem (see Table 4–3). 
Other skin toxicities will be graded according to CTCAE Version 3.0. Please note that Hand -
Foot Ski
n Reaction will be graded and recorded as an adverse event according to NCI-CTC
Version 3.0 in the CRF.
Table 4–3:  Grading for Hand -Foot Skin Reaction 
Grade 1 Numbness, dy sesthesia/paresthesia, tingling, pa inless swelling or er ythem a 
of the hands and/or feet and/or discomfort, which does not disrupt normal 
activities.
Grade 2 Painful e rythema and swelling of the hands and/or feet and/or discomfort 
affecting the patient’s activities. 
Grade 3 Moist desquamation, ulceration, blistering or severe pain of the hands and/or 
feet and/or severe discomfort that causes the patient to be unable to wo rk or 
perform activities of daily living.
According to the grade and incidence of skin toxicity  (including rash and h and-foot s yndrome) 
for a given patient, the following dose modification schedule will be followed (see Table 4–4).
                                                
tt:  Hand -Foot Syndrome w as change d to Hand -Foot Skin React ion under Amendment 3.  See Section 10.3, 
Modification 6.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 21of 147
Table 4–4:  Skin Toxicity Criteria for Dose Delay and Dose Modification of Sorafenib
Toxicity Grade During a Course of 
TherapyDose for Next Cycle
Grade 1 Maintain dose level Maintain d ose lev el
Grade 2 1st appearance Interrupt until resolved to 
grade 0 -1Maintain dose level
2nd appearance Interrupt until resolved to 
grade 0 -1Decrease by one dose level
3rd appearance Interrupt until resolved to 
grade 0 -1Decrease by two dose l evels
4th appearance Discontinue treatment permanently
Grade 3 1st appearance Interrupt until resolved to 
grade 0 -1Decre ase by one dose levela
2nd appearance Interrupt until resolved to 
grade 0 -1Decrease by two dose levels
3rd appearance Discontin ue treatment permanently
aFor patients who require a dose reduction for grade 3 rash or hand -foot syndrome, the dose of 
study drug may be increased to the starting dose after one full cycle of therapy has been 
administered at the reduced dose without the a ppear ance of rash or hand foot s yndrome 
grade 1.
Patients with discomfort due to hand foot s yndrome may be treated with topical emollients, low 
potency  topical steroids, or urea -containing cream. 
For patients who require a dose reduction for Grade 3 r ash o rhand -foot s yndrome, the dose of 
study  drug may  be increased to the starting dose after one full cy cle of therapy  has been 
administered with the reduced dose, without the appearance of rash or hand foot sy ndrome 
Grade 1 . uu, vv, ww, xx, yy, zz, aaa, bbb, ccc, ddd, eee,fff, ggg, hhh, iii, jjj, kkk, lll, mmm, nnn
                                                
uuReference to erlotinib remov ed since none of the subjects that transferred into this stud y were assigned to erlotinib 
from study 1291 7. See Se ction 10.4, Modification 2..
vvThe w ord placebo w as removed to clar ify that subjects receiving so rafenib in Study 12444 did not receive placebo 
under Amendmen t 4.  See Section 10.4, Modificat ion 4.
wwThe w ord placebo w as removed to clarify th at subjects receiving sorafenib in S tudy 12444 did not receive 
placebo under Amendment 4.  See Section 10.4, Modification 4.
xxRem oved entire Section 4.5.2.2 So rafenib and capecitabine combination with Amendment 8. See Section 10.6.4 , 
Modification 3 .
yyThe w ord placebo w as removed to clarify that subjects receiving sorafenib in Study 12444 did not receive place bo
under Amendment 4.  Se e Section 10.4, Modification 4.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 22of 147
4.5.2.2 Sorafenib and capecitabine combination
This section extensively  described the specific dose modifications for the sorafenib capecitabine 
combination therap y and is not applicable an ymore because all patients treated with th is 
combinati on are off the study . The entire section and subsections wereremoved with Amendment 
8 to avoid confusion for th e remaining patients none of who m are receiving sorafenib and 
capecitabine .ooo
4.5.2.3 Sorafenib and TACE combination
This section described the specific dose modifications for t he sorafenib TACE combination 
therap y and is not applicable an ymore because all patients treated with this combination are off 
                                                                                                                                                             
zzRemoved entire Section 4.5.2.2.1 Dose reduction levels with Amendment 8. See Section 10.6.4 , Modification 4.
aaaRemo ved entire Section 4.5.2.2.2 Dose modification for hematologic toxicities with Amendm ent 8. See Section 
10.6.4 , Modificatio n4.
bbbThe w ord placebo w as removed to clarify that subjects receiving sorafenib in Study 12444 did not r eceive 
placebo under Amendment 4. See Section 10.4, Modification 4.
cccRemov ed entire Section 4.5.2.2.3 Do se modification for non -hematologic toxicities with Amendment 8. See 
Section 10.6.4 , Modification 4.
dddThe w ordplacebo w as removed to clarify that subjects recei ving sorafenib in Study 12444 did no treceive 
placebo under Amendm ent 4.  See Section 10.4, Modification 4.
eeeThe word placebo wasremoved to clarify that subje cts receiving sorafenib in Study 12444 did not rece ive 
placebo under Amendment 4.  See Section 10.4, Modification 4.
fffThe w ord place bo w as removed to clarify that subjects rece iving sor afenib in Study 12444 did not receive placebo
under Amendment 4.  See Sectio n 10.4, Modification 4.
gggRemoved entire Section 4.5.2.2.4 Dose modification and m anagement of sorafenib specific toxicities w ith 
Amend ment 8. See Section 10.6.4 , Modification 4.
hhhRemoved entire Section 4.5.2.2.5 Dose modification and management of capecitabine specific toxicities with 
Amendment 8. See Secti on 10.6.4 , Modif ication4.
iiiRemoved entire Sectio n4.5.2.2.6 Dose modification for other non -hematol ogic toxicities (excluding fatigue, 
dermatologic toxicities, gastr ointestinal toxicities, hypertension and toxicities attributable to capecitabine) w ith 
Amendment 8. See S ection 10.6.4 , Modification 4.
jjjRemoved entire Section 4.5.2.3 Sorafenib and TACE combinatio nwith Amendment 8. See Sectio n 10.6.4 , 
Modification 4.
kkkAdded the CTC version used to grade liver functio n abnorma lities. See Section 10.4, Modif ication 6.
lllAdded the CTC version u sed to grade liver function ab normalities. See Section 10.4, Modification 6.
mmm Addition of a new section to present the guid ance on Sorafenib dose modification in combination with TACE.  
See Section 10.4, Modification 5 .
nnnThe w ord placebo w as removed to cl arify that subjects receiving sorafenib in S tudy 12444 did not receive 
placebo under Amendment 4.  See Section 10.4, Mod ification 4.
oooAdded explainin g text as to why sorafenib capecitabine combination therapy s ections were removed with 
Amendment 8. See S ection 10.6.4 , Modification 4.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 23of 147
the study . The entire section wasremoved with Amendment 8 to avoid confusion for the 
remaining patients none of whom are receiving sorafenib and TACE.ppp
4.5.3 Identity of Investigational Productqqq
4.5.3.1 Sorafenib
BAY 43-9006 w illbe packed b y the Sponsor and will be labeled according to the requirements of 
local law and legislation.  L abel text will be approved according to agreed procedures, and the 
master labels w ill be available in the study  file(s).
Label text will be approvedaccording to agreed Bay er procedures, and a copy  of the labels will 
be made available to the study  site upon request.
Sorafenib (Nexavar )table ts are red in colo
r and are manufactured b y Bayer.  The 200 mg tablets 
are packed in bottles contain ing 1 40 tabl etsor in blister packs depending on the climate zone of 
the respective country . 
The active compound of BAY 43 -9006 is 4
-{4-[3-(4-chloro-3- trifluoromethy l-phen yl) -ureid ]-
phenox y}-pyridine -2-carboxy lic acid methy lamide -4-methy lbenzenesulfo -nat e, an dits m olecular 
weight is 637 Daltons.
The drug is poorl y soluble in aqueous media.  The tablets need not be protected from light.  The 
formulation is presented as an i mmediate release dosage form, ie,the active ingredient is 
completely  dissolved und er in-vitrotest conditions within a short period of time.
                                                
pppAdded explaining text as to why sorafenib TACEcombination therapy section wasremoved w ith Amendment 8. 
See Secti on 10.6.4 , Modification 4.
qqq:  With the inclusion of subjects from the SEARCH study and t he RESILIENCE study, this section was modified 
un
der Amendment 3 to include information on sorafenib, erlotinib, an d capecitabine as separa te sub-sections.  See 
Section 10.3, Modification 5.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 24of 147
Supply , packaging, labe ling and storage
BAY 43 -9006 tablets will be packed in bottles containing 140 tablets per bottle in countries with 
clima te zones I /II. In case of blister packaging 10 tablet s are packedper blister. Fourteen blister 
strips are packed in one card box, which thus contains 140 tablets in total. rrr
Participating countries and center s will be provided with the study  medication a ccording to the 
number of 
potential patients from othe r Bay er/Onyxsponsored studies and receipt of the 
registration form b y Bayer .  Once the drug has been received, the drug should be kept in a dry , 
safe place , at controlled room temperature of < 25°C.
The study  drug must exclusively  be used for the patients specified in this protocol and it wil l only  
be accessible to authoriz ed staff.  
Only  the Investigator or a person assigned b y him/her will be allowed to s upply  and administer 
the drug to the patient. The dispensing and return of sorafenib (Nexavar ) to apatient will be 
recorded on a Drug Accountability  Form maintained either in the Pharmacy or in the patient’s 
files.  In addition, dosing information should be captured on the appropriate page(s) in the CRF.
sss
Capecitabine is commercially  approved for breast cancer and readil y available in many  countries 
including generic sources. Subjects on treatment with both capecitabine and sorafenib at the end 
of the 12444 RESILIENCE trial who are switched to the STEP study  will switch to commercial 
supply  capecitabine. In addi tion, subjects will continue to receive sorafenib as clinical supply .ttt
                                                
rrrReference to study sites in Japan removed with Amendment 8. See Section 10.6.8 , Modification 8.
sssReferenc e to erlotinib rem oved since at the time of Amendment 4 none of th e subjects that transfer red into this 
study were assig ned to erlotinib and sorafenib in study 12917. See Section 10.4, Modification 2. At a later time, a 
patient in Taiwan, who was taking sorafenib in combinatio n with erlotinib w as tra nsfer red from SEARCH into the 
STEP trial. This w as explained in local Amendment 6 , on 25 JUL 2017.
tttText changed to clarify that capecitabine will be supplied commercially and not by  the sponsor under Amendment 
4.  See Section 10.4, Modifica tion 3 .
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 25of 147
4.5.4 Method of Assigning Subjects to Treatment Groups
As thestudy  is an openlabel allocation, randomiz ation is not required.
4.5.5 Selection of Doses in the Study
Patients will receive sorafe nib (Nexavar ) 200 mg tablets and should continue receiving the same 
dose they  were receiving in their original trial. Patients receiving soraf enibuuuor
sorafenib/capecitabine combination should continue the same doses as in the originating trial.
vvv
4.5.6 Selection and Timing of Dose for Each Subject -amended
The patient should continue receiving the same dose they  were receiving in the previous trial.
Dose increase bey ond the dose the patient i s currently  receiving is not acceptable.
Sorafenib (Nexavar )www
,and capecitabine may be decreased in the event of toxicity  based on the 
Dose Modification criter ia outlined in Section 4.5.2.vvv
4.5.7 Blinding
This study  is an open label st udy therefore blinding is not applicable.
4.5.8 Prior and Concomitant Therapy
Any medication which is considered necessary  for the patient’s welfare, and which is not 
expected to interfe re w iththe evaluation of the study  drug, may  be given at the discretion of the 
Investigator.  This information must be recorded in the patient’s source documents.
                                                
uuuReference to erlotinib removed since no ne of the subjects that transferred into this study were assigned to 
erlotinib from s tudy 12917. See Section 10.4, Modification 2.
vvv:  Participation of subjects from t he SEARCH trial (Study 12917) or the RESILIE NCE trial (Study 12444) w as 
added under Amendment 3.  See Sec tion 10.3, Modification 5.
www Reference to er lotinib removed since none of the subjects thattransferred i nto this st udy were assigned to 
erlotinib fr om study 12917. See Section 10.4, Modifi cation 2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 26of 147
Permissible concomitant medicatio n/therapies:
Patients t aking concomitant medications, known to be metabolized by  the liver, should be 
closely  observed for side effects .  Patients taking narrow therapeutic index medications that 
are hepaticall y metabolized (liver P450 s ystem) should be mo nitored proactively  forserum/ 
plasma levels of warfar in, pheny t oi n, quinidine, carbamazepine and phenobarbital. Treatment 
with non- conventional therapies (for example herbs or acupuncture), and vitamin/mineral 
supplements is acceptable provided that the p atient continues to be monitored by  the patient’s 
physician.  
In general, patients should be closel y monitored for side effects of all concomitant 
medications regardless of path of elimination, especially  those with narrow therapeutic 
indices, such a digo xin, warfarin, quinidine, pheny toin, phenobarbitol, carbama zepineand 
cyclosporine.
Patients may  receive palliative and supportive care for an y underl ying illness.  Patients who 
receive bisphosphonates prophy
lacticall y or for bone metastases may continue w hile on study  
drug.  
Palliative radiotherap y during t he pr ogram is permitted.  Study  drug may  be continued during 
palliative radiother apy.
Since there is a possibility  of decreased sorafenib (Nexavar )efficacy  upon chronic co -
administration of CYP3A4 indu cers with sorafenib (Nexavar), chronic co -administration of
CYP 3A4 inducers with sorafenib (Nexavar ) should be avoided to the extent po ssible.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 27of 147
Non-permissible concomitant medication/therapies:
Anticancer chemotherapy ,except TACE
,xxx yyyand capecitabine ,zzzimmunotherapy  or liveaaaa
vacc
ines during the study.
4.5.9 Treatment Compliance
An adequate rec ord o freceipt, distribution and return (or destruc tion) of all study  medication 
supplies must be kept in the form of a Drug Accountability Form provided by  the sponsor. In 
addition, information r egarding treatment with sorafenib (Nex avar) in this protoco l should be 
recorded on the appropriate page in the CRF.
4.6 Study Variables
The primary  objective is to enable patien ts receiving sorafenib (Nexavar ) in a completed 
Bayer/Onyx-sponsored Clinical Tri alto continue treatment in this extension program.  
4.6.1 Efficac
y Var iables - amended
Not applicable.bbbb cccc
4.6.2 Safety Variables
All observations pertinent to the safet y of the study medication will be recorded inthe patient’s 
source documents and be made available at the request of the sponsor.
                                                
xxx  Th is text regarding concurrent anti -cancer chemothera py was modified to add TACE under Amendmen t 4 to be 
consisten t with the exclusion criteria modified in Am endm ent 2.  See Section 10.4, Modificati on 5.
yyyReferen ce to erlotinib removed since none of the subjects that transferred into this study were assi gned to 
erlotinib f rom study 1 2917. See Section 10.4, Modification 2.
zzz: Participation of subjects fro m the SEARCH tr ial (Study 12917) or the RESILIENCE trial (Study 12 444) was 
added under Amendment 3.  Therefo re, erlotinib and c apecitabine are not excl uded therapies. See Section 10.3, 
Modificatio n5. 
aaaa:  In Amendme nt 3, the information rega rdingvaccines was clarified to refer to live vacci nes. See Section 10.3, 
Modificat ion 6.
bbbb:  Overall survival was added as an efficacy variable by Amendment 3. See Section 10.3, Modi fication 1.
ccccEfficacy variable modified by Amendment 7 to remove 
overall survival (OS). See Section 10.5.2 , Modification 2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 28of 147
The following data must be re porte din the source documents:dddd
Vital signs (heart rate, blood pressure, temperature)
Concomitant medications
In addition to the above parameters, t he following data must be recorded in the CRF pr ovide dand
the source documents:
All treatment related adve rse events (any grade)
All adverse events NCI -CTCAE Version 3.0 Grade 3 or higher (regardless of attribution) . eeee
All Serious Adverse Events, regardless of relationship to study  drug
ECOG performanc e statusj
Laboratory  parameters 
Hematology  –Hgb, HCT, pla telets , RBC,WBC, differential
Blood chemistry  –ALT, AST, amy lase, lipase
Coagulation 
–INR as applicable for patients receiving coagulation therap y
Start and stop dates of sorafenib (Nexavar ) treatmen t as well as the dose of sorafenib
(Nexavar )
Reason for ter mination of study  medicationffff
                                                
dddd :  ECOG performa nce status was moved from the list of data that must be reported in the so urce docume nts to 
data the mustbe recorded in the CRF and the source documen ts as of Amendment 3. See Section 10.3, Modification 
2.
eeee:  Language specifi c to the recording of adverse event information in Japan was added unde r Amendment 3.  See 
Section 10.3, Modification 2. Language specific to the recording of adv erse event informatio n in Japan was removed 
with Amendment 8. See Section 10.6.8 , Modification 8. 
ffff:  The bull et for Date of death was d eleted in Amendment 3. See Section 10.3, Modification 2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 29of 147
4.6.3 Assessment Perio ds- amended
Prior to a site’s participation [and receipt o f open label sorafenib (Nexavar )]in this L ong Term 
Extension Program , Ethics Committee/I B and Regulatory  approval must be received.
Only  patients particip
ating in a Bay er/Ony x clinical trial may  be included in this L ong Term 
Extension Program.
Upon receipt of the medication for the Long Term Extension Program, the patient should be 
schedu led for a final visit for their original stud y and the Case R eport Form for the original stud y 
completed.  At th e same time, medication should be dispensed f or the Long Term Extension
Program and requested data transferred from the originating CRF to the CRF for the Long Term 
Extension Program.
Observations and Measureme nts
Once enrolled in this program, patients wi ll be evaluated according to local routine practice or at 
least every  8 weeks (±7 day s) for safet y.  Every  other visit must be a mandatory  on-sitevisit for 
examination and drug dispensing with the other v isit being e ither in person or as a phone call. It is 
at the discretion of the i
nvestigator based on the patient’s current condition and adverse event 
profile to determine if the visit will be pe rformed on site or as a phone visit .Any scheduled phone 
visit is mandatory and it will be at the discretion of the investigator to decide if aphone visit is 
sufficient. I f the patient needs a phy sical examination, the visit will be performed on site. If the 
investigator feels the patient is stable with no new safe ty concerns nor new AEs in between visits 
a phone c all with labs, ECOG and review of AEs would be enoughggggAll observations pertinent 
to the safet y of the patient must be recorded in the patient’s source documents.  The following 
must be recorded in the CRF provi ded:
Assessment of Adverse Events 
                                                
ggggThevisit window  and saf ety follow -up have been modified by Amendmen t 7 to lessen the travel burden on 
patients. See Section 10.5.3 , Modifi cation 3.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 30of 147
oTreatment r elated event –all CTC grades
oAny CTC Grade 3 or 4 event (regardless of attribution)
ohhhhAny Serious Adverse Event (regardless of attribution)
Study medic ation (date dispensed and returned, number of tablets dispe nsed and returned)
Laboratory  Assessments
oHem atology (hemoglobin, hematocrit, RBC, WBC, platelets, differential)
oBlood Chemistry  (ALT, AST, amy lase, lipase)
oPT-INR (for patients receiving a nticoag ulation therap y)
Other variablesiiii
oECOG performance sta tus
oS
urvivalstatus 
End of treatment
In addition t o the above parameters, please record the following in the CRF and source 
documents:
The reason for termination 
Date of last dose 
                                                
hhhh:  Language specific to the recording of adverse event information in Japan was added under Amendment 3.  
See Section 10.3, Modification 2. Language specific to the recording of adverse event informat ion in Japan w as 
removed with Amendment 8. See Sect ion 10.6.8 , Modification 8.
iiii:  The bullet for other variables and the corres ponding sub -bullets for ECOG performance status and survival were 
added in Amen dment 3.See Section 10.3,Modification 1 a nd Modification 2.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 31of 147
Survival statu s (de ad or alive and date of death or date of last contact)jjjj
Follow-up period
All subjects will be followed until 30 days after the last dose of study drug.kkkk llll
If a patient discontinues due to an adverse event or clinical laboratory  abnormality , the pati ent 
should be followed until the event resolves , the patient stabi lized, or 30 days, whichever is 
shorter.  If a patient dies within 30 day s of the last dose of study  medication, the SAE 
complementary  form should be completed and forwarded to Bay er Global Drug Sa fety.mmmm
4.7 Data Quality
Monitoring and auditing procedures defined/agreed by  the sponsor will be followed, in order to 
comply  with GCP guidelines.  Each center will be visited by  a monitor to ensure compliance with 
the study  protocol, GCP and legal aspe cts.  T
his will include on- site checking of the specific data
recordedinthe case report forms (CRF) for comple teness and clarit y, cross -checking with source 
documents, and clarific ation of administrative matters, and review of the clinical supplies.
4.8 Docu mentati on
Entries made in the CRF must be either verifiable a gains tsource documents, or have been 
directly  ente red into the CRF, in which case the entry  in the CRF will be considered as the source 
data.  The source data parameter to be verified and the id entification of the source document must 
be documented.  The study file
and all source data should be retained u ntil notification given b y 
the sponsor for destruction.
                                                
jjjj:  This bullet for s urvival status w as ad ded in Amendment 3. See Section 10.3, Modification 1.
kkkk:  The text regarding assessment o f survival in the follow -up period w as added in Amendment 3. See Section
10.3, Modificat ion 1.
llll  This bullet for survival limiting was added in Amendmen t 7. See Section 10.5.5 Modification 5.
mmmm :  Sectio n 4.6. 4, Drug Concent ration Measurements, was deleted in Amendment 3. Se e Section 10.3, 
Modification 6.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 32of 147
4.9 End of Study
According to Directive EU 2001/20/EC the end of the trial will be notified tothe competent 
authorities of the member states concerned b ased on the following definition. For the member 
states involved, the end of trial will be reached when the last visit of the last patient for all centers 
in the territory  of this member state h
asoccu rred. This can be reached base d on t he last patient 
stopping study  medication or being switched to any  other form of study  drug suppl y
.In the event 
that any  other mechanism of drug s upply is established, the present stud y will end when all 
patientshave transitioned or discontinued from this study  for another reason (e.g. consent 
withdraw al, lost to follow -up, death, sponsor decision). Until the transition, patients will contin ue 
to follow all the procedures and visits required in the cu rrent version of the protocol.nnnnAs soon 
as the end 
of trial according to this definition has been reached in all participating centers within 
and outside the community  has occurred, the complete end of trial will be reached.
5. Ethical and legal aspects
5.1 Ethic s Com mittee (EC) or Institutional Review Board (IRB )
Documented approval from appropriate Ethics Committee(s)/I RBs will be obtained for all 
participating centers/countries prior to study  start, a ccordin g to GCP, local laws, regulations and 
organizations .When necessary, an extension, amendment or renewal of the Ethics Committee 
approval must be obtained and also forwarded to the Sponsor.  The Ethics Committeesoooomust 
supply  to the Sponsor, upon re quest, 
a list of the Ethics Committee members involved in the vote
anda statement to confirm that the Ethics Co mmittee is organized and operates according to GCP 
and applicable laws and regulations.
                                                
nnnnAdded clarification on the definition of the end of study with Am endment 8 . See Section 10.6.7 , Mod ification 7.
oooo :  Addition al text was added  in Amendment 3 to incl ude the head of the center for sites in Japan .See Section 
10.3, Modification 3. Text to include the head of the center for study sites in Japan removed w ith Ame ndment 8. See 
Section 10.6.8 , Modifica tion 8.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 33of 147
5.2 Ethical Conduct of the Study
The procedures set out in this protocol, pertaining to the conduct, evaluation, and docu menta tion
of
this study , are designed to ensure tha t the Sponsor and Investigator abide by  Good Clinical 
Practice Guidelines and under the guiding principles detailed in the Declaration of Helsin ki.  The 
study  will also be carried out in keeping with appli cable local law(s) and regulation(s).  This may  
include an inspection b y the Sponsor representatives and/or Regulatory  Authority  representatives 
at an y time.  The Investigator must agree to the i nspecti on of study -related records b y the 
Regulatory  Authorit y/Sponsor representatives, and must allow direct ac cess to source documents 
to the Regulatory  Authority /Sponsor representatives.  
The study  site will be monitore d by Bayer Representatives to ver ify thetimely  and accurate 
reporting of treatment related Se rious Adverse Events, dispensing of Clinical Suppli es to 
appropriate patients and accurate maintenance of CRF as well as Study  and Regulatory  
Documents.
Modifications to the study  protocol will n ot be i
mplemented b y either the Sponsor or the 
Investigator w ithou tagreement by  both parties. However, the Investigat or may  implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard(s) to the trial 
subjects without prior E C/IRB/S ponsor approval/favorable opinion. As soon as possibl e, the
impleme nted deviation or change, the reasons for it and if appropriate the proposed protocol 
amendment should be submitted to the EC/I RB/Sponsor. Any deviations from the protocol must 
be fully  explained and documented b y the Investigator.
Regulator y Authority Approvals/Authorizations
Regulat ory Authority  approvals/authoriz ations/notifications, where required, must be in place and 
fully  documented prior to study  start.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 34of 147
5.3 Subject Information a nd Cons ent
A core information and Informed Consent Form will be pr ovide d. Prior to the beginning of the 
study , the Investigator must have the ECs/I RB written approval/favorable opinion of the written 
Informed Consent Form and any  other written information to be 
provided to subjects.  The 
written approval of the EC/ IRB togetherwith the approved subject information/ Informed Consent 
Forms must be filed in the study  files.
Written informed consent must be obtained before any  study  specific procedure takes pla cein 
this program .  To ensure continuing administration of m edica tion, patients will be consented and 
registere d for this program while still participating in their original trial (see Section 4.6.3).
Participa tion in the study and date of informed consent given b y the s ubjec tshould be 
documented appropriately  in the su bject’s files.
5.4 Insurance
All subjects participating in the study  will have insurance coverage b y the Sponsor, which is in 
line with applicable l
aws and/or regulations.
5.5 Confidentiality
All records identify ing th esubjectwill be kept confidential and, to th e extent permitted by  the 
applicable laws and/or regulations, will not be made publicly
 available. 
Subject names will not be supplied to the Sp onsor. Only  the subject number will be recorded on 
any study related documents or forms , and if the subject nam e appears on any  other document 
(eg, pathologist report), it must be obliterated before a cop y of the document is supplied to the 
Sponsor.  Stud y findings stored on a computer will be stored in accordance with local data 
protection laws.  The subjects will be informed in writing that representatives of the Sponsor, 
EC/I RB, or Regulatory
 Authorities may  inspect their medical records to verify  the i nformat ion 
collected, and that all personal information made avail ablefor inspection will be handled in 
stricte st confidence and in accordance with local data protection laws.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 35of 147
If the results of the stud y are published, the subject’s identity  will remain c onfiden tial. 
The Investigator will maintain a list to enable subjects’ records to be identified.
6. Statistical me thods and determination of sample size
6.1 Statistical and Analytical Plans -amended
After the end of the s tudypppp, descriptiv e analy sesqqqqof demograph y, adverse events (including 
serious)
, laboratory data, and reasons for t ermination of t reatmentrrrrsssswill be provided in the 
form of a written report.ttttuuuu
6.2 Determination of Sample Size
Not applicable
7. Adverse events
7.1 Warnings/Precaution s
As ou tlined in the I nvestigator Brochure and Safety  Section s of t he Product Labeling.
7.2 Adverse E vent Monitoring
Subjects must be carefully monitored for adverse events.  This monitoring also includes specified 
clinical laboratory  tests.  Adverse events should be assessed in terms of their seriousness, severity  
                                                
pppp : The timepoint was corrected with Amendment 8. See Section 10.6.9 , Modification 9.
qqqq:  Text regarding the presentation of data was modified un der Amendment 3. See Sect ion 10.3, Modification 6.
rrrr
:  Duration of treatment and overall survi val were added in Amendme nt 3. See Section 10.3, Modification 1 and 
Modification 6.
ssssStatistical and Analytical Plans were modif ied by Amendment 7 to remove overall survival (OS). See Section 
10.5.2 , Modification 2.
tttt:  Da
te of enrollment will be used f orcases in which the o riginating trial was not randomiz ed.
uuuu:  Information regarding the analysis of survival data was added in Amendment 3. See Section 10.3, 
Modification 1.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 36of 147
and relationsh ip to study  medication .  Ade quate medical care will be provided to the subjects for 
any adverse events, and the event
s will be followed up until resolution or stabilization .vvvv
7.3 Adverse Ev ent Def initions
7.3.1 Adverse Event
An adverse event is an y untowar d medi caloccurrence in a subject or clinical inves tigation subject 
administered with a pharmaceutical product. The adverse event does not necessarily  have to have 
a causal relationship with thi s treat ment.  An adverse event can therefore be any  unfavorab le an d
unint ended sign (including an abnormal labor atory finding), s ymptom, or disease temporally  
associated with the use of an investigational product, whether or not considered related to the 
medicina l product.
Adverse events associated with the use of a drug in humans, whether or not cons idered drug 
related, include the following: 
An adverse event occurring in the course of the use of a drug product in professional practice.
An adverse event o ccurring from an overdose whether accidental or intentional.
An ad verse e vent occurring from drug abuse.
An adve rse event occurring from drug withdrawal. 
An adverse event where there is a reasonable possibility  that the event occurred purel y as a 
result of the s ubject’s participation in the study  (eg, adverse event or serious adverse event 
due to dis continuation of anti-hypertensive drugs during wash- out phase) must also be 
reported as an adverse event even if it is not related to the investigational produ ct.
                                                
vvvv:  Sentence regardi ng the follow -up of adverse events was added in Amendment 3. See Section 10.3, 
Modification 4.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 37of 147
Theclinical manifestation of an y failure of expected pha rmaco logicalaction is not recorded asan 
adverse e vent if it is already  reflected as a data point captured in the CRF.  If, however, the event 
fulfills any  of the criteria for a “serious” advers e event, it must be recorded and reported as such.
If progres sive dise aseleads to signs and s ymptoms that meet the “serious” criteria ( ie,
hospitalization, disability , death or an important medical event), the signs and sy mptoms should 
be reported as an S AE and not the underly ing cause ( ie,progressive disease).
7.3.2 Serious Adve
rse Event
A serious adverse event is any  untoward medical occurrence that at any  dose: 
Results in death.
Is life -threatening.
Requires in
-patient hospitalization or prolongation of existing hospitalization.
Results in persistent or significant d isabi lityorincapacit y.
Is a congen ital anomal y orbirth defect.
Is an important medical event.
Life-threatening: The term “life -threatening” in the definition of “serious” refers to an adverse
event in which the patient was at risk of death at the time of the event. It does not refer to a n 
adverse event which h ypothetically  might have caused death if it were more severe
Hospitalization: Any adverse event leading to hospitalization or prolongat ion of hospitalization 
will be considered as Serious, UNL ESS at least oneof the following except ions is met:
The admission results in a hosp ital stay  of less than 12 hours wwww
OR
                                                
wwww:  The e xception regarding Japan was added in Amendment 3. See Section 10.3, Modification 4. The 
except ion regarding Japan was removed with Amendment 8. See Section 10.6.8 , Modification 8.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 38of 147
The admission is pre- planned ( ie, elective or scheduled surgery  arranged prior to the start of 
the study ). 
OR
The admission is not associa ted w ithan adverse event ( eg, socia l hospitalizati on for purposes 
of respite care).
However ,it should be noted that invasive treatment during an y hospitalization may fulfil the 
criteria of ‘med ically important’ and as such may be reportable as a serious adver seeven t 
dependant on clinical judgement.  In addition where local R egulatory  authorities specificall y 
require a more stringent definition, the local regulation takes precedent
Disability means a s ubstantial disruption of a person’s ability  to conduct normal life’s functions.
Important medical event : Any adverse event may  be considered serious because it may  
jeopardize the subject and may  require intervention to prevent another serious condition. A s 
guidance for determination of important medical events refer to the “WHO Adverse Reaction 
Terminology  –Critical Terms L ist” . These terms either refer to or might be indicative of a 
serious disease state. 
Such reported events warrant special attention because of their possible association with a serious 
diseas e s tateand may  lead to more de cisive action t han reports on other terms.
7.3.3 Unexpected Adverse Event
An unexpected adverse event is any  adverse drug event, the specificity  or severit y of which is not
consistent with the current I nvestigator Brochure (or Pack ageInsert for marketed product s).  
Also, repo rts which add significant information on specificit y or severity of a known, alread y 
documented adverse event constitute unexpected adverse even ts.Theexpectedness of AEs will 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 39of 147
be determined by the Sponsor acco rding to the applicable referen cedocument and according to 
all local regulations .xxxx
7.3.4 Relationship of Adverse Event to Investigational Product
The assessment of the relationship of an adverse event t o the administration of study  drug is a 
clinical decis ion b ased on all available informati onat the time of the completion of the case 
report form.
An assessment of ‘No’ would include:
The existence ofa clear alternative explanation ,eg, mechanical bleedi ng at surgical site.
OR
Non-Plausibility ,eg, the subj ect is struck by an automobile when th ere is no indication that 
the drug caused disorientation that may  have caused the event; cancer developing a few day s 
after the first drug administration.
Anassess ment of ‘Yes’ indicates that there is a reasonable sus picion t hat the adverse event is 
associated with the use of the investigational drug.
                                                
xxxx:  The sentence r egarding expectedness of AEs was added in Amendment 3. See Section 10.3, Modification 4.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 40of 147
Factors to be considered in assessing the relationship of the adverse event to study  drug include: 
The tempo ral seq uence from drug administration: The event should occu r after the drug is 
given.  The leng thof time from drug exposure to event should be evaluated in the clinical 
context of the event.
Recovery  on discontinuation (de -challenge), r ecurrence on rein troduct ion (re -challenge): 
Subject’s response after drug disc ontin uation (de-challenge) or subjec tsresponse aft er drug 
re-introduction (re -
challenge) should be considered in the view of the usual clinical course of 
the event in question.
Underl ying, concomitant, intercurrent diseases: Each report should be evaluat ed in the 
context of the natural his tory and course of the disease being treated and any  other disease the 
subject may  have.
Concomitant medication or treatment: The other drugs the subject is t aking or the treatment 
the subject receives should be examine d to determine whether an y of them m aybe suspected
to cause the event in question.
Known response pattern for this class of drug:
The pharmacology  and pharmacokinetics of the test drug: The ph armacok inetic properties 
(absorption, distribution, metabolis m and e
xcretion) of the test drug(s), coupled with the 
individual subject’s pharmacod ynamics should be considered.
7.3.5 Severity of the 
Serious Adverse Event
The following classification should be used:
The intensity  or severit y of serious adverse events should be document ed using the National 
Canc
er Institute- Common Terminology Criteri a, Version 3.0 (NCI -CTC v. 3.0). 
Treatment related Serious adverse events (SAEs), as assessed b y the investigator, including
laboratory  test abnormalities fulfilling the definition of se riou s, after signing the inf ormed consent 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 41of 147
and during follow-up period must immediately  (within 24 hours of the investigator’s awareness) 
be reported to the person detailed in the study  file.  A serious adverse event Form must also be 
completed with in 24 hours of the investigator awar eness and forwa rded to the designated person 
as detailed in the stud y file. Each serious adverse event must be followed up until resolution or 
stabilization by submis
sion of updated reports to the designated person.
7.3.6 Adverse Event D ocumentation
All treatme ntrelated adve rse events or adverse events NCI -CTCAE Version 3.0 Grade 3 or 
higher (regardless of attribution) occurring after the subject has signed the info rmed co nsent must 
be fully  recorded in the subject’s case rec ord f orm.
yyyyDocumentation must be supported b y an en try in the subject’s file. A laboratory  test 
abnormality  considered clinically  relevant, eg, causing the subject to withdraw from the study , 
requiremen
t treatment or causing apparent clinical manifestations, or judged relevant b y the 
investi gator, should be reported as an adverse event.  Each event should be described in detail 
along with start and stop dates, severit y, relationship to investigati onal pr oduct, action taken and 
outcome.
7.4 Reporting of Serious Adverse Even ts/Pregnancy
Serious adverse events (SA Es), including laboratory  test abnormalities fulfilling the definition of 
serious, after signing the informed consent and during the follow -up period m ust immediately  
(within 24 hours of the investigator’s awar
eness) be reported to the person detailed in t he study  
file. A serious adverse event form must also be completed within 24 hours of the investigator’s 
awareness and forwarded to the designat ed pers on as detailed in the study  file.  Each serious 
advers e eve ntmust be followed up until re solution or sta bilization by  submission of updated 
reports to the designated person.  An isolated laboratory  abnormality  that is assigned Grade 4, 
according to CTC de finition, is not reportable as an SAE, unless the inve stiga t
or assesses that the 
                                                
yyyy:  La nguage specific to the recording of adverse event information in Japan was added under Amendm ent 3.  
See Section 10.3, Modification 2. Language specific t o the recording of adverse event i nform ation in Japan w as 
removed un der A mendment 8. See Section 10.6.8 , Modification 8.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 42of 147
event mee tsstandard ICH criteria for an SA E.  CTC Grade 4 baseline laboratory  abnormalities 
that are part of the disease profile should not be reported as an SAE, spec ificall y when they  are 
allowed or not excluded by  the protocol inc lusion/ exclusion criteria.  If aninvestigator is in doubt 
about the applicable reporting obligations, he/she should consult with the study  monitor for the 
Sponsor.
CTC Grade 4 lab abnormali ties wi ll be documented in the lab data and will be reviewed on a 
r
egular basis.
When required, a nd according to local law and regulations, serious adverse events must be 
reported to the Ethics Committee and Regulatory  Authorities.
Pregnancy  occurring duri ng a cl inical investigation, although not considered a seriou s adv erse 
event, must be reported to B ayer within t he same timelines as a serious adverse event on a 
Pregnancy  Monitoring Form. The outcome of a pregnancy  should be followed up carefull y and 
any abnorma l outcome of the mother or the child should be reporte d. This alsoapplies to 
pregnancies fo llowing the a dministration of the investigational product to the father prior to 
sexual intercourse.
8. Use of data and publication
All data and results and all intell ectual propert y rights in the data and results derived from the 
study will be the property of the sponsor , who may  utilize the data in various way s, such as for 
submission to government regulatory  authorities or disclosure to other investigators.  T he 
investigator, whilst free to utilize the data derived from the 
study for scientific purposes, must 
discuss any publication with the sponsor prior to release and obtain written consent of the sponsor 
on the intended publication.  The sponsor recognizes t he righ t of the investigator to publish the 
results upon comp letionof the study .  However, the i nvestigator must send a draft manuscript of 
the publication or abstract to the sponsor thirty  days in advance of submission in order to obtain 
approval prior t o submi ssion of the final version for publication.  This will be re
viewed promptl y
and approval wil
l not be withheld unreasonabl y.  In case of a difference of opinion between the 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 43of 147
sponsor and the investigator(s), the contents of the publication will be disc ussed i n order to find a 
solution which satisfies both partie s.
9. Reference s
Investigator’s brochur e BAY 43- 9006/Raf Kinase Inhibitor, Safety  Section of the Product 
Information leaflet
10. Protocol amendments
The original study  protocol was dated 05 July  2007 and alocal protocol amendment (Amendment 
1) was instituted in Germa ny on 07 February  2008. The cha nges made to th e protocol under 
Amendment 1 are described in Section 10.1. However, as Amendment 1 was a local amendment 
only, the change s applicable to Germany  are not incorporated into the body of this integrated 
protocol.
A global amendment (Amendment 2) was instituted in February  2011. The changes made to the 
protocol under Amendment 2 are described in Section 10.2 and are incorporated into the bod y of 
this int egrat
ed prot ocol.  
Another global a mendment (Amendment 3) was instituted in March 2012. The changes made to 
the protocol under Amendment 3 are described in Section 10.3 and are incorporated into the bod y 
of thi s integrated protocol.  
Afurther global amendment (Amendment 4) was instituted in March 2014. The changes made to 
the protocol under Amendment 4 are described in Section 10.4 and are incorporated into the bod y 
of this integra tedprotocol .
In addition, a local p rotocol amendme nt (Amendment 5) was instituted in China on 19 JAN 2016. 
The reason for Amendment 5 was the following: A statement was added to allow patients in 
China who reached End of Treatment in their originating Bay er/Ony x spon sored study , but who
continued to receive sorafenib funded b y a Bay er-sponsored program ,to enter the STEP trial at 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 44of 147
any time . This change was made so that these patients may  continue to rece ive sorafenib and be 
monitored for safety  through the STEP trial.
A further local protocol amendment (Ame ndment 6) was instituted in Taiwan on 25 JUL  2017. 
The global protocol amendments are described below. The reason for Amendment 6 was the 
follow ing: The rationale for this amendment is the transfer of ongo ingTaiwanese patients from 
SEARCH ( sorafenib + erl otinib in HCC) into the STEP trial.The amendment allows for 
combination therap y with erlotinib and sorafenib for subjects in the STEP trial.
A global amendment (Amendment 7) was instituted on 15 M AY2018. The c hanges made to the 
protocol un
der Amendment 7 are described in Section 10.5 and are incorporated into the bod y of 
this integrated protocol.
A global amendment ( Amendme nt 8) was instituted on 26 MAY 2020. The changes made to the
proto
col under Amendment 8 ar e described in Section 10.6 and are incorporated into the bod y of 
this integrated protocol.
The changes for all global amendments a re desc ribed below.
10.1 Amendment 1
10.1.1 Overview of Changes
Modificat ion 1 :Inclu sion and Exclusion Crite ria
The inclusi on criterion regarding the use of contraception by  men and women of childbearing age 
was clarified to state that the investigator should advise the pat ient regarding what form of 
contraception he/she feels is most appropriate for the patient .
The exclusion criterion regarding the concomitant use of potent inhibitors of CYP 3A4 was 
clarified to state that the consumption of grapefruit should also b e avoided during treatment with 
study  drug.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 45of 147
The protocol sect ions af fecte d by these changes are Section 4.2.1, Inclusion Criteria, and Section 
4.2.2, Exclusion Criteria.
Modificati on 2: P rior and Concomitant Therapy
The paragraph describing the p
roactive monitoring of patients using concomit antnarrow 
therapeutic index medications that are hepatically  metabolized (liver P450 sy stem) was modified 
to include INR ( International Normali zed Rat io)measurements for warfarin and phenprocoumon 
as par t of 
the rec ommended monitoring.  
Thestatement pr oviding examples of concomitant medications with narrow therapeutic indices 
was modified to add phenprocoumon to the list of medications. 
The p rotocol section affected b y these changes is Section 4.5.8, Prior and Concomitant T herap y.
10.1.2 Changes to the Protocol Text
In this section, all affected protocol sections are detailed; the sequence of sections follows the 
structur e of th
e original protocol.  In the display  of modifications, the “old te xt” refers to the 
protoc ol version prec eding this amendment ( ie, protocol version 5.2).  Deletions are crossed out
in the “old text” and additions are underlined in the “new text” ( ie, Amend ment 1/Version 1.0).
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 46of 147
Section 4.2.1, Inclusion Criteria
Old te xt:
Women of childbearing pot
ential and men must agree to use adequate contraception prior to 
study  entry  and for the duration of study  participation, including the 30 day s period after la st 
study drug dosing.  The investigator should advise the pat ient how to achieve an adequate 
contraception.
New text:
Women of childbearing potential and men must agree to use adequate contraception prior to 
study  entry  and for the duration of study  partic ipation , including the 30 days period after last 
study  drug dosing .The investigator should advi sethe patient how to achieve an adequate 
contraception with methods he feels to be most appropriate for the patient .
Section 4.2.2   Exclusion Criteria
Old te xt:
Concomitant use of potent inhibitors of CYP 3A4 including ketoconazol e, itraconazole and 
ritronavir. Consumption of grapefruit juice should also be avoided.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 47of 147
New text:
Concomitant use of potent inhibitors of CYP 3A4 including ketoconazole, itraconazole and 
ritronavir. Consumption of grapefruits and grapefruit jui ce sh ould al so be avoided .
Section 4.5.8   Prior an d Concomitant Therapy
Old text : 
Patients taking concomitant medications, known to be metabolized by  the liver, should be closel y 
observed for side ef fects.  Patients taking narrow therapeutic index medic ations that are 
hepaticall y metaboli zed (liver P450 system) should be monitored proactively  for serum/ plasma 
levels of warfarin, phen ytoin, quinidine, carbamazepine and phenobarbital.
In general , patie nts should be closel y monitored for side effects of al l conco mitan t medications 
regardless of path of eli mination, especiall y those with narrow therapeutic indices, such a 
digoxin, warfarin, quinidine, phen ytoin, phenobarbitol, carbemazepam and cy closporine.
New text:
Patients taking concomitant medications, known to be metabolized by  the liver , should be clo sely 
observed for side effects.  Patients taking narrow therapeutic index medications that are 
hepaticall y metabolized (liver P450 sy stem) shoul d be mo
nitored proactively  with INR 
(International Normalized Ratio)meas urements for warfarin an d phenprocoumon ; and for serum/ 
plasma levels for phen ytoin, quinidine, carbamazepine and phenobarbital.
In general, patients should be closel y monitored for s ide eff ects of all concomitant medications 
regardless of path of eliminat ion, especiall y those wi thnarrow thera peutic indices, such as 
digoxin, warfarin, phenprocoumon, quinidine, pheny toin, phenobarbitol, carbamazepine and 
cyclosporine.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 48of 147
10.2 Amendment 2
10.2.1 Overview of Changes
Modification : Inclusion and Exclusion Criteria
Aninclusio n criterion was added to a llow subjects who received combination treatment with 
sorafenib (Nexavar) and TACE (transarterial chemoembolization) in their originating study  to be 
eligibl e for t his extension study .  The exclusion criterion regardin g con c urrent anti-cancer 
chemotherap y was, therefor e, modified to clarify  that the exclusion did not apply  to subjects
being treated with sorafenib in combination with TACE.
This change was made to allo w subjects from the SPACE study  to continue to receive sorafenib 
under this extension prot ocol.  The SPAC E study , a randomized, double -blind study  of sorafenib 
vs placebo in patients with hepatic cellular carcinoma who are receiving TACE treatment, will be
closed in the near future.  Subjects from this study  who a r
ereceiving sorafenib and cont inue to 
benefit from the therap y may now, under this amendment protocol be enrolled in the STEP 
program may  continue to receive TACE along with sorafenib.
In addition , this single criterion covering concurrent anti- cance r che mothera py, concurrent 
immunothe rapy, and concu rrent hormonal therap y was split into three distinct bullets.  This 
change was made clarit y and does not represent a change to stud y conduct.
The proto
col sections affected b y these changes are Se ction 4.2.1, Inclusion Criteria, and Section 
4.2.2, Exclusion Criteria.
10.2.2 Changes to the Protocol Text
In this section, all affe cted pr otocol sections are detailed; the sequence of sections follows the
structure of the origin alprotocol.  I n the display  of modifications, the “old text” refers to the 
protocol version preceding this amendment ( ie, protocol version 5.2).  Deletions ar e cross ed out
in the “old text” and additions are underlined in the“new text” (ie, Amendment 2/Version 6.0).
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 49of 147
Section 4.2.1, Inclusion Criteria
Old text:
Patient is receiving sorafenib (Nexavar ) as a monotherapy  in their originating protocol.  Patients 
who were being treated with sorafenib (Nexavar ) in combination w ith other ch emotherapies in 
the orig inal study , but continued on single agent sorafenib (Nexavar ) after discontinuation of the 
combination agent will be eligible.
New text:
Patient is receiving sorafeni b (Nexavar ) as a monotherapy  in their originating prot ocol. Patie nts 
who were being treatedwith sorafenib (Nexavar ) in combination with other chemotherapies in 
the original stud y, but continued on single agent sorafenib (Nexavar ) after discontinua tion of the 
combination agent will be eligible.
Patients who are r eceivin g concurrent combination with sorafenib (Nexavar) and TACE
(transarterial chemoembolization) in their originating stud y will be eligible.
Section 4.2.2, Exclusion Criteria
Old text:
Concurre nt anti- cancer chemotherap y, immunotherap y (including monoc lonal a ntibodies) or 
hormonal t herapy, except 
for bisphosphonates, during or within 30 day s prior to start of study  
drug
New text:
Concurrent anti -cancer chemotherap y, except TACE (transarte rial chemoembolization)
Concurrent immunotherapy  (including m onocl onal an tibodies), during or wit hin 30 day s 
prior to start of study  drug
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 50of 147
Concurrent hormonal therap y, except for bisphosphonates, during or within 30 days prior 
to start of study  drug 
10.3 Amendm ent 3
10.3.1 Overview of Changes
Modification 1: Inclusion of an Eva luati onof Overall Survival
It is no w planned that data from the STEP trial will be transferred to the Integrated Sorafenib 
Database. Data from individual patients from their originating trial arealrea dy part of that 
database; therefore collecting surviva l status forthis cohort is felt to be valuable for future 
descriptive data anal ysis and publication.
The protocol sections affected b y this change are Section 2, Study  Objectives; Secti on 4.1, Study  
Design and Plan; 
Section 4.6.1, Efficacy  Variables; Section 4.6.3, Assessment Periods ; Secti on 
6.1, Statistical and Analytical Plans ;and Section 11 , Study  Flow Chart
Modification 2: Evaluation of Safety 
Publication of the safet y results of the collected data from STEP is now planned.  T herefore,
including safet y as a stated objective is needed . The main o
bjective of this program remains 
unchan ged. 
The protocol section affected b y thischange isSection 2 , Study  Objectives, 
The inclusion of an a ssessme nt of EC OGperformance status was added to Secti on 4.1, S tudy 
Design a nd Plan, for consistency  with the rest of the protocol.  In addition, for consistency , 
ECOGperformance status was added to Section 4.6.3 , Assessment Periods under Safet
y
Variables.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 51of 147
The CRF was has b een modified to collect information on the ECOG performance status in the 
CRF as well as the subject’s source documentation.  Therefore, the ECOG performance s tatus 
must now also be captured in the subject’s CRF.
The pro tocol section affected by  this chang e is Section 4.6.2 , Safety  Variables
Date of death was re moved from the safet y variables as survival status (including date of deat h 
when applicable) is collected elsewhere
The protocol section aff ected by  this change is Section 4.6.2 , Safety  Variables .
Finally , in accordance with Japanese regulatory  requirements for the recording of adverse e vent 
data, the protocol was modified to require the recording of AL
Ladve rse events regardless of
NCI-CTCAE grade and regardless of attribution for patients treated at study  sites in Japan.
The protocol sections affected b y this change are Section 4.6.2, Safety  Variables, Section 4.6.3, 
Assessment Periods, and Section 7.3.6, Adverse Event Documentation.
Modification 3: Head of the Center for Sit es in Japan
In accordance with local regulatory  requir ement s ,specific mention of the head of the center for 
sites in Japan has been added to Section 4.4, Premature Termination of Study /Closure of Centre 
and Section 5.1, Ethics Committee (EC) or Ins titutional Review Board (IRB).
Modifica tion 
4: Adverse Events
In accordance with local regulatory  requirements in Japan, specific language has been added to
Section 7.2, Adverse Event Monitoring and Section Section 7.3.3, Unexpected Adverse Event 
In accordance with local Japanese regulatory  requirements, Secti on 7.3.2, Ser ious Ad verse Event, 
was modified to clarify  that, in Japan, a ny adv e rse event leading to hospital ization or 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 52of 147
prolongation of hospitalization is to be considered as serious regardless of the length of 
hospitalization or prolongation of hospitalization.
Modif ication 5:  Inclusion of Subjects From the SEARCH Study (Stud y 12917) andthe 
RESILIENCE Study (S tudy 12444)
The Sponsor has made the decision to allow patients from the SEARCH study , in which patients 
receive sorafenib in combination with erlotinib, or the RESI LIENCE Study , in which patients 
receive sorafenib in c ombin a
tion w ith cap ecitabine, to rec eive continued treatment in the 
Sorafenib Long Term Extension Program (STEP).  Therefore, all necessary information regarding 
the inclusion of these subjects i nto STE P has been included in the protocol under this amendme nt 
(Amendment 3).
The protocol secti ons affected by the inclusion of these subjects are Section 1 , Introduction, 
Section 2, Study Objectives, Secti on 4.1, Study Design and Plan, Section 4.2.1, I nclusion 
Criteria, Section 4.2.2, Exclusion Criteria, Section 4.5.1 , Treatments to be Adm inistered, Section
4.5.2, Dose Modification, Section 4.5.3, I dentity  of Investigational Product(s), Section 4.5.5, 
Selection of Dose s in 
the Stu dy, Section 4.5.8 , Prior and Concomitant Therapy , and Section 11, 
Study  Flow Chart.
Modification 6:  Minor Changes
Contact names for the Study  Manager , Statistician, and Medi c
al Exp ert were updated on the title 
page of t he protocol. 
The information in Section 2 regarding the conditions whereb y patients may receive treatmen t 
under this protocol was modified slightly  to clarify  that, if sw i t ching to commercially  availab le
product, the re should be no interruption in the patient’s treatment schedule.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 53of 147
The text regarding presentation of data as “a summary” was modified in Section 6.1, Statistical 
and Anal ytical P lans, to clarify  that descripti veanaly siswould be performed.  Duration of 
treatment was added to list of variables for which such analyseswould be prepared.
Patients receiving long -term s orafeni b may  be appropriate candidates f or vaccination. Howev er, 
t
here are no safet y data availab lewith live va ccine sand,given the propensity  for sorafenib to 
cause l ymphopenia, it is felt that administering live vaccine to patients receiving sorafenib may  
represent a safet y risk.
The protocol section affected b ythischange is Section 4.5.8 , Prior and Concomitant Therap y.
An e ditorial change was made to delete S ection 4.6.4 ,which is not applicable to this protocol .
In Section 4.5.2, Dos e Mod ification, reference to “Hand-Foot s yndrome” was change to “Han d-
Foot Skin Reaction.”
10.3.2 Changes to the Protocol Text
In this section, all affected protocol sections are detailed; the se quence of sections follows the 
structure of the original prot ocol. In the display  of modifications , the “old te xt” refers to the 
protocol version preceding this amendment (ie, protocol version 6.0).  Deletions are crossed out
in the “old text” and additions are underlined in the “new text” (ie, Amendment 3/ Version 7).
Title P age
Old text:
PPD
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 54of 147
New text:
Section 1, Introduction
Old text:
Theonly process to provide sorafenib to these patients who have a non- approved /reimbursed 
tumor ty pe is through a clinical trial. The intention of this program is to enable these patien ts who 
are still benefiting from sorafenib in a completed clinical trial to continue to receive sorafenib .  
New text:
The only  process to provide sorafenib to these patients who have a non-approved /reimbursed 
tumor ty pe is through a clinical trial. The intention of this program is to enable these patients who 
are still benefiting from treatment in a completed clini cal trial to continue to receive treatment .  
Section 2, Study Objectives
Old text:
The primary  purpose of program is to enable patients, curre ntly receiving single agent sorafenib 
(Nexavar ) in a Bay er/On yx sponsored clinical trial, to cont inue sorafenib treatment after their 
respective stud y has met its primary endpoint and/or has reached the end as defined in the 
original protocol.  Patients wi ll be a ble to continue sorafenib (Nexavar®) treatment until t he 
treating physician feels the pati ent is no longe r benefiting from the treatment or sorafenib 
PPD
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 55of 147
(Nexavar®) becomes commercially  available, and reimbursed for the respective indication as 
applicable in t he country  in which the patient lives. 
New text:
The prima rypurpose of program is to ena ble patients, c urrent ly receiving sorafenib (Nexavar ) in 
a Bay er/Ony x sponsored clinical trial, to continue sorafenib treatment after their respective study  
has met i ts primary  endpoint and/or has reached the end as defi ned i nthe o riginal protocol.  
Patie nts will be abl e to continue treatment until (i) the treating ph ysician feels the patient is no 
longer benefiting from the treatment or (ii)the treatment beco mes com mercially  available and 
reimbursed for the respective indic ation a s applicable in the coun try in which th e patient lives and 
the patient can obtain suitable amounts of drug for treatment through standard mechanisms of 
commercial availability  (ie, th ere sho uld be no interruption in the patient’s treatment sche dule 
when sw itching to commerciall y available product).
Additional objectives include assessment of the safet y of Nexavar or Nexavar combination 
treatment and evaluation of overall survival (OS).
Secti on 4.1, Study Design and Plan
Old text:
This is an open la bel program that will enable pa tients receivin g sorafenib (Nexavar ) in a 
completed Bay er/On yx sponsored clinical trial to continue single agent sorafenib (Nexavar®) 
treatment. A completed study  is one….
The patients will continue receiving single agen t sorafenib (Nexavar ) at the same do seand 
schedule as in their original Clinical Trial.  
Patients will continue receiving single agent sorafenib (Nexavar ) as long as the treating phy sician 
feels the patient is continuing to benefit from treatment or until sor afenib becomes commerciall y 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 56of 147
available and reim bursed for the respective indication in the country in which the patient lives. 
The patient may  also continue sorafenib until he/she withdraws c onsent ,is non -compliant, is lost 
to follow up, or if an unac cepta ble tox icity occurs.
Prior to 
being dispensed study  medication ….  Patients will continue with single agent sorafenib 
(Nexavar ) in this program at the same dose and schedule the patient was receiv ing in their 
original clinical trial.  
Sorafenib (Nex avar) will be provided as 200 mg tab le ts.  The pati ent should be evaluated 
according to Good Medical Practices as well as local therapeutic and diagnostic 
standards…….. Bimonthly  safet y evaluations include vital signs (ie, heart rate, blood pressure, 
temper ature ), ECOG performance status, lab oratory  evaluations (hematology , ALT, AST, lipase 
and am ylase, PT -INR as applicable for anticoagulated patients) and a review of any  new or 
ongoing adverse eve nt or c oncomitant medications as well as study  medication tak en du ring th e 
visit interval.  All a dverse event, and laboratory  data as well as End of Treatment information and 
study  medication taken must be clearl y and accurately recorded in the Case Report Form 
provided.  All other data, including but not limited to, vit a l signs, ECOG performance stat us,
concomitant medications and date of death must be recorded in the patient’s source documents 
and may  be requested at the discretion of the Sponsor.  
Following th e End of Treatment assessments from the original study, the follow ing information 
will be re corded in the long term extension CRF:  demography , date of f irst dose of sorafenib 
(Nexavar ) in originating study , originating study
 number, ECOG performanc e status and survival 
status ( dead or alive and date of death or date of last contact)   and ongoi ngadverse even ts…..
New text:
This is an open label program that will enable patients receiving sorafenib (Nexavar) in a 
completed Bay er/On yx sponsored clinic al tria
lto continue treatment. A completed study  is 
one…..
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 57of 147
The pa tients will continue receiving single agent so rafenib (Nexavar), sorafenib and erlotinib if
transferred from study  12917 (SEARCH), or sorafenib and capecitabine if transferred from Study  
12444 (RE SILIENCE), at the same dose and schedule as in their o riginal Clinical Trial.  
Patients w ill continue re ceiving single agent sorafenib (Nexavar ; as single agent or combination 
treatment )as long as the treating phy sician feels the patient is contin uing to benefit from 
treatment or until sorafenib (as single agent or com bination treatment ) beco mes commerciall y 
available and reimbursed for the respective indication in the country  in which the patient lives. 
The patient may  also continue treatment until he/she withdraws consent ,is non -compliant, is lost 
to foll ow up, or if an unacceptable toxicit y occurs.  
Prior to being dispensed study  medication …..  Patients will continue with single agent sorafenib 
(Nexavar), sorafenib and erlotinib if transferred from s tudy 12917 ( SEARCH ),or sorafenib and 
capecitabine if trans ferred from Study  12444 (RESILI ENCE), in this program at the same dose 
and schedule the patient was receiving in their original clinical trial.  
Sorafenib (Nexavar) will be provided as 200 mg tablets. Erlotinib will be provided as 150 mg, 
100 mg, and 25 mg table ts for patients receivin g the sorafenib /erlotinib combination and 
transferring from Study  12917 (SEARCH) . Capecitabine will be provided as 150 mg and 500 mg 
tablets for patients receiving th e sorafenib/capecitabine combination and transferring from Study 
12444 (RESILIENCE).  The patient should be evaluated according to Good Medical Practices as 
well as local therapeutic and diagnostic standards…….. Bimonthly  safet y evaluations include v ital 
signs (ie, heart rate, blood pressure, temperature), Eastern Coopera tive Oncology  Group ( ECO G )
performance status, laboratory  evaluations (hematology , ALT, AST, lipase and am ylase, PT -INR 
as applicable for anticoagulated patients) and a review of an y new or ongoing adverse event or 
concomitant medications as we ll as study medication taken during the visit inter val.  All adverse 
event s, laboratory  data, ECOG performance status and survival status ( dead or alive and date of 
death or date of last contact), as we ll as End of Treatment information and study  medicatio n tak en
must be clearl y and accurate lyrecorded in the Case Report Form provided.  All other data, 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 58of 147
including but not limited to, vital signs, concomitant medications must be recorded in the 
patient’s source documents and may  be requested at the discretion of the Spons or.  
Following the End of Treatment assessments from the original stud y, the following information 
will be recorded in the long term extension CRF:  demograph y, date of f irst dose of sorafe nib 
(Nexavar ) in originating study , date of first dose of er lotinib if the patient is tran sferred from 
SEARCH (study  12917 ), date of first dose of capecitabine if the patient is transferred from 
RESILIENCE (Study  12444), originating stud y number, ECOG performance status and survival 
status ( dead or alive and date ofdeath or date of last contac t)and ongoing adverse events.
Section 4.2.1, Inclusion Criteria
Old text:
Patients, who are participating in a previous Bay er/Ony x sponsored study  that has re ached i ts 
endpoint (statistical and regulatory  or study  end)… …
Patie nts w ho are receiving concurr ent combination with sorafenib (Nexavar) and TACE
(transarterial chemoembolization) in their originating study  will be eligible.
Patients who have completed th e End of Treatment assessments in their originating study …...  
Newtext:
Patients, who are parti cipating in a p
revious Bay er/Ony x sponsored study  that has reached its 
endpoint (statistical and regulatory  or study  end)……
Patients who are receiving concurre nt combination with sorafenib (Nexavar) and TACE
(transarteri al ch e
moembo lization) in their origi nating study  will be eligible.
Patients who are receiving concurrent combination with sorafenib (Nexavar) and erlotinib in 
their originating stud y 12917 (SEARC H) will be eligible.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 59of 147
Patients who are receiving concurrent co mbina tion with sorafenib (Nexavar) and capecitabine
in their originating stud y 12444 (RESILIENCE) will be eligible.
Patients who have completed the End of Treatment assessments in their originat ing stu dy…...  
Section 4.2.2, Exclusion Criteria
Old text:
Exclud edtherapies and medications, p revious and con comitant:
Concurrent anti -cancer chemotherap y, except TACE (transarterial chemoembolization) …….
New text:
Excluded therapies and medications, pr evious 
and concomitant:
Concurrent anti -cancer chemotherap y, except TACE (transarterial chemoembo li zation) ,
erlotinib, and cap ecitabine
Section 4.4, Premature Termination of Study/Closure of Centre
Old text:
The Sponsor has the right to close this study , and the Investigator/Sponsor has the right to close a 
center ,at anytime, although this should occur only  after consultation between involved parties.   
The EC/I RB must be informed.……..
New text:
The Sponsor has the right to close this study , and the Investigator /Sponsor has the right to close a 
center , at any  time, although th is should occur only  afterconsultation between involved parties.  
The EC/I RB (or the head of the center forsites in Japan) must be informed .
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 60of 147
Section 4.5.1, Treatments to be Administ ered
Old text:
The study  drug will be supplied as 200 mg tablets. Patients should continue on the same dose as 
they were receiving in the patient’s originating Bay er/Ony x-sponsored Clinical Trial. 
New text:
Sorafenib will be supplied as 200 mg tablets. E rlotini b will be supplied as 150 mg, 100, and 25 
mg tablets and  c apecita bine will be provided as 1 50 mg and 500 mg tablets. Patients should 
continue on the same dose as they  were receiving in the patient’s originating Bay er/Ony x-
sponsored Clinical Trial.
Section 4.5.2, Dose Modification
Old text:
If the starting dose is 600 mg bid the modifications o f sorafenib (Ne xavar ) will follow the pre -
defined dose levels:
Dose level 1 600 mg (3 x 200 mg) po q 12 hr…….
Only  for the purpose of dose modifications, pat ients e xperiencing Hand
-Foot syndrome should 
have their signs and symptom s graded according to th e following s ystem (see Table 4 -3). Other 
skin toxicities will be graded according to CTCAE Version 3.0.  Please note that Hand Foot 
Syndrome will be graded an d recor ded as an adverse event according to NCI -CTC Version 3 .0 in
the CR F.
Table 4 -3:  Grading f orHand -Foot Syndrome 
Grade 1 Numbness, dy sesthesia/paresthesia, tingling, painless swelling or er ythem a 
of the hands and/or feet and/or discomfort, which do es not disrupt normal 
activities……
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 61of 147
New Text:
4.5.2.1  Sorafe nib m onother apy
If the starting dose is 600 mg bid the modi fications of sorafenib (Nexavar ) will follow the pre -
defined dose levels:
Dose level 1 600 mg (3 x 200 mg) po q 12 hr.........
Only  for the purpose of dose modifications, patients experiencing Ha nd-FootSkin Reaction
should have th eir signs and s ymptoms graded according to the following sy stem (see Table 4 -3). 
Other skin toxicities will be graded according to CTCAE Version 3.0.  Please n ote tha t Hand 
Foot Skin Reaction will be graded and recorded as an advers e event according to NCI -CTC 
Version 3. 0 in the CRF.
Table 4 -3:  Grading for Hand -Foot Skin Reaction
Grade 1 Numbness, dy sesthesia/paresthesia, tingling, painless swelling or er ythema 
of the hands and/or feet and/or discomfort, which does not disrupt normal 
activities……
4.5.2 .2  Sorafenib a nd erlotinib combination
Doses will be delay ed or reduced for clinically  significant hematologic and non -hematologic 
toxicities that are related to protocol therap y according to the guidelines shown in the Dose
Delays/Dose Modifications tabl e that follows.  Dose modifications will follow predefined dose 
levels: Dose adjustments for hematologic toxicity are based on the blood counts obtained in 
preparatio n for the day  of treatment.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 62of 147
Table 4-5:  Dose Modificat ion L evels for Sorafenib
Dose Soraf enib
Starting Dose 400 mg twice daily
-1 400 mg once daily
-2 400 mg ever y other day
Table 4-6:  Dose Modification Levels for Erlotinib
Dose Erlotinib
Starting Dose 150 mg once a day
-1 100 mg once a day
-2 50 m g onc ea day
Except for an event o f hypertension, the first agent to dose reduce for the 1st episode of an y 
toxicity  will be erlotinib
If a subject experiences more than one toxicity , dose reduction s hould be according to the 
toxicity  with the highest gr ade 
Inthe case of two or more toxi cities of the same grade, the investigator may dose reduce 
according to the toxicity  deemed most causally  related to study  treatment
Subjects for whom one agen t is he ld may  continue to receive the other agent if all the 
protocol- defined dose modification s teps have been taken and, in the opinion of the treating 
investigator, the subject may  continue to benefit from treatment
Subjects with toxicities that are man ageable with supportive therapy  may  not require dose 
reductions (e g,nausea/vomiting may  be treat edwith antieme tics, diarrhea may  be treated with 
loperamide rather than by dose reduction). A subject will be withdrawn from the study  if 
he/she fails to reco ver fro m a treatment -related toxicity  to CTCAE Grade 0- 1, or toler able 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 63of 147
grade 2 (or within 1 grade of starting va lues for pre -existing laboratory abnormalities) within 
30 day s, unless the investigator and sponsor agree that the subject should remain in the study  
because the investigator believes the subject is/may  derive benefit from continuing study  
treatment. 
Table 4-7:  Dose Modification Plan for Hematologic Toxicities
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafenib Erlotinib
Gr 1 Treat on t ime No change in dose No change in dose
Gr 2 No change
Gr3* Treat on time
Re-evaluate weekly1stepisode: n o change in dose 1st episode: reduce 
erlotinib to
level -1 (100mg once a day)
2nd episode: reduce sorafenib 
to  level -1 (400mg once daily )2nd ep isode: no change to 
above modified dose
3rdepisode : no change to above 
modified dose3rdepisode: red uce 
erlotinib to 
level -2 (50mg once a day)
4thepisode: reduce sorafenib
to level - 2 (400mg every other 
day)4th episode: no change to 
abov e modif ied dose
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 64of 147
Table 4-7:  Dose Modification Plan for Hematologic Toxicities
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafenib Erlotinib
Gr 4* Holdaboth agents 
until <Gr 2
Re-evalu ate w eekly1stepisode: no change in dose 
upon cont inuation of treatment1st episode: reduce 
erlotinib   to 
level -1 (100mg once a day) 
upon continuation of 
treatment
2nd episode: reduce soraf enib 
tolevel -1 (400mg once daily) 
upon continuation of trea tment2nd ep isode: no change to 
abov e modified dose upon 
continuation of treatment
3rdepisode: no change to above 
modified dose upon 
continuation of treatment3rd episode: reduce 
erlotinib   to 
level -2 (50mg once a day) 
upon continuation of 
treatment
4thepiso de: reduce sorafenib
to level -2 (400mg every other 
day) upon continuation of 
treatment4th episode: no change to 
above modified dose upon 
continuation of treatment
aIf no recovery after 30 day delay, treatment will be discontinued unless subj ect isderiv ing clinical 
benefit.
*Intervention/Supportive care regarding Gr 3 or 4 Heme toxicity as per investigator.
If more than 4 dose reductions are required, study treatment will be discont inued.
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 65of 147
Table 4 -8:  Dose Modification Plan for non- Hematologic Tox icity except ILD, and 
Hyperte nsion
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafenib Erlotinib
Gr 1 Treat on time No change in dose No change in dose
Gr 2 No change
Gr 3* Holdaboth agents
until <Gr 2
Initiate supportive 
care
Re-evalu ate w eekly1st episode: no change in dose 
upon cont inuation of treatment1st episode: reduce 
erlotinib to level -1 (100mg 
once a day ) upon 
continuation of treatment 
2nd episode: reduce sorafe nib
to level -1 (400mg once daily) 
upon continuation of treat ment2nd epi sode: no change to 
above m odified dose upon 
continuation of treatment
3rd episode: no change to 
above modified dose upon 
continuation of treatment3rd episode: reduce 
erlotinib   tolevel -2 (50mg 
once a day ) upon 
continuation of treatment 
4thepisod e: reduce sorafenib
to level -2 (400mg every other 
day) upon continuation of 
treatment 4th episode: no change to 
above modified dose upon 
continuation of treatment
Gr 4* REMOVE FROM
STUDY
a If no recovery after 30 day delay, treatment will be disconti nued unless subject is d eriving clinica l 
benefit.
If more than 4 dose reductions, study treatment will be discontinued.  Excludes alopecia, 
nausea/vomiting that has not been pre -medicated, a nd diarrhea not treated with supportive 
care/loperamid e.
4.5.2 .2.1  Anti -rash and Anti -diarrhea Thera pies
Skin rash or dermatosis has been observed in many  subjects during treatment with erlotinib.  No 
clinical trials have formally  evaluated tre atments for rash induced by  erlotinib, and there are 
currentl y no evidenc e - based recommendations for its managem ent. 
Integrated Clin ical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 66of 147
Subjects who develop a mild rash characterized by pustules or raised, red areas may  be treated 
with topical therap y, such as corticosteroi ds.  If the rash is more severe or there is indication of 
secondar yinfec tion, topical clindam ycin or tetracy cline, or oral minocy cline may be used at the 
discretion of the investigator.  (NOTE:  minocy cline is known to interfere with anticoagulants and 
oral cont raceptives.  Therefore, subjects treated with minocy cline w hoare taking anticoagulants 
and/or oral contr aceptives should be monitored accordingl y).  Guidance concerning modification 
of study  drug dosing is provided in Table 4-8.
Because the patholo gy of such a rash is not related to acne pathology , retinoids and other a cne 
medications, such as benzoy l peroxi de, are not recommended, because these agents are more 
likely  to exacerbate the rash due to their drying effects on the skin.  
Anti- diarrhea me dicatio ns may  be introduced if s ymptoms occur.  Previous tria ls haveshow n that 
the frequency  and severity  of di arrhea rarel y hindered the administration of erlotinib and that the 
diarrhea could be managed with loperamide.  The recommended dose of loperamide is 4 mg at 
first onset, followed b y 2 mg every  2 to 4 hour s until the subject is diarrhea-free f or 12 hours.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 67of 147
Table 4 -9:  Dose Modification Plan for Hypertension
GradeDose 
InterruptionDose ReductionAntihypertensive 
TherapyBlood Pressure 
MonitoringHypertensive NCI 
CTCA E V3
Sorafenib Erlotinib
Gr 1 Treat o ntime
Initiate 
supportive 
careNo change in 
dose No change in dose None Routine Asymptomatic, 
transient, (<24hrs) 
increase by >20 
mmHg (diastolic) or 
to >150/100 if 
previously W NL; 
interv ention not 
indicated.
Gr 2 Treat on time
Initiate 
supportive
careNo cha nge in 
dose No change i n dose (asympt omatic)
Initiate monotherapy 
(suggest 
dihydropyridine 
calcium -channel 
blocker).(asymptomatic)
Increase frequenc y 
and monitor (by health 
profess ional) every 2 
days until stabilized.Recurrent or 
persistent (>24 hrs) 
or symptomatic 
increase b y 
>20mmHg 
(diastolic) or to > 
150/100 if previously 
WNL; monotherapy 
may be indicated.(symptomatic 
/persistent)
OR
Diastolic BP > 110 
mmHg
Add agent(s):
Ca++ channel blocker 
(if not already used)
K+ channel opene r 
(angiotens in 
blockers), 
Beta- blocker
Thiazide diuretic(symptomatic/ 
persistent)
OR
Diastolic BP > 110 
mmHg
Increase frequenc y 
and monitor (by health 
professional) every 2 
days until stabilize d.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 68of 147
Table 4 -9:  Dose Modification Plan for Hypertension
GradeDose 
InterruptionDose ReductionAntihypertensive 
TherapyBlood Pressure 
MonitoringHypertensive NCI 
CTCA E V3
Sorafenib Erlotinib
Gr3 Hold both 
agents until 
≤Gr 2
Initiate 
supportive 
care
Re-evaluate 
weekly1stepisode:  
reduce 
sorafen ib to 
level –1 (400 mg 
once daily) upon 
continuation of 
treatment.1stepisode:  no 
change in dose 
upon continuation 
of treatment.Add agent(s):
Ca++ channel blocker 
(if not already used) 
K+ channel opener 
(angiotensin blockers) 
Beta- blocker 
Thiazide diureticIncrease frequenc y 
and monitor (by health 
professional) every 2 
days until stabilized.Requiring more than 
one drug or more 
intensive therapy
than previously.
2ndepisode:  no 
change in dose 
upon 
continuation of 
treatment.2ndepisode: 
reduce erlotinib 
to level – 1 (100 
mg once a day ) 
upon continuation 
of treatment.
3rdepisode: 
reduce 
sorafenib to 
level –2 (400 mg 
every other da y) 
upon
continuation of 
treatment. 3rdepisode:  no 
change in dose 
upon continuation 
of treatment.
4thepisode:  no 
change in dose 
upon 
continuation of 
treatment.4th episode:  
reduce erlotinib
to level – 2 (50 mg 
once a day ) upon 
continuation of 
treatment.
Gr 4 REMOVE 
FROM STUDYLife-threatening 
consequences (e.g., 
hypertensive crisis)
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 69of 147
4.5.2.2.2  Dose Modification for Hand -Foot Skin Reaction
Subjects experiencing Hand -Foot Skin Reaction should have their signs and sy mptoms 
graded according to the following s ystem (see Table 4 -10). Other skin toxicities will be 
graded according to CTCAE Version 3.0.
At first occurrence of hand foot skin reaction, independent of grade, prompt institution of 
supportive measures such as topical emollients, low p otency  steroids, or urea -containing 
cream should be administered.
Table 4 -10:  Grading for Hand -Foot Skin React ion
Grade 1 Numbness, dy sesthesia/paresthesia, tingling, painless swelling or 
erythema of the hands and/or feet and/or discomfort, which does n ot 
disruptnormal activities.
Grade 2 Painful er ythem a and swelling of the hands and/or feet and/or discomfort 
affecting the subject’s activities. 
Grade 3 Moist desquamation, ulceration, blistering or severe pain of the hands 
and/or feet and/or severe discomf ortthat causes the subject to be unable 
to work or perform activities of daily living.
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 70of 147
Table 4 -11:  Do se Modification Plan for Hand Foot Skin Reaction
NCI CTC 
V3.0Dose 
InterruptionDose Reduction HFSR
NCI CTCA E V3.0 Sorafenib Erlotinib
Gr 1 Treat on
timeNo change of 
dose No change of 
dose Numbness, 
dysesthesia/paresthesia, 
tingling, painless swelling or 
erythema of the hands 
and/or feet and/or 
discomfort, which does not 
disrupt normal activities.
Gr 2 No change Painful er ythem a and 
swelling of the hands 
and/or feet and/or 
discomfort affecting the 
subject’s activities.
Gr 3 Holdaboth 
agen ts until 
<Gr 2
Initiate 
supportive 
care
Re-evaluate 
weekly1st episode: no 
change in dose 
upon continuation 
of treatment.1st episode: 
reduce er lotinib
tolevel -1 (100 mg 
once a day ) upon 
continuation of 
treatment.Moist desquamation, 
ulceration, blisteri ng or 
severe pain of the hands 
and/or feet and/or severe 
discomfort that causes the 
subject to be unable to 
work or perform activities of 
daily living.2nd episode: 
reduce sorafenib
to level - 1 (400 mg 
once daily) upon 
continuation of 
treatment.2nd epi sode: no 
change to above 
modified dose 
upon continuation 
of treatment.
3rd episode: no 
change to above 
modified dose 
upon continuation 
of treatment .3rd episode: 
reduce erlotinib
to level - 2 (50 mg 
once a day ) upon 
continuation of 
treatment.
4th ep isode: 
reduce sorafenib
to level - 2 (400 mg 
every other day) 
upon continuation 
of treatment.4th episode: no 
change to above 
modified dose 
upon continu ation 
of treatment.
Gr 4 REMOVE 
FROM 
STUDY
a If no recovery after 30 day delay, treatment will be discontinued unless subject is deriving clinical 
benefit.
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 71of 147
4.5.2.2.3  Dose Modification for Keratitis 
For all grades of suspected keratitis, the erlot inib dose should be held and supportive 
measures instituted.  Subjects with dry  eyes should be advised to use an ocular lubricant.  
Subjects who continue to wear contact lenses may have an increased risk of ocular AEs (eg, 
keratitis).  Subjects may  continue t o wear contacts but should discuss this issue with their 
treating oncologist before entering the stud y.  In addition, any  elective ophthalmological 
surgery  while the subject is taking study  drug must first be discussed between the investigator 
and the S ponsor.
4.5.2.2.4  Dose Modification for Interstitial Lung Disease
For all grades of suspected interstiti al lung disease (ILD), the erlotinib dose should be held 
and supportive measures instituted.  I f ILD is confirmed, erlotinib and sorafenib must be 
discontinued permanently.  Acute d yspnea or cough may  be signs of ILD.  If a subject 
presents with acute d yspnea or cough, interruption of treatment with erlotinib may  be 
considered, at the discretion of the treating ph ysician, until resolution of sympt oms or unt il 
ILD can be ruled out.  If a subject presents with symptoms such as shortness of breath, 
dyspnea, cough, or fever, a chest X -ray or chest CT and, if needed, additional tests to evaluate 
pulmonary  function, as clinically  indicated, should be con sidered aspart of the work up.  If a 
diagnosis of ILD is confirmed, appropriate treatment measures according to best medical 
practice and local standards should be initiated.
4.5.2.3  Sorafenib and capecitabine combination
Doses of capecitabine or sorafen ib/plac ebomay be reduced/interrupted in the setting of any  
AE that is:
Not controlled by  optimal supportive car e, or
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 72of 147
Not tolerated due to s ymptomatology , disfigurement, or interference with normal 
daily  activities, regardless of severit y.
Dose modificatio ns will bebased on the worst grade of an AE or laboratory  abnormality  
during a given cy cle.  If multiple AEs ar e observed, the dose modification should be based on 
the most severe (ie, worst grade) event. 
Dose modifications should take into consideration AEs an d dose modifications alread y 
occurred in study  12444 (RESILIENCE).
Treatment delay s of sorafenib/placebo for up to 21 day s are acceptable in order to allow for 
resolution of sy mptoms to NCI -CTCAE v3.0 Grade 1 or less.  For subjects with NCI -CTCAE 
v3.0 Grad e 2or greater toxicities at baseline (screening), resolution of s ymptoms to baseline 
severit y (ie, Grade 2 or greater) is acceptable.
Subjects requiring interruption of study  treatment for more than 21 day s will be discontinued 
from study  treatment .  These s ubjects will, however, be followed until death or overall 
completion of the trial, whichever comes fir st. 
Subject requiring further dose reductions bey ond 500 mg/m2 BID of capecitabine or 200 mg 
(1tablet) twice daily  every  other day  of sorafeni b will be discontinued from study  drug.  In 
the event a subject meets the criteria to discontinue all study  drug s (capecitabine plus 
sorafenib), the subject will be followed until death or overall completion of the trial, 
whichever comes first. 
NOTE:
Subjects fo r whom it is medically  appropriate to stop capecitabine administration 
(eg,due to intolerance) must also discontinue sorafenib.  
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 73of 147
Subjects for whom it is medically appropriate to stop sorafenib administration 
(eg,due to intolerance) may  continue t o recei ve capecitabine .
Capecitabine and sorafenib/placebo treatment interruptions are regarded as lost treatme nt 
days and missed doses should not be replaced; the planned treatment dosing schedule should 
be maintained in the event of a treatment interrup tion. 
4.5.2.3.1  Dose -reduction levels
Dose -reduction levels of sorafenib and capecitabine for the management o f AEs are outlined 
in Table 4-12 and Table 4 -13, respectively .
Table 4-12:  Predefined Dose Levels of Sorafenib
Study 
drug:
SorafenibDose Lev el
0 -1 -2 -3
Applicable 
if sorafenib 
was never 
escalated 
higher than 
600 mg/d 
in study 
12444200mg/1 
tablet in 
the 
morning, 
400mg/2 
tablets in 
the 
evening200mg/1 
tablet 
twice 
daily 200mg/1 
tablet 
twice 
daily, 
every 
other day —
Applicable 
if sorafenib
was 
escalated 
to 800 
mg/d 
following 
cycle 1 in 
study 
12444400mg/2 
tablets, 
twice daily200mg/1 
tablet in 
the 
morning, 
400mg/2 
tablets in 
the 
evening200mg/1 
tablet 
twice 
daily 200mg/1 
tablet 
twice 
daily, 
every 
other day 
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 74of 147
Table 4-13: Pre defined Dose Levels of Capecitabine
Study drug:
CapecitabineDose Level
0 -1 -2 -3
Applicable if 
capecitabin e dose 
was not escalated 
to 1,250 mg/m2
BID daily in study 
124441,000 mg/m2
twice daily750mg/m2
twice daily 500mg/m2
twice daily —
Applic able if
capecitabine was 
escalated to 
1,250 mg/m2BID 
daily in study 
124441,250 mg/m2
twice daily1,000 mg/m2
twice daily 750mg/m2
twice daily 500mg/m2
twice daily 
4.5.2.3.2  Dose modification for hematologic toxicities
In general, doses of soraf enib shoul d not be reduced for hematologic events, except for Grade 
4 hematologic toxicities.  Any  subject exper iencing an y of the following hematologic 
toxicities should have capecitabine therap y held until the toxicity  has resolved to Grade 1 or 
less.
Absolute neu trophil count < 1,000/mm3 (≥ Grade 3) for > 7 day s and/or febrile 
neutropenia.
Platelet count < 50,000 /mm3 ( ≥ Grade 3).
At the re -start of capecitabine following these toxicities, the dose of capecitabine should be 
reduced b y at least one level ( see Table 4-7and Table 4-8).  Additional dose reductions may  
occur as needed in subsequent cy cles.  If a subject requires dose reduction below capecitabine 
500mg/m2 twice dail y or sorafenib/placebo 200 mg twice da ily, eve ryother day , study  drug 
must be permanentl y discontinued.
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 75of 147
If the described hematologic toxicity  persist s for more than 21day s, the subject should 
discontinue capecitabine treatment and, therefore, also sorafenib .  
Dose modifications of capecitabi ne and s orafenib for hematologic toxicities are out lined in 
Table 4-14 and Table 4 -15.
Granulocy te colony  stimul ating factor and ery thropoietic growth factors should not be 
administered as proph ylaxis may  be used.  The d oseof capecitabine must be reduced by two 
dose levels with the first episode of febril e neutropenia. 
Table 4-14: Dose Modifications for Hematolog ic Toxicities: Neutropenia and A nemia
Toxicity ANC
(x109/L)Hemoglobin 
(g/dL)Capecitabine Sorafenib
Grade 1 1.5 < LLN –10.0 No change No chang e
Grade 2 1.0  to < 1.5 < 10.0 –8.0 No change No change
Grade 3a0.5  to < 1.0 < 8.0 Delay drug until 
toxicity has resolved to 
Grade 2 or less, then 
reduce by one dose 
levelNo change
Grade 4a< 0.5 Life-
threatening 
consequence; 
urgent 
intervent ion 
indicatedDelay drug until 
toxicity has resolved to 
Grade 2 or less, then 
reduce by two dose 
levelsDelay drug until 
toxicity has resolved to 
Grade 2 or less, then 
reduce by one dose 
level
Febrile 
Neutropeni a— — Delay drug until 
toxicity has resolved
(neutropenia to 
Grade 1 or less and 
fever resolved) , then 
reduce by two dose 
levelsDelay drug until 
toxicity has resolved 
(neutropenia 
resolved to Grade 1 
or less and fever 
resolved), then 
reduce by one dose 
level
ANC=Absolute neutrophil count
a:  For a nANC of less than 1 x 109/L (≥ Grade 3) fo r > 7 days, drug should be held until 
toxicity has resolved t o Grade 1 or less.
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 76of 147
Table 4-15: Dose Modifications for Hematologic Toxicities: Thrombocytopenia
Toxicity Platelets    
(x 109/L)Capecitabine Sorafenib
Grade 1 ≥75 No change No change
Grade 2 50 to < 75 First occurrence, delay drug until toxicity 
has resolved to Grade 1 or less, restart 
at same dose. On subsequent 
occurrences, delay drug until toxicity has 
resolved to Grade 1 or less, then reduce 
by one dose level.No cha nge
Grade 3 25to < 50 Delay drug until toxicity has resolved to 
Grade 1 o r less, then reduce by one 
dose levelNo change
Grade 4 < 25 Delay drug until toxicity has resolved to 
Grade 1 or less, then reduce by two 
dose levelsDelay drug until toxicity
has resolved to Grade 1 
or less, then reduce by 
one dose level
4.5.2.3.3  D ose modification for non -hematologic toxicities
Dose modification for toxicities common to both sorafenib and capecitabine
Dermatologic toxicities (eg, HFSR, rash), gastrointesti nal toxicities (e g, diarrhea), and fatigue 
are common to both sorafenib and ca pecitabine.  Therefore, because it may  not be possible to 
identify  the causative agent should these events present in this trial, a pragmatic approach to 
dose adjustments has bee n taken to ensure subject safet y. 
Hand Foot Skin Reaction
Subjects experienci ng HFSR should have their signs and s ymptoms graded according to
Table 4-16.
Subjects with discomfort due to HFSR should be treated with topical emollients, low -potency  
topical steroids, or urea -containing creams. 
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 77of 147
Table 4-16:  Grading for Hand -Foot Skin R eaction
Grade 1 Grade 2 Grade 3
Palmar -plantar 
erythrodysesthesia 
syndromeMinimal skin 
changes or 
dermatitis 
(eg,erythem a, 
edem a, or 
hyperkeratosis
) without painSkin change s 
(eg,peeling, 
blisters  
bleeding, 
edem a, or 
hyperkeratosi
s) with pain; 
limiting 
instrumental 
activities of 
daily living 
(ADL)Severe skin 
changes (eg, 
peeling, 
blisters, 
bleeding, 
edem a, or 
hyperkeratosis
) with pain; 
limiting self-
care ADL
Further 
descr iption / 
examples of 
skin changesNumbness, 
dysesthesia/pa
resthesia, 
tingling,
painless 
swelling, or 
erythema of 
the hands 
and/or feetPainful 
erythema and 
swelling of 
the hands 
and/or feetMoist 
desquamation, 
ulceration, 
blistering, or 
severe pain of 
the hands 
and/or feet
Effect on 
activitiesDoes not 
disrupt normal 
activitiesLimiting 
instrumental 
activities of 
daily life 
(eg,preparin
g meals, 
shopping for 
groceries or 
clothes, using 
the 
telephone, 
managing 
money)Limiting self -
care activities 
of daily l ife 
(eg, bathing,
dressing and 
undressing, 
feeding self, 
using the 
toilet, tak ing
medications) 
and not 
bedridden
a:  Palmar -plantar erythrodysesthesia syndrome is a disorder characterized by redness, marked 
discomfort, swelling, and tingling in the palms of hands or the s oles of the feet.
The dose -modification schedule outlined b elow and in Table 4-17 should be followed as 
appropriate based on (i) the grade of the toxicity (ies), (ii) the incidences of skin toxicity  
(including rash and HFSR), gastrointestinal toxicity , and fatigue, and (iii) the cy cle of 
treatment. 
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 78of 147
All dose modifi cations will follow the predefined dose levels presented in Table 4-12 and 
Table 4-13 (Section 4.5.2.3.1 ). 
General guidelines for dose modification for toxicities common to both
sorafenib and ca pecitabine
Grade 1: If any dermatologic toxicities, gastroin testinal 
toxicities or fatigue occur at grade 1, maintain doses 
of capecitabine and sorafenib/placebo.  No dose 
modification is required for an y occurrence of Grade 
1 fatigue, de rmatologic toxici ty or gastrointestinal 
toxicity .  The investigator should use symptomatic 
treatment to alleviate the toxicity .
Grade 2 or 
Grade 3:If dermatologic toxicities, gastrointestinal toxicities, 
or fatigue occur at Grade 2 or Grade 3, both drugs
(ie,capecitabin e and sorafenib) should be held until 
the toxicity  resolves t o Grade 1 or less. 
The algorithm in Table 4 -10 should be followed for 
dose modifications when re- starting study  treatment.  
This algori thm should also be used for each 
recurrenc e of these toxici ties to determine which 
drug (ie, capecitabine or sorafenib) should be 
reduced.  Actions to be taken at each occurrence are 
outlined below.
At the first occurrence of Grade 2 or Grade 3 
fatigue, de rmatologic toxicity , and/or 
gastrointestin al toxicity , the dose of capecitabine 
should be reduced b y one dose level when restarting 
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 79of 147
study  treatment (see Table 4 -6).  Sorafenib should 
be restarted at the same dose a s prior to the onset of 
the event(s).
At th e second occurrence of Grade 2 or Grade 3
fatigue, dermato logic toxicity , and/or 
gastrointestinal toxicity , the dose of
sorafenib/placebo should be reduced b y one dose 
level when restarting study  treatment (see Table 4-
5).  Capecitabine should be restarted at the same 
dose as prior to the onset o f the event(s).
As a general rule, at an y subsequent occurrence of 
Grade 2 or Grade 3 fatigue, dermatologic toxicity, 
and/or gastr ointestinal toxicity , if the last dose 
modification was made for sorafenib/placebo, 
sorafenib/placebo should be restarted at t he same 
dose as p rior to the onset of the event(s), and the 
dose of capecitabi ne should be reduced by  one dose 
level.  If, on the other hand, the last dose 
modification was made for capecitabine, 
capecitabine should be restarted at the same dose as 
prior t o the onset of th e event(s), and the dose 
sorafenib/placebo should be reduce b y one dose 
level.  
Subjects who continue to experie nce toxicity  and 
require a dose reduction below the lowest dose level 
of capecitabine (500 mg/m2twice daily ) or 
Integrated Clinic al Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 80of 147
sorafenib/ pl acebo (200 mg/1 placebo tablet twice 
daily  every  other day ) must discontinue study  drug.
Grade 4: Grade 4 toxicities require bo th study  drugs to be 
discontinued permanently.
Integrated Clinical Study Protocol Amend ment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 81of 147
Table 4-17:  Recommended Dose Modifi cations for Fatigue, Dermatologic Toxicit ies and/or GI Tox icities
Grade 1
No interruption of study  drugs or dose redu ctions of stud y drugs are required for Grade -1 adver se events.
Grade 2 or Grade 3 -FIRST occurrence including occurrences in study  12444
If dose at onset of event is: Then: When event resolv es, resume treatment at:
Sorafenib 200 mg/1 tablet in the am
and 400 mg/ 2 tablets in the 
pm 
ORa
400 mg/ 2 tabl ets twice daily Hold both 
sorafenib and 
capecitabine until 
the AE has 
resolved to 
Grade 1 or less 
then resume 
treatment as 
directed.bSorafeni b
Same dose 
as prior to 
event200 mg/1 tablet in the am 
and 4 00mg/ 2 tablets in 
the pm 
ORa
400 mg/2 tablets twi ce daily 
Capecitab
ine1,000 mg/m2 twice daily 
ORa
1,250 mg/m2 twice dailyCapecit abine
Reduce dose750 mg/m2 twice daily
ORa
1,000 mg/m2 twice daily
Grade 2 or Grade 3 -SECOND occurrence includin g occurrences in study  12444
If dose at onset of ev ent is: Then: When event resolves, resume treatment at:
Sorafenib 200 mg/1 tablet in the am 
and 400 mg/ 2 tablets in the 
pm, daily
ORa
400 mg/ 2 tablets twice dailyHold both 
sorafenib and 
capecitabine 
until the AE has 
resolved to 
Grade 1 or less 
then res ume 
treatment as 
directed.bSorafenib
Reduce dose200 mg/1 tablet twice daily
ORa
200mg/1 tablet in the am 
and 400 mg/ 2 tabl ets in the 
pm, da ily
Capecitab
ine750 mg/m2 twice daily
ORa
1,000 mg/m2 twice dailyCapecitabine
Same dose 
as prior to 
event750mg/m2 twice daily
ORa
1,000 mg/m2 twice daily
a:  The dose at which study drug is resumed is based on the dose being admini stered at the ons et of the AE and must follow the predefined dose levels as 
specified in Table 4 -12(sorafenib) and Table 4 -13(capecitabine).
b:  Interruption in administration of either study drug for more than 21 days requires permanent discontinuation o f that study drug .
Integrated Clinical Study Protocol Amend ment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 82of 147
Table 6 -10:  Recommended Dose Modifications for Fatigue, Dermatologic Toxicities and/or GI Toxicities (continued)
Grade 2 or Grade 3 –THIRD and all SUBSEQUENT occurrences including occurrences in 12444
If dose at onset of event is: Then: When event resolves, resume treatment at:
Sorafenib 200 mg/ 1 tablet twice daily
ORa
200 mg/ 1 tablet in the am 
and 400 mg/ 2 tablets in the 
pm, dailyHold both 
sorafenib 
and 
capecitabine 
until the AE 
has r esolved 
to Grade 1 
or less then 
resume 
treatment as 
direct ed.bSorafenib
Same dose 
as prior to 
event200 mg/ 1 tablet t wice 
daily
ORa
200 mg/ 1 tablet in the am 
and 400 mg/ 2 tablets in 
the pm, daily
Capecitabi
ne750 mg/m2twice daily
ORa
1,000 mg/m2twice dailyCapecitabine
Reduce dose500 m g/m2 twice daily
ORa
750 mg/m2 twice daily
Sorafenib 200 mg/ 1 tablet twic e daily
ORa
200 mg/ 1 tablet in the am 
and 400 mg/ 2 tablets in the 
pm, dailyHold both 
sorafenib 
and 
capecitabine 
until the AE 
has resol ved 
to Grade 1 
or less then 
resume 
treatm ent as 
directed.bSorafenib
Reduce dose200 mg/ 1 tablet twice 
daily, every ot her day
ORa
200 mg/ 1 tablet twice 
daily
Capecitab i
ne500 mg/m2twice daily
ORa
750 mg/m2twice dailyCapecitabine
Same dose 
as prior to 
event500 mg/m2 twice daily
ORa
750 m g/m2 twice daily
Sorafenib 200 mg/ 1 tablet twice daily Hold both 
sorafeni b 
and 
capecitabine 
until the AE 
has resolved 
to Grad e 1 
or less then 
resume 
treatment as Sorafenib
Same dose 
as prior to 
event200 mg/ 1 tablet twice 
daily 
Capecita bi
ne750 mg/m2twice daily Capecitabine
Reduce dose 500 mg/m2 twice daily
Integrated Clinical Study Protocol Amend ment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 83of 147
directed.b
Sorafenib 200 mg/ 1 tablet twice daily, 
every othe r day Hold both 
sorafenib 
and 
capecitabine 
until the AE 
has resolved 
to Grade 1 
or less then 
resume 
treatment as 
directed.bSorafenib
Same dos e 
as prior to 
event200 mg/ 1 tablet twice 
daily, every other day
Capecitabi
ne750 mg/m2twice daily Capecitab ine
Reduce dose 500 mg/m2 twice daily
a:  The dose at which study drug is resumed is based on the dose being administered a t the onset of th e AE and must follow the predefined dose 
levels as specified inTable 4 -12(sorafenib) and Table 4 -13(capecitabi ne).
b:  Interruption in administration of either study drug for more than 21 days re quires permanent discontinuation of that study drug.
Table 6 -10:  Recommended Dose Modifications for Fatigue, Dermatologic Toxicities and/or GI Toxicities (continued)
Sorafenib 200 mg/ 1 tablet twice daily, 
every other dayDiscontinue both 
drugs 
permanently —
Capecitabi
ne500 mg/m2twice daily
Grade 4 toxicities require both study drugs to be discontinued per manently.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 84of 147
4.5.2.3.4  Dose modification and managem ent of sorafenib -specific toxicities
Sorafenib dose modifications or delay s will not impact capecitabine therapy.  Subjects who 
require a delay or dose modification of sorafenib/placebo should continue to receive 
capecitabine as scheduled.
Dose modificatio n and management of sorafenib- specific toxicities should follow Section 
4.5.2.1 (Sora fenib monotherap y)
4.5.2.3.5  Dose modifi cation and manage ment of capecitabine -specific toxicities 
If the following to xicities occur, they  will be deemed to be primaril y related to capecitabine.  
Such toxicities, therefore, warrant specific dose modificat ions for capecitabine only  as 
described h ere and in Table 4-18. 
Subjects who require a delay  or dose modification of c apecitabine should continue to receive 
sorafenib as scheduled.
1) Stomatitis (Grade 2 or higher)
If Grade 2 or 3 stomatitis occurs, administration of capecitabine should be immediately  
interrupted until the event resolves to Grade 1 or less.  The subject should be treated 
symptomaticall y.  Subsequent doses of capecitabine should be administered in accordance 
with the algorithm in Table 4 -18.
2) C ardiac toxicity
Subjects with cardiac tox icity greater tha n Grade 2, which is attributable to capecitabine, will 
be per manently  discontinued from capecitabine therapy  and withdrawn from study  treatment.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 85of 147
3)Dihydropyrimidine dehydrogenase deficiency
If a subje ct develops clinical manifestations consi stent with suspec ted DHPD deficiency , 
including Grade 3 or 4 neutropenia, muco sitis, diarrhea, and/or encephalopathy , within the 
first or second cy cle of study  treatment, the subject should be tested for DHPD levels or 
genetic pol ymorphisms if such testing is locall y avail able.  If DHPD deficiency  is confirmed, 
the subject should be permanently  discontinued from capecitabine and with drawn from the 
trial.  If such testing is not available and DHPD deficiency  is suspec ted, the subject should be 
permanentl y discontinued from c apecitabine and withdrawn from study  treatment.
Table 4-18: Dose Modification for Stomatitis A ssociated With Ca pecitabine
Grade 2 Grade 3 Grade 4
First occurrence Interrupt treatment until 
resolved to Grade 0 -1, then 
continue at same dose with 
prophyl axis where possible.Interrupt treatment until 
resolved to Gr ade 0 -1, 
then continue at 75% of 
the original dose.Discontinue 
permanently.
Second 
occurrenceInterrupt treatment until 
resolved to Gra de 0-1, then 
continue at 75% of the 
original dose.Interru pt treatment until 
resolved to Grade 0 -1, 
then continue at 50 % of 
the original dose.—
Third 
occurrenceInterrup t treatment until 
resolved to Grade 0 -1, then 
continue at 50% of the 
original dose.Discontinue permanently. —
Fourth 
occurre nceDiscontinue p ermanently. — —
Note: For Grade -1 toxicity, maintain current dose of capecitabine.  No dose interruption or 
modification is required.
Occurrences should include events in study 12444
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 86of 147
4.5.2.3.6  D ose modification for other non -hematologic toxicities (exc luding fatigue, 
dermatologic toxicities, gastrointestinal toxicities, hypertension and toxicities 
attributable to capecitabine)
For other non -hematologic toxicities (excluding fatigue, dermatologic toxicities, 
gastrointestinal toxicities, hy pertension and toxicities attributable to capecitabine), dose 
modifications are to be handled as outlined in Table 4 -19. For the toxicities alopecia, altered 
taste, and nail changes, which are considered unlikely  to become serious or life threatening, 
treatment can be co ntinued at the same dose without reduction or interruption.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 87of 147
Table 4-19:  Dose Modification for Other Non- Hemat ologic Toxicities (Excluding Fatigue, Dermatologic Toxicities, 
Gastrointestinal Toxic ities, Hypertension and Toxicities A ttributable to Capecit abine)
Toxicity 
GradeOccurrenceSorafenib Capecitabine
Dose 
InterruptionDose 
ReductionDose 
InterruptionDose 
Reduction
Grade 1 Any None None None None
Grade 2 First None None Delay until 
resolved to 
Grade 1 or 
lessResume at 
full dose
Subsequent None None Delay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,b
Grade 3 Any Delay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,bDelay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,b
Grade 4 Any Discontinue 
study drug— Discontinue 
study drug—
a:  If re cover y is not achieved after 21 days of interruption , study drug should be discontinued. 
b:  Subjects who continue to experience toxicit y and require a dose reduction below the lowest dose level of capecitabine 
(500 mg/m2twice daily) or sorafenib/placebo (200 mg/1 placebo tablet twice daily, every other day ) must discontinue study drug.
Occurrences should include events in study 12444
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 88of 147
Section 4.5.3, Identity of Investigationa l Product(s)
Old text:
Section 4.5.3  Identity of Investigational Product(s)
BAY 43 -9006 will be packed by  the Sponsor and will b
e labeled according to the 
requirements of local law and legislation.…….
New text:
Section 4.5.3  Identity of Investigational Product(s)
4.5.3.1  Sorafenib
BAY 43 -9006 will be packed by  the Sponsor and wi ll be labeled according to the 
requirements of local law and legislation.…….
4.5.3.2  Erlotinib
Erlotinib tablets are manufactured b y Sch wartz Pharma Manufacturing, Inc. for OSI 
Pharmaceuticals, Inc. 
The tablet formulation consists of erlotinib and the ex cipients lactose monohydrate, 
hypromellose, h ydroxypropyl cellulose, magnesium stearate, microcry stalline cellulose, 
sodium starch gl ycolate, sodium laury l sulfate, and titanium dioxide.  The 25 mg, 100 mg, 
and 150 mg strengths are supplied as round white, film-coated, bi -convex tablets with no 
imprint. The active compound of erlotinib is N- (3-ethynylphen yl)-6, 7 -bis(2- methoxy ethox y)-
4-quinazolinamine and its molecular weight is 4 29.90 Daltons.
Supply, packaging, labeling and storage
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 89of 147
The erlotinib tablets will be supplied in high -density , polyethylene bottle s of 30 tablets each.  
The bottles will have a tamper- evident seal and a child -resist ant cap.  Each bottle of erlotinib
will h ave a 1 -panel sta ndard label or booklet label affixed.  For the 100 mg and 150 mg 
erlotinib doses, two bottles will be further pac kaged into a subject pack with a 2- panel 
standard label or booklet label affixed.  Fo r the 50 mg erlotinib dose, four bottles of erlotinib 
25 m g tablets will be further packaged into a subject pack with a 2-panel standard label or 
booklet label affixed.  O ne panel of the label will be permanently  attached to the subject pack 
while the othe r portion will be a tear- off section that will be appended to the dispensing 
documentation. This label will contain the study  ID, sponsor ID, contents, directions for use,
storage requirements, batch, and investigational use statement as well as spaces to record the 
subject number and date dispen sed. The label wi ll also include any  other text as required by  
local law and l egislation. Each subject pack label will also have a unique pack number.  The 
labels on the bottles within the pack will have the same pa ck number.  The labels will not 
contain a ny unblinding inf ormation. Erlotinib must be stored at room temperature and no t 
above 25°C (77°F).
Once the stud y medication has b een received, it must be stored in a dry , secure location (ie, 
locked cabinet) accessible only  to authorized staff.  
The stud y drug must be used exclusively  for the investigation specified in this protoc ol.  The 
investigative site must acknowledge receipt of drug supplies.  Generally , acknowledgement 
for this study  will be done using the IVRS/I WRS sy stem.  The confirmation of re ceipt sent by  
theIVRS/I WRS sy stem must be printed and filed appropriatel y in the investigative site file.  
Occasionall y, the IVRS /IWRS may  not be available.  The site will be instructed on using the 
Dispatch Order Form for acknowledgment in that situation .  The CRA will i nstruct the site on 
how to sign the Dispatch Order Form and r eturn it to the shipping unit.
Only  the investigator or a person(s) assigned will be allowed to dispense the study  
medications to the sub ject.  To have complete control over the distribution and use of study  
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 90of 147
drugs, drug accountability must be performed at every  subject visit.  Empty  bottles/blisters 
must be returned to the investigator along with all unused medication.  Drug accountabilit y 
will be performed throughout the study .  Destruction of all unused material (ie, empty  bottles, 
unused tablets, etc) mu st be documented and performed per standard operatin g procedures.  
One cop y of the destruction certificate must be kept in the investigat or’s file and the other 
copy  must be sent to the Bay er rep resentative.  
4.5.3.3  Capecitabine
The chemical name for ca pecitabine is 5' -deoxy -5-fluoro-N- [(penty loxy) carbo nyl]-cytidine 
and its molecular weight is 359.35 daltons. Capecitabine is available i n 150- mg and 500- mg, 
film-coated tablets and is supplied a s biconvex, oblong tablets. The 150 -mg tablet is light 
peach in color and the 500 -mg tablet is peach colored. Eac h tablet contains the following 
inactive ingredients: anhydrous lactose, croscarmello se sodium, hy droxypropyl 
methy lcellulose, microcry stalline cellulose, magnesium stearate and purified water. The film 
coating contains h ydrox ylpropyl meth ylcellulose, talc , titanium dioxide, and sy nthetic yellow 
and red iron oxides.
Sponsor -supplied capeci tabine 150 -mg and 500- mg tablets will be supplied in child -resistant 
blister packs (wallets) of 20 tablets each.  Each blister pack of capecitabine will have a 2 -
panel sta ndard label or booklet label affixed.  One portion of the label will be permanently  
attached to the subject pack while the oth er portion will be a tear -off section that will be 
appended to the dispensing documentation.  This label will contain the trial I D, sponsor ID, 
contents, directions for use, storage requirements, batch, and investig ational use statement as 
well as spaces to record the subj ect number and date dispensed.  The label will also include 
any other text as required by  local law and legislati on.  The capecitabine must be stored in its 
original, immediate package at a temperat ure not above 30°C (86°F).  
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 91of 147
Alternativel y, capecitabine m ay be supplied locally  according to institutional procedures or 
may be supplied by  the sponsor to the site in loc ally available commercial packaging labeled 
for the stud y.  
Section 4.5.5, Selection of Doses in the Study
Old text:
Patient s will receive sorafenib (Nexavar ) 200 mg tablets and should continue receivin g the 
same dose they  were receiving in their origina l trial
New text:
Patients will receive sorafenib (Nexavar ) 200 mg tablets and shou ld continue receiving the 
same dose they  were receiving in their original trial .  Patients receiving sorafenib / erlotinib or 
sorafenib/capecitabine combination should conti nue the same doses as in the originating trial.
Section 4.5.6, Selection and Timing o f Dose for each Subject
Old text:
Sorafen ib (Nexavar) may be decreased in the event of toxicity  based on the Dose 
Modif ication criteria outlined in Section 4.5.2.vvv
New text:
Sorafenib (Nexavar), erlotinib, an d capecitabine may be decreased in the ev ent of toxicity  
based on the Dose Modification criteria outlined in Section 4.5.2.vvv
Section 4.5.8, Prior and Concomitant Therapy
Old text:
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 92of 147
Non-permissible concomitant medication/therapies:
Anticancer chemoth erapy , immunother apy or vaccines during the study.
New text:
Non-permissible concomitant medication/therapies:
Anticancer chemothe rapy, except erlotinib and capecitabine , immunotherapy  or live
vaccines during the st udy.
Section 4.6.1, Efficacy Variables
Old text:
Not appl icable
New text:
Overall Survival (OS)
Section 4.6.2, Safety Variables
Old text:
Primary objective
All observati ons pertinent to the safet y of the study medication will be recorded in the 
patient’s source documents and available at the re quest of the spon sor.
The following data must be reported in the source docume nts:
ECOG performance status
Vital signs (heart rate , blood pressure, temperature)
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 93of 147
………
In addition to the above parameters, the following data must be recorded in the CRF provided 
andthe source documents:
All treatment related adverse events (an y grade)
All adverse events NCI -CTCAE Version 3.0 Grade 3 or hig her (regardless of attribution). 
All Serious Adverse Events, regardless of relatio nship to study  drug
Laboratory  parameters ………..
Reason for termination of study  medication
Date of death, as applicable
New text:
All observations pertinent to the safet y of the study  medication will be recorded in the 
patient’s source documents and availa ble at the request of the sponsor.
The fo llowing data must be reported in the source documents:
Vital signs (heart rate , blood pressure, temperature)
…………
In addition to t he above parameters, the following data must be recorded in the CRF provided 
andthe source documents:
All treatment related a dverse events (an y grade)
All adverse events NCI -CTCAE Version 3.0 Grade 3 or higher (regardless of attribution).  
Study Sites in Japan: In accordance with Japanese regulatory  requirements ALL adverse 
events regardl ess of NCI -CTCAE grade and regardless of attribution are t o be recorded.
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 94of 147
All Serious Adverse Events, regardless of rela tionship to study  drug
ECOG performance status
Labor atory  parameters …………
Reason for termination of study  medication
Section 4.6.3, Asses sment Periods
Old text:
Observations and Measurements
Once enrolled in this program………
Assessment of Adverse Events 
oTreatment related event –all CTC grades
oAny CTC Grad e 3 or 4 event (regardless of attribution)
oAny Serious Adverse Event (regardless of a ttribution)
Study  medication (date dispen sed and returned, number of tablets dispensed and returned)
Laboratory  Assessm ents ………
End of treatment
In addition to the above p arameters, please record the following in the CRF and source 
documents:
The reason for termination 
Date of last dose 
Date of death, if applic able
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 95of 147
Follow up period
If a patient discontinues due to an adv erse event or clinical laboratory  abnormality , the patient 
should be followed until the event resolves, the patient stabilized, or 30 days, whichever is 
shorter………..
New text:
Observations and Me asurements
Once enrolled in this program………
Assessment of Adverse Events 
oTreatment related event –all CTC grade s
oAny CTC Grade 3 or 4 event (regardless of attribution)
Study Sites in Japan: In accordance with Japanese regulatory  requirem ents ALL 
adverse events regardless of NCI -CTCAE grade and regardless of attrib ution are to be 
recorded.
oAny Serious Adverse Event (regardless of attribution)
Study  medication (date dispensed and returned, number of tablets dispensed and returned)
Laborator y Assessments ………
Other variables
oECOG performance status
oSurvival status 
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 96of 147
Endof treatment
In addition to the above parameters, please record the following in the CRF and source 
documents:
The reason for termination 
Date of last dose 
Survival status (de ad or alive and d ate of death or date of last contact)
Follow up period
All su bjects will be followed for survival. Assessment of survival status will be performed 
approximately  every  3 months in the follow -up period.
If a patient discontinues due to an ad verse event or cl inical laboratory  abnormality , the patient 
should be followed until the event resolves, the patient stabilized, o r 30days, whichever is 
shorter……..
Section 4.6.4, Drug Concentration Measurements
Old text:
Section 4.6.4, Drug Concentration Measurements
Notapplicable
New text: 
There is no new text; this section was deleted
Section 5.1, Ethics Committee (EC) or Insti tutional Review Board (IRB)
Old text:
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 97of 147
…….. .  When necessary , an extension, amendment or renewal of the Ethics Committee 
appro val must be obtained and also forwarded to the Sponsor.  The Ethics Committees supply  
to the Sponsor, upon request, a list of the Ethics Committee members involved in the vote and 
a statement to confirm that the Eth ics Committee is organized and operates a ccording to GCP 
and applicable laws and regulations.
New text:
……  When neces sary, an extension, amendment or renewal of the Ethi cs Committee 
approval must be obtained and also forwarded to the Sponsor.  The Ethics Committees or the 
head of the center for sites in Japan must supply  to the Sponsor, upon request, a list of the 
Ethics Committee members involved in the vote and a statem ent to confirm that the Ethics 
Committee is organized and operates according to GCP a nd applicable laws and regulations.
Secti on 6.1, Statistic al and Analytical Plans
Old text:
At the time that the last patient last visit occurs, a summary of demograph y, adverse events 
(including serious), laboratory  data andreasons for termination of tr eatment will be provided 
in the form of a written report. Later on information on overall survival may be provided .
New text:
At the time that the last patient last visit occurs, descriptive anal ysesof demography , adverse 
events (including serious), labo ratory  data, reasons for termination of t reatment, duration of 
treatment ,and overall survival will be provided in the form of a written report. 
Overall survival (OS) wil lbe measured from the date of randomization /date of enrollmentgg
in the originating trial until the dat e of death due to any  cause. Ifa subje ct is still alive at the 
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 98of 147
date of database cutoff , the subject will be censored at the date of the last contact (l ast time 
the subject was known to be alive) . Subgroup analy ses may be performed, if n ecessary .
gg: Date of enrollment will be used f orcases in which the o riginating trial was not randomized.
Section 7.2, Adverse Event Monitoring
Old text:
….Adverse event s should be assessed in terms of their seriousness, severity  and relationship 
to stud y medication. 
New text:
………  Adverse events should be as sessed in terms of their seriousness, severit y and 
relationsh ip to study  medication. Adequate medical care will b e provided to the subjects for 
any adverse events, and the events will be followed up until resolution or stabilization.
Secti on 7.3.2, Serious Adverse Event 
Old text:
Hospitalization:   Any  adverse even t leading to hospitalization or prolongation of 
hosp
italization will be considered as Serious, UNLESS at least one of the following 
exceptions is met:
 The admission results in a hospital stay  of less than 12 hours
OR……
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 99of 147
New text:
Hospitalization :  Any adve rse event leading to hospitalization or prolongation of 
hospitalization will be considered as Serious, UNLESS at least one of the followi ng 
exceptions is met:
 The admission resul ts in a hospital stay  of less than 12 hours (because of local 
regulatory  requi rements, this exception is not applicable to Japan ).
OR……
Section 7.3.3, Unexpected Adverse Event 
Old text:
……Also, reports which add s ignificant information on specificit y or severity  of a kno wn, 
alread y documented adverse event constitute unexpected ad verse events.
New text:
……  Also, reports which add significant information on specificity  or severity  of a known, 
alread y documented ad verse event constitute unexpected adverse events. 
The expe ctedness of 
AEs will be determined by the Sponsor according t o the applicable reference document and 
according to all local regulations.
Section 7.3.6, Adverse Event Documentation
Old text:
All tre atment related adverse events or adverse events NCI -CTCAE Version 3.0 Grade 3 or 
higher (regardless of attribution) occ urring after the subject has signed the informed con sent 
must be fully  recorded in the subject’s case record form.
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 100of 147
Documentation must be supported b y an entr y in the subject’s fi le……….
New text:
All treatment related adverse events or adverse events NCI -CTCAE Version 3.0 Grade 3 or 
higher (regardless of att ribution) occurring after the subject has signed the informed consent 
must be fully  recorded in the subject’s case record form.
Study Sites in Japan: In accordance with Japanese regulatory  requirements AL L adverse 
events regardless of NCI- CTCAE grade and r egardless of attribution are to be recorded.
Documentation must be supported b y an en try in the subject’s file………..
Section 11, Appendices 
Oldtext:
Activity Visit 1 Minimum 
Every
8 weeksEnd of 
Treatme nt
Demography a, b…………. X
ECOG performance X X X
Adverse events a  …………………… … … …
Laboratory evaluations a  ………………….. … … …
Dispe nse/return sorafenib aX X X
Reason for termination of tr eatment aX
Date of death, as applicable aX
Concomitan t medications X X X
aRecord these data in the CRF and source documents.
bIncludes …...
cFor anticoagulated patients only
New text:
Activity Visit 1 Minimum 
Every
8 weeksEnd of 
Treatment
Demography a, b…………… X
ECOG performanceaX X X
Survival status (dead or alive, date of death or X Xd
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 101of 147
date of last contact, as applicable)
Adverse events a  …………………… … … …
Laboratory evaluati ons a  ………………….. … … …
Dispense/return s orafenib (and erl otinib or 
capecitabine if applicable)aX X X
Reason for term ination of treatment aX
Concomitant medications X X X
aRecord these data in the CRF and source documents.
bIncludes …...
cFor ant icoagulated patients only
d F or patients in long term foll ow up, survival status is assessed at a minimum of every 3months
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 102of 147
10.4 Amendment 4
10.4.1 Overview of Changes
Modification 1 Change of responsibility for the Study Manager and Medical Expert . 
Contact names for the Study  Manager and Medical Expert were updated on the title page of 
the protocol.   A line was also added for the signature of the Global Clinical L ead.
The protoco
l section affected by  this change is the title page.
Modification 2 Removal of all re ferences to erlotinib.
All references to erlotinib were re moved since none of the subjects that transferred into this 
study were assigned to erlotinib+sorafenib in study  12917 (SEARCH) .  Where entire sections 
were removed, this also changed the section num bering in subsequent sections and tables.
The protocol sec tions affected by  this change are Section 
4.1Study  design and Plan, Section 
4.2.1 Inclusion Criteria, Secti on 4.2.2 Excl usion Criteria, Section 4.5.1 Treatments to be 
Administered, Section 4.5.2.2 Sorafenib and erlotinib combination therap y, Section 4.5.2.2.1
Anti
-rash and Anti- diarrhea Therapies, Section 4.5.2.2 .2Dose Modificat ion for Hand- Foot 
Skin Reaction, Section 4.5.2.2.3 Dose Modif ication for Keratitis, Section 4.5.2.2.4 Dose 
Modifi cation for Interstitial L ung Disease, Section 4.5.3.2 Erlotinib, Section 4.5.5 Selection 
of Doses in the Study , Section 4.5.6 Selection and Timing of Dose for Each Subject and 
Section 4.5.8 Prior and Concom itant Therap y.
Modification 3Clarificati on regarding the 
supply of capecitabine for subjects from 
Study 12444 changing from clinical supply by the sponsor to commercial s upply.
The protocol current language suggest that for those subjects who will be tran sferred from the 
RESILIENCE stud y (12444) and taking a com bination of capecitabine and sorafenib, both 
sorafenib and ca pecitabine will be provided by  the sponsor. However, capecitabine is 
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 103of 147
commerciall y approved for breast cancer and readily available in man y countries including 
generic sources, th e study team prop oses to modify  the protocol to reflect that capecitabine 
willNOT be provided b y the sponsor but should be source d from commercial sources for 
those subjects who are on combination treatment. Only  sorafenib will be provided by  the 
sponsor.
The protocol sec tions affected by  this change are Section 4.1 Study  design and Plan, Section 
4.5.1 and Treatments to be Admi nistered and Section 4.5.3.3 Capecitabine .
Modification 4 Removal of references to placebo in association with sorafenib 
administration in Study 12444 (RESILIENCE).
In Stu dy 12444 (RESILIENCE), subjects received either capecitabine and sorafenib or 
capecit abine and placebo.  I n this protocol, t
hetext as written can be misinterpreted to 
indicate that subjects from Study  12444  received both sorafenib and placebo andnone of the
subjects received sorafenib and placebo in Study  12444 .  This modification remov es the word 
placebo when referring to sub jects in Study  12444 who received sorafenib.
The protocol sections affected b ythis change are Section 
4.5.2.2 Sorafenib and capecitabine 
combination, Section 4.5.2.2.2 Dose modification for hematologic toxicities, 
Section
4.5.2.2.3 Dose modification for non -hematolo gic toxicities, Sectio n 4.5.2.2.4 Dose 
modification and management of sora fenib -specific toxicities and Section 4.5.2.2. 6Dose 
modification for other non
-hemat ologic toxicities (excluding fatigue, der matologic toxicit ies, 
gastrointestinal toxicities, hy pertension and toxicities attributable to capecitabine).
Modification 5Addit ion of TACE to the permissible anticancer chemotherapies in 
Section 4.5.8 Prior and Concomitant Th erapy and addition of guidance on Sorafenib 
dose modification in combination with TACE in Section 4.5.2.3.
One of the changes implemented during Amendment 2 (16 Mar 2011) was t o modify  the 
exclusion criteria to allow patients who were rece iving TACE and so
rafenib in a Bay er 
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 104of 147
sponsored study to participate in the STEP study . This is reflected in protocol Section 4.2.2
(Exclusion criteri a) and in Section 10.2.2 that descr ibes the changes and rationale for the 
amendment. However, Se ction 4.5.8(Prior and Concomitant Therap y) was not modified to 
allow t he concomitant use of TACE and sorafenib and is not in line wit h the intent of 
Amendment 2 and the related text in Section 4.2.2. 
The lack of chang ing Section 4.5.8t o be in line with the other sections of the protocol was an 
unintentional oversi
ght. The study  team issued an administrative letter on 11 Dec 2013 to 
clarify  that since the implementation of Amendment 2, concomitant TACE and sorafenib is 
permissible as per the protocol ( Section 4.2.2 and 10.2.2) . This disc repancy  in Section 4.5.8
is now being corrected in this amendment to r
eflect that TACE is pe rmissible.
Meanwhile, the guidance on Sor afenib dose modif ication in combination with TACE is added 
as the Section 4.5.2.3.
The protocol section affected b y this change areSection 4.5.2.3 Sorafenib and TACE 
combination and Section 4.5.8 Prior and Conc omitant Therap y (Non-permissible concomitant 
medication/therapies) .
Modificati on6 Clarification of which CTC version was used for the grading of liver 
function abnormalities.
Since there are differences between CTC versions in the definitions of severity  grades for
liver function test abnormalities, it was decided to specify  the ve rsion of CTC used as a 
reference for the grading.
The pro tocol section affected b y this change isSection 4.5.2.3 Sorafenib, Table 4-13 and 
Table 4-14.
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 105of 147
10.4.2 Changes to the Protocol Te xt
In this section, all affected protocol sections are detailed; the sequence of sections follows the 
structure of the original pr otocol.  In the display  of modifications, the “old text” refers to the 
protocol versi on preceding this amendment (ie, protocol version 7.0).   Some section numbers 
and table numbers changed from those in t he preceding protocol due to the removal of some 
section detailed in this section.   Deletions are crossed out in the “old text” and addit ions are 
underlined in the “new text” (ie , Amendment 4/ Version 8.0).
Title Page
Old text:
Date
Date
Date
New Text:
Date
Date
Date
PPD
PPD
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 106of 147
Section 4.1, Study Design and Plan
Old te xt: 
The patients in this open -label program will continue receiving single -agent sor afenib 
(Nexavar) , sorafenib and erlotinib combination if transferred from study  12917 (SEARCH),
or sorafenib and capeci tabine combination if transferred from Stud y 12444 ( RESILIENCE) 
at the same dose and schedule as in their original Clinical Trial.
Prior to being dispensed study  medication for this long term ex tension program, patients will 
be req uired to complete their End of Treatment visit in their originating study .  Once the End 
of Treatment visit in the originating stud y is complete, patients will b e required to provide 
informed consent fo r this long term extension program.  Patients will con
tinue with single 
agent sorafenib (Nexavar) , if transferred from Study 12917 (SEARCH), or sorafenib and 
capecitabine if transferred from Study 12444 (RESILIENCE) in this program at the same 
dose and schedule the patient was receiving in their original clin ical trial.
Sorafenib (N exavar) will be provided as 200 mg tablets. Erlotinib will be provided as 
150mg, 100 mg, and 25 mg tablets for patients receiving the so rafenib/erlotinib 
combination and transfe rring from Study 12917 (SEARCH). Capecitabine will be provided
as 150 mg and 500mg tablets for patients receiving the sorafenib/ca pecitabine combination 
and transferring from Study 12444 (RESILIENCE) .
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 107of 147
New text:
The patients in this open -label program will continue receivin g single -agent sorafenib 
(Nexavar) or sorafenib and capecitab ine combination if transferred from Study 12444 
(RES ILIENCE) at the same dose and schedule as in their original Clinical Trial.
Prior to being dispensed study  medication for thi s long term exten sion program, patients will 
be requir ed to complete their End of Treatment visit in their originating study .  Onc e the End 
of Treatment visit in the originating stud y is complete, patients will be r equired to provide 
informed consent for t his long term extension program.  Patients will contin ue with single 
agent sor afenib (Nexavar) or sorafenib and capecitabine if tr
ansferred from Study 12444 
(RESILIENCE) in this program at the same dose and schedule the patient was receiving in 
their origi nal clinical tria l.  
Sorafenib (Nexavar) will be prov ided as 200 mg tablets. Capecitabine is available in many 
countries includin g generic sources and will be commercially supplied as 150 mg and 
500mg tablets for patients receiving the sorafenib/capecitabine combination and 
transferring from Study 12444 (RES ILIENCE) .
Section 4.2.1, Inclusion Criteria
Old text:
Patients who are recei ving concurrent combination with sorafenib (Nexavar) and 
erlotinib in their originati ng Study 12917 (SEARCH) will be eligible.
New text:
None
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 108of 147
Section 4.2.2, Exclusion Criteria
Old text:
Excluded therapi es and medications, previous and concomitant
Concurr ent anti -cancer chemotherap y, except TACE (transarterial chemoembolization) , 
erlotini b,and capecitabine
New text:
Excluded t herapies and medi cations, previous and concomitant
Concurrent anti -cancer chem otherap y, except TACE (transarterial chemoembolization) 
and capecitabine
Section 4.5.1, Treatments to be Administered
Old text:
Sorafen ibwill be supplied as 200 mg tablets. Erlotinib will be supplied as 150 mg, 100, 
and 25 mg tab lets, and capecitabine w ill be provided as 150 mg and 500 mg table ts.  
Patie nts should continue on the same dose as they  were receiving in the patient’s originat ing 
Bayer/Onyx-sponsored Clinical Trial.
New text:
Sorafen ibwill be supplied as 200 mg tablets . Patients should conti nue on the same dose 
as they were receiving in the p atient’s originating Bayer/Onyx -sponsored Clinical Trial.
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 109of 147
Section 4.5.2.2, Sorafenib and erlotinib combination therapy
Old te xt:
4.5.2.2 Soraf enib and erlotinib combination therap y
Doses will be delayed or reduced for clinically significant hematologic an d non -
hematologic toxicities that are related to protocol therapy according to the gu idelines 
shown in Table 4 5andTable 4 6. Dose modifications will follow predefined dose levels .  
Dose adjustments for hematologic toxicity are based on the blood counts o btained in 
preparation for the day of treatment.
Table 4-5:  Dose Modification Levels for Sorafenib
Dose Sorafenib
Starting Dose 400 mg twice daily
-1 400 mg once daily
-2 400 mg every other day
Table4-6:  Dose Modification Levels for Erlotinib
Dose Erlotinib
Starting Dose 150 mg once a day
-1 100 mg once a day
-2 50 mg once a d ay
Except for an event of hypertension, the first agent to dose reduce for the 1st episode of
any toxicity will be erlotinib
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 110of 147
If a subject experiences more than one toxic ity, dose reduction should be according to 
the toxicity with the highest grade 
In th e case of two or more toxicities of the s ame grade, the in vestigator may dose 
reduce according to the toxicity deemed m ost causally related to study treatment
Subjects for whom one agent is held may continue to receive the other agent if all the 
protocol -defined dose modification steps have been taken and, in the opinion of the 
treating investigator , the subject may contin ue to benefit from treatment
Subjects with toxicitie s that are manageable with supportive therapy may not require 
dose reductions (eg, na usea/vomiting may be treated with antieme tics; diarrhea may be 
treated with loperamide rather t han by dose reduction). A subject will be withdrawn 
from the study if he/she fails to recover from a treatment -related toxicity to CTCAE 
Grade 0 -1, or tolerable grade 2 (or within 1 grade of starting values for pre -existing 
laboratory abnormalities) within 30 days, unless the inv estigator and sponsor agree that 
the subject should remain in the study because the investigator believes the subject 
is/may derive benef it from continuing study treatment. 
Table 4-7:  Dose Mod ification Plan for Hematologic Toxici ties
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafenib Erlotinib
Gr 1 Treat on time No change in dose No change in dose
Gr 2 No change
Gr 3* Treat on time
Re-evaluate weekly1stepisode: no change in 
dose1st episode: reduce 
erlotinib to 
level -1 (100 mg once a 
day)
2nd episode: reduce 
sorafenib to   level -1 (400 mg 
once daily)2nd episode: no change to 
above modified dose
3rdepisode: no ch ange to 3rd episode: reduce 
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 111of 147
Table 4-7:  Dose Mod ification Plan for Hematologic Toxici ties
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafenib Erlotinib
above modified dose erlotinib to 
level -2 (50 mg once a day)
4thepisode: reduce sorafe nib
to level - 2 (400 mg every other 
day)4th episode : no change to 
above modified dose
Gr 4* Holdaboth agents 
until <Gr 2
Re-evaluate w eekly1stepisode: no change in 
dose upon continuation of 
treatment1st episode: reduce 
erlotin ib  to 
level -1 (100 mg once a 
day) upon continuation of 
treatment
2nd e pisode: reduce 
sorafenib to level -1 (400 mg 
once daily) upon continuation 
of treatme nt2nd episode: no change to 
above modifi ed dose upon 
cont inuation of treatment
3rdepisode: no change to 
above modi fied dose upon 
continuation of treatment3rd episode : reduce 
erlotinib to level -2 (50 mg 
once a day) upon 
continuation of treatment
4thepisode: reduce sorafenib
to level - 2 (400 mg every oth er 
day) upon continuation of 
treatmen t4th episode: no change to 
above modified dose upon 
continuation of treatme nt
aIf no recovery after 30 day delay, treatment will be discontinued unless subject is deriving 
clinical benefit.
*Intervent ion/Supportive ca re regarding Gr 3 or 4 Heme toxicity as per investigator.
If more than 4 dose reductions are required, study trea tment will be discontinued.
Table 4 -8:  Dose Modification Plan for non -Hematologic Toxicity except ILD, and Hypertension
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafe nib Erlotinib
Gr 1 Trea t on time No change in dose No change in dose
Gr 2 No change
Gr 3* Holdaboth agents 
until <Gr 21st episode: no change in 
dose up on continuation of 1st episode: reduce 
erlot inibto level -1 
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 112of 147
Table 4 -8:  Dose Modification Plan for non -Hematologic Toxicity except ILD, and Hypertension
NCI CTC 
V3.0Dose Interruption Dose Reduction
Sorafe nib Erlotinib
Initiate supportive 
care
Re-evaluate weeklytreatment (100 mgonce a day) upon 
continuation of treatment 
2nd episode: reduce 
sorafenib to level -1 (400 mg 
once daily) upon continuation 
of treatm ent2nd episode: no change to 
above modif ied dose upon 
continuation of treatment
3rd episode : no change to 
above mod ified dose upon 
continuation of treatment3rd episod e: reduce 
erlotinib to level -2 (50 mg 
once a day) upon 
continuation of treatment 
4th episode: reduce sorafenib
to level - 2 (400 mg every o ther 
day) upon continuation of 
treatm ent 4th episode: no cha nge to 
above modified dose upon 
continuation of trea tment
Gr 4* REMOVE FRO M 
STUDY
a If no recovery after 30 day delay, treatment will be discontinued unless subject is derivi ng 
clinical benef it.
If more than 4 dose reductions, s tudy treatment will be d iscontinued.  Excludes alopecia, 
nausea/vomiting tha t has not been pre -medicated, and diarrhea not treated with supportive 
care/loperamid e.
New text (change in section number ing):
Section 4.5 .2.2 Sorafenib and capecitabine combi nation
Section 4.5.2.2. 1, Anti -rash and Anti -diarrhea Therapies
Old text:
4.5.2.2.1 Anti -rash and Anti -diarrhea Therapies
Integrated Clinical Study Protocol Amen dment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 113of 147
Skin rash or dermatosis has been obser ved in many subjects during treatment wit h 
erlotinib.  No clinical trials have formally evaluated treatments for rash i nduced by 
erlotinib, and there are currently no evid ence -based recommendations for its management. 
Subjects who develop a mild rash char acterized by pustules or raised, red area s may be 
treated with topical therapy, such as cortico steroids.  If the rash i s more severe or there is 
indication of secondary in fection, topical clindamycin or tetracycline, or oral minocycline
may be used at the discretion of the investigator.  (NOTE:  minocycline is kn own to 
interfere with anticoagulants and oral contraceptives.   Therefore, subjects treated with 
minocycline who are taking anticoagulants and/or oral contraceptives should be monitored 
accordingly).   Guidance concerning modification of stu dy drug dosing is provided inTable 
4-8.
Because the pa thology of such a rash i s not related to acne pathology, retinoids and other
acne medications, such as benzoyl peroxide, are not recommended, because these agent s 
are more likely to exacerbate the rash due to their dryi ng effects on the skin.  
Anti-diarrh ea medications may be in troduced if symptoms occur.  Previous trials have 
shown that the frequency and severity of diarrhea rarely hindered the administration of
erlotinib and that the diarrhea could be managed with lop eramide.  The recommended dose 
of loperamide is 4 mg at first onset, followed by 2 mg every 2 to 4 hours until th e subject is 
diarrhea- free for 12 hours.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 114of 147
Table 4 -9:  Dose Modification Plan for Hype rtension
GradeDose 
InterruptionDose Re duction Antihyper tensive 
TherapyBlood Pressure 
Monito ringHypertensive NCI 
CTCAE V3 Sorafenib Erlotinib
Gr 1 Treat on time
Initiate 
supportive 
careNo change in 
dose No change in 
dose None Routine Asymptom atic, 
transient, (< 24hrs) 
increase by 
>20mmHg 
(diastol ic) or to 
>150/100 if 
previously WNL ; 
intervention not 
indic ated.
Gr 2 Treat on time
Initiate 
supportive 
careNo change in 
dose No change in 
dose (asymptomatic)
Initiate monotherapy 
(suggest 
dihydropyridine 
calcium -channel 
blocker).(asymptomatic)
Increase frequency 
and monitor (by 
health professional) 
every 2 d ays until 
stabilized.Recurrent or 
persistent 
(>24hrs) or 
symptomatic 
increase by 
>20mmHg 
(diastolic) or to 
>150/100 if 
previously WNL; 
monotherapy may 
be indicated.(symptomatic 
/pers istent)
OR
Diastolic BP 
>110mmHg
Add agent(s): 
Ca++ chann el 
blocker (if not 
already used)
K+ channel opener 
(angiotensin 
blockers), 
Beta -blocker
Thiazide diuretic(symptomatic/ 
persistent)
OR
Diastolic BP 
>110mmHg
Increase frequenc y 
and monitor (by
health professional) 
every 2 days un til 
stabilized.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 115of 147
Table 4 -9:  Dose Modification Plan for Hype rtension
GradeDose 
InterruptionDose Re duction Antihyper tensive 
TherapyBlood Pressure 
Monito ringHypertensive NCI 
CTCAE V3 Sorafenib Erlotinib
Gr 3 Hold both 
agents until 
≤Gr 2
Initiate 
supportive 
care
Re-evaluate 
weekly1stepisode:  
reduce sorafenib 
to level – 1 
(400 mg once 
daily) u pon 
continuation of 
treatment.1stepisod e:  no 
change in dose 
upon 
continuation of 
treatment.Add agent(s): 
Ca++ chan nel 
blocker 
(if not already used) 
K+ channel opene r 
(angiotensin 
blockers) 
Beta -blocker 
Thiazide diureticIncrease frequency 
and mon itor (by 
health professional) 
every 2 day s until 
stabilize d.Requiring more 
than one drug or 
more intensive 
therapy tha n 
previously.
2ndepisode:  no 
change in dose 
upon continuation 
of treatment.2ndepisode: 
reduce erlotinib 
to level – 1 
(100 mg once a
day) upon 
continuation of 
treatment.
3rdepisode: 
reduce sorafenib 
to level – 2 
(400 mg e very 
other day) upon 
continuation of 
treatment. 3rdepisode:  no 
change in dose 
upon 
continuation of 
treatment.
4thepisode:  no 
change in dose 
upon conti nuation 
of treatment.4th episode:  
reduc e erlotinib
to level –2 (50 mg 
once a day) upon 
contin uation of 
treatment.
Gr 4 REMOVE 
FROM  
STUDYLife-threatening 
consequ ences (eg, 
hypertensive 
crisis)
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 116of 147
New text (change in section numbering) :
Section 4.5 .2.2.1 Dose -reduction levels
Section 4.5.2.2.2, Dose Modi fication for Hand -Foot Skin Reaction
Old text:
4.5.2.2.2 Dose Modification for Hand -Foot Skin Reaction
Subjects e xperiencing Hand- Foot Skin Reaction should have their signs and symptoms 
graded accor ding to the following system (seeTable 4 -10). Other skin t oxicities will be 
graded according to CTCAE Version 3.0.
At first occurrence of hand foot skin reaction, independ ent of grade, prompt institution of 
supportive measures such as topical emollients, l ow potency steroids, or urea- containing 
cream should be administered.
Table 4 -10:  Grading for Hand -Foot Skin Reaction
Grade 1 Numbness, dysesthesia/paresthesia, tinglin g, painless swelling or 
erythema of the hands and/or feet and/or discomfort, which do es not 
disrupt normal activities.
Grade 2 Painful erythem a and swelling of the hands and/or fe et and/or 
discomfort aff ecting the subject’s activities. 
Grade 3 Moist de squamation, ulceration, blistering or severe pain of the 
hands and/or feet and/or sev ere discomfort that causes the subject 
tobe unable to wor k or perform activities of daily livi ng.
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 117of 147
Table 4 -11:  Dose Modification Plan for Hand Foot Skin Reaction
NCI C TC 
V3.0Dose 
InterruptionDose Reduction HFSR
NCI CTCAE V3.0 Sorafenib Erlotinib
Gr 1 Treat on time No change of 
dose No change of 
dose Numbness, 
dysesthesia/paresthesi a, 
tingling, painless sw elling 
or erythema of the hands 
and/or feet and/or 
discomfort, which does 
not disrupt normal 
activities.
Gr 2 No change Painful erythe ma and 
swelling of the hands 
and/or feet and/or 
discomfort affecting the 
subject’s activities.
Gr 3 Holdaboth 
agents until 
<Gr 2
Initiate 
supportive 
care
Re-evaluate 
weekly1st episode: no 
change in dose 
upon 
continuation of 
treatment.1st episode: 
redu ce erlotinib
to level - 1 
(100 mg once a 
day) upon 
continua tion of 
treatment.Moist desquamation , 
ulceration, blistering or 
severe pain of the hands 
and/or feet and/or seve re 
discomfort that causes 
the subject to be unable 
to work or perform 
activities of d aily living. 2nd episode: 
reduce soraf enib
to level - 1 
(400 mg once 
daily) upon 
continuation of 
treatment.2nd episo de: no 
change to above 
modified dose 
upon 
continuati on of 
treatment.
3rd episode: no 
change to above 
modified dose 
upon 
continuation of 
treatment.3rd episode: 
reduce erlotin ib
to level - 2 (50 mg 
once a day) upon 
continuation of
treatment.
4th epis ode: 
reduce sorafenib
to level - 2 (400 
mg every othe r 
day) upon 
continuation of 
treatment.4th episode: no 
change to above 
modified dose 
upon 
continuation of 
treatment.
Gr 4 REMOVE 
FROM  
STUDY
a If no recovery after 30 day dela y, treatment will be dis continued unless subject is deriving 
clinical benefi t.
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 118of 147
New text (change in section numbering):
Section 4.5.2.2.2 Dose modification for hematologic toxicities
Section 4.5.2.2.3 , Dose Modificati on for Keratitis
Old text:
4.5.2.2.3 Dose Modification for Ke ratitis
For all grades of suspected keratitis, the e rlotinib dose should be held and supportive 
measures instituted.  Subjects with dry eyes should be advised to use an ocular lu bricant.  
Subject s who continue to wear contact lenses may have an increased r isk of ocular AEs 
(eg, keratitis).  Subjects may con tinue to wear contacts but should discuss this issue with 
their treating oncologist b efore entering the study.  In addition, a ny elective 
ophth almological surgery while the subject is taking study drug mu st first be discussed 
between the investigator and t he Sponsor.
New text (change in section numbering) :
Section 4.5.2.2.3 Dose modificati on for non -hematologic toxicities
Section 4.5.2.2.4, Dose Modification for Interstitial Lung D isease
Old text:
4.5.2.2.4 Dose Modification for Interstitial Lung Disease
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 119of 147
For all grades of suspected interstitial lung disease (ILD), the erlotinib dose should be held 
and supportive measures institut ed.  If ILD is co nfirmed, erlotinib and sorafenib must be 
discontinued permane ntly.  Acute dyspnea or cough may be signs of ILD.  If a subject 
presents with acute dyspnea or cough, interruption of treatment with erl otinib may be 
considered, at the discreti on of the treatin g physician, until resolution of symp toms or until 
ILD can be ruled out.  If a subject presents with symptoms suc h as shortness of breath, 
dyspnea, cough, or fever, a chest X -ray or chest CT and, if needed, additional tests to 
evaluate pul monary function, as clinically indicated, should be co nsidered as part of the 
work up.  If a diagnosis of ILD is confirmed, appropriate treatment measures according to 
best medical practice and local standards shoul d be initiated.
New text (change in secti on numbering) :
Section 4.5.2.2.2 Dose modification and management of sorafenib -specific toxicities
Section 4.5.2.3, Sorafenib and capecitabine combination
Old text:
Doses of capecitabine or sorafenib /placebo may be reduced/interrupted in the setting of an y 
AE that is:
Notcontrolled by optimal supportive car e, or
Not tolerated due to symptomatology, disfigurement, or interference wi th normal daily 
activities, regardless of severity.
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 120of 147
New text:
Section 4.5.2.2 Sorafe nib and capecitabine combination
Doses of capecitabine or sorafenib may be reduced/interrupted in the setting of any AE that 
is:
Not controlled by optimal supportive care, or
Not tolerated due to symptomatology, disfigurement, or interference with normal daily 
activities, regardless of severity.
Section 4.5.2.3, Sorafenib and TACE combination (new section)
New text:
Doses of sorafenib maybe be delayed or reduced for clinic ally significant hematologic and 
non-hematologic toxicities that are related to Soraf enib and TACE combination. 
Dose modifications should take into consideration AEs and dose modi fications already 
occurr ed in Study 12918 (SPACE).
Sorafenib dose modificati on in combination with TACE should follow the sorafenib 
monotherapy section guideline s (section 4.5.2.1) except dose modificat ion for liver fun ction 
test abnormalities. The followi ng tables (Table 4–13 an d Table 4 –14) illustrate dose 
reductions and interru ptions of Sorafenib if ALT or AST increase to CTC Grade 3 or 4 
within 72 hours post -
TACE along with the instruction for dose r e-escalation foll owing dose 
reduction for TACE related liver function test abnormalities. 
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 121of 147
Table 4 -13: Criteria for Dose Reduction and Dose Interruption of Sorafenib if A LT or 
AST Increase to CTC Grade 3 or 4 within 72 hours Post T ACE
Criteria for Dose In terruption and Dose Modification of Sorafenib if ALT/AST increased to CTC 
Grad e 3 within 72 hours post TACE
DURATION of ALT/AST elevation ACTION DOSE MODIFICATION
1 Grade 3  within 72 h post TACE Continue study d rug No
2 Grade 3  persists >1 weeks post TACE Continue st udy drug YES: 
Decrease one dose 
level a
3 Grade 3  persists >2 weeks post TACE Continue study drug YES: 
Decrea se dose further b
4 Grade 3  persists >3 weeks post TACE cSTOP     study drug YES: 
OFF Protocol Therapy
Criteria for Do se Interruption a nd Dose Modification of Sorafenib if ALT/AST increased to CTC
Grade 4 within 72 hours post TACE
DURATION of abn ormal ALT/AST or 
bilirubinACTION DOSE MODIFICATION
5Grade 4 AST or ALT for up to 1 week 
following TACE and biliru bin ≤2x pr e-
TACE valueContinue study drug, 
check ALT/AST, 
bilirubin every 1 -2 daysNo change 
6Grade 4 AST or ALT at any time within 
1 week following TACE and bilirubin 
>2x pre -TACE valueSTOP study drug until 
a.) biliru bin decreased 
to ≤2x pre -TACE v alue, 
and
b.) ALT and AST 
decreased to grade 3 
(check ALT/AST, 
bilirubin every 1 -2 days
)Once bilirubin <2x pre -
TACE value and ALT 
and AST decreased to 
grade 3 or less within 1 
week of TACE, continue 
study drug at 
DECREASED dose (one 
level) aand follow g rade 
3 table above (criteria 3)
7Grade 4 AST or ALT persists >1 week 
and bilirubin remains at ≤ 2 x pre -
TACE valueContinue study drug DEC REASE one dose 
level a and follow grade 
3 table above (criteria 3)
8Grade 4 AST or ALT persists > 1 week 
or bilirubin has not decreased to ≤2x 
pre-TACE value after 1 week STOP study drug OFF Protocol Therapy
a   to 400 mg daily , if pre -TACE dose was fu ll dose (or to 400mg every  other day , if pre -TACE dose was 400 mg daily )
b   to 400 mg every  other day  (or discontinue, if pre -TACE dose was 400 mg dai ly)
c   if more than 2 dose reductions are required, patient is off protocol therapy
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 122of 147
Table 4 –14: Post -TACE Sor afenib Dose Re -Escalation Scheme
CAUSE FOR DOSE 
REDUCTIONRE-ESCALATE to 
400 mg every other 
day, ifRE-ESCALATE to 
400 mg every day, 
ifRE-ESCALATE to 
400 mg twice dail y, 
if
1 Grade 3  ALT or AST 
persisted >1 week 
post -TACEN/A N/A Grade 2 (or less) 
ALT and AST for at 
least 2 weeks under 
400mg daily
2 Grade 3  AL T or AST 
persisted >2 weeks 
post -TACEN/A Grade 2 (or less) 
ALT and AST for at 
least 2 weeks under 
400mg every other 
dayGrade 2 (or less) 
ALT and AST for at 
least 2 additional 
weeks
under 400mg daily
3 Grade 4  ALT or AST 
persisted >1 week 
and bilirub in 
remained at <2x pre -
TACE valueN/A N/A Grade 2 (or less) 
ALT and AST, and 
bilirubin ≤2x pre -
TACE val ue for at 
least 2 weeks under 
400mg daily
Note: Liver function test abnormalities will be graded using the CTCAE v. 3.0
The rationale for additiona l criteria for ALT/AST increase within 72 ho urs following 
TACE is as follows:
Transarterial Chemoembolization (TACE) induces necrosis of tumor cells and to some 
degree affects normal liver tissue near the tumor tissue targeted by the TACE procedure.  A 
common observation after TACE is a transient, r eversible rise of liver enzymes peaking at 
24-36 hours. One previous study confirmed AST and ALT levels increased 1 –3 days after 
embolization and normalized to near pre -embolization values 1
-month post procedure.
Therefore, ALT/AST increases within 72 hours after TACE should be handled with 
different dose modification guidelines, reflecting the duration of Grade 3/4 ALT/AST 
increases as well as bilirubin levels.Note: Liver function test abnormalities will be graded using the CTCA E v. 3.0
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 123of 147
Section 4.5.2.3.2, Dose modification for hematologi c toxicities
Old text:
At the re -start of capecitabine following these toxicities, the dose of capecitabine should be 
reduced by at least one level ( see Table 4 -14 and Table 4-15).  Additional dose reductions 
may occur as needed in subsequent cycles.  If a subject requires dose reduction below 
capec itabine 500 mg/m2 twice daily or sorafenib /placebo 200mg twice daily, every other 
day, study drug must be permanently discontinued.
New text:
Section 4.5.2.2.2 Dose modification for hematologic toxicities
At the re-start of capecitabine following these to xicities, the dose of capecitabine should be 
reduced by at least one level ( seeTable 4 -14 and Table 4-15).  Additional dose reductions 
may occur as needed in subsequent cycles.  If a subject requires dose reduct ion below 
capecitabine 500 mg/m2 twice daily or sorafenib 200 mg twice daily, every other day, study 
drug must be permanently discontinued.
Section 4.5.2.3.3, Dose modification for non -hematologic toxicities
Old text:
General guidelines for dose modificat ion for toxicities common to both 
sorafenib and capecitabine
Grade 1: If any dermatologic toxicities, gastrointestinal toxicities 
or fatigue occur at grade 1, maintain doses of 
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 124of 147
capecitabine and sorafenib/placebo.  No dose 
modification is required for any occurrence of Grade 1 
fatigue, dermatologic toxicity or gastrointestinal toxicity.  
The investigator should use symptomatic treatment to 
alleviate the toxicity.
Grade 2 or Grade 3: If dermatologic toxicities, gastrointestinal toxicities, or 
fatigue occur at Grade 2 or Grade 3, both drugs 
(ie,capec itabine and sorafenib) should be held until the 
toxicity resolves to Grade 1 or less. 
The algorithm in Table 4 -17 should be followed for dose 
modifications when re -starting study treatment.  This 
algorithm shoul d also be used for each recurrence of 
these 
toxicities to determine which drug (ie, capecitabine 
or sorafenib) should be reduced.  Actions to be taken at 
each occurrence are outlined below.
At the first occurrence of Grade 2 or Grade 3 fatigue, 
dermatologi c toxicity, and/or gastrointestinal toxicity , the 
dose of capecitabine should be reduced by one dose level 
when restarting study treatment (see Table 4-13).  
Sorafenib should be restarted at the same dose as prior to 
the onset of the event(s).
At the second occurrence of Grade 2 or Grade 3 fatigue, 
dermatologic toxicity, and/or gastrointestinal toxicity, the 
dose of sorafenib /placebo should be reduced by one dose 
level when restarting study treatment (see Table 4-12).  
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 125of 147
Capecitabine should be restarted at th e same dose as 
prior to the onset of the eve nt(s).
As a general rule, at any subsequent occurrence of Grade 
2 or Grade 3 fatigue, dermatologic toxicity, and/or 
gastrointestinal toxicity, if the last dose modification was 
made for sorafenib /placebo , sorafen ib/placebo should be 
restarted at the same dose as prior to the onset of the 
event(s), and the dose of capecitabine should be reduced 
by one dose level.  If, on the other hand, the last dose 
modification was made for capecitabine, capecitabine 
should be re started at the same dose as prior to the ons et 
of the event(s), and the dose sorafenib /placebo should be 
reduce by one dose level.  
Subjects who continue to experience toxicity and require 
a dose reduction below the lowest dose level of 
capecitabine (500 mg/m2 twice daily) or 
sorafenib/placebo (200 mg/1 placebo tablet twice daily 
every other day) must discontinue study drug.
Grade 4: Grade 4 toxicities require both study drugs to be 
discontinued permanently.
New text:
Section 4.5.2.2.3 Dose modificati on for non -hematologic toxicities
General gu idelines for dose modification for toxicities common to both 
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 126of 147
sorafenib and capecitabine
Grade 1: If any dermatologic toxicities, gastrointestinal toxicities 
or fatigue occur at grade 1, maintain doses of 
capecit abine and sorafenib.  No dose modification i s 
required for any occurrence of Grade 1 fatigue, 
dermatologic toxicity or gastrointestinal toxicity.  The 
investigator should use symptomatic treatment to alleviate 
the toxicity.
Grade 2 or Grade 3: If dermatol ogic toxicities, gastrointestinal toxicities , or 
fatigue occur at Grade 2 or Grade 3, both drugs 
(ie,capecitabine and sorafenib) should be held until the 
toxicity resolves to Grade 1 or less. 
The algorithm in Table 4 -17 should be followed for dose 
modifi cations when re -
starting study treatment.  T his 
algorithm should also be used for each recurrence of 
these toxicities to determine which drug (ie, capecitabine 
or sorafenib) should be reduced.  Actions to be taken at 
each occurrence are outlined below.
At the first occurrence of Grade 2 or Grade 3 f atigue, 
dermatologic toxicity, and/or gastrointestinal toxicity, the 
dose of capecitabine should be reduced by one dose level 
when restarting study treatment (see Table 4-13).  
Sorafenib should be restarted at th e same dose as prior to 
the onset of the eve nt(s).
At the second occurrence of Grade 2 or Grade 3 fatigue, 
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 127of 147
dermatologic toxicity, and/or gastrointestinal toxicity, the 
dose of sorafenib should be reduced by one dose level 
when restarting study treatment (s eeTable 4-12).  
Capecitabine should be restarted at the same dose as 
prior to the onset of the event(s).
As a general rule, at any subsequent occurrence of Grade 
2 or Grade 3 fatigue, dermatologic toxicity, and/or 
gastrointestinal toxicity, if the last do se modification was 
made for sorafenib, sora fenib should be restarted at the 
same dose as prior to the onset of the event(s), and the 
dose of capecitabine should be reduced by one dose level.  
If, on the other hand, the last dose modification was 
made for capecitabine, capecitabine should be restart ed 
at the same dose as prior to the onset of the event(s), and 
the dose sorafenib should be reduce by one dose level.  
Subjects who continue to experience toxicity and require 
a dose reduction below the lowest dose level of 
capecitabine (500 mg/m2 twice d aily) or sorafenib 
(200 mg tablet twice daily every other day) must 
discontinue study drug.
Grade 4: Grade 4 toxicities require both study drugs to be 
discontinued permanently.
Section 4.5.2.3.4, Dose modifi cation and management of sorafenib- specific toxicities
Old text:
Integrated Clinical Stud y Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Vers ion 7.0 Page: 128of 147
Sorafenib dose modifications or delays will not impact capecitabine therapy.  Subjects who 
require a delay or dose modification of sorafenib /placebo should continue to receive 
capecitabine as scheduled.
New text:
Section 4.5.2.2.4 Dose modification and management of sorafenib -specific toxicities
Sorafenib dose modifications or delays will not impact capecitabine therapy.  Subjects who 
require a delay or dose modification of sorafenib should co ntinue to receive capecitabine 
as scheduled.
Section 4.5.2.3.6, Dose modification for other non -hematologic toxicities (excluding 
fatigue, dermatologic toxicities, gastrointestinal toxicities, hypertension and toxicities 
attributable to capecitabine)
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 129of 147
Old text:
Table 4 -19:  Dose Modification for Oth er Non -Hematologic Toxicities (Excluding Fatigue, Dermatologic Toxicities, 
Gastrointestinal Toxicities, Hypertension and Toxicities Attributable to Capecitabine)
Toxicity 
GradeOccurrenceSorafenib Capecitabine
Dose 
InterruptionDose 
ReductionDose 
InterruptionDose 
Reduction
Grade 1 Any None None None None
Grade 2 First None None Delay until 
resolved to 
Grade 1 or 
lessResume 
at full 
dose
Subsequent None None Delay until 
resolved to 
Grade 1 or 
lessReduce
dose by 
one dose 
levela,b
Grade 3 Any Dela y until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,bDelay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,b
Grade 4 Any Discontinue 
study drug— Discontinue 
study drug—
a:  If recovery is not achieved after 21 days of interruption , study drug should be discontinued. 
b:  Subjects who continue to experience toxicity and require a dose reduction below the lowest dose level of 
capecitabine (500 mg/m2twice daily) or sorafenib /placebo (200 mg/1 placebo tablet twice daily, e very other day) must 
discontinue study drug.
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 130of 147
Table 4 -19:  Dose Modification for Oth er Non -Hematologic Toxicities (Excluding Fatigue, Dermatologic Toxicities, 
Gastrointestinal Toxicities, Hypertension and Toxicities Attributable to Capecitabine)
Toxicity 
GradeOccurrenceSorafenib Capecitabine
Dose 
InterruptionDose 
ReductionDose 
InterruptionDose 
Reduction
Occurrences should include events in Study 12444
New text:
Section 4.5.2.2.6 Dose modification for other non -hematologic toxicities (excluding fatigue, dermatologic toxicities, 
gastrointestinal toxicities, hyp ertension and toxicities attributable to capecitabine)
Table 4 -12:  Dose Modification for Other Non- Hematologic Toxicities (Excluding Fatigue, Dermatologic Toxicities, 
Gastrointestinal Toxicities, Hypertension an d Toxicities Attributable to Capecitabine)
Integrated Clinical Study Protocol Amendment 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 131of 147
Toxicity 
GradeOccurrenceSorafenib Capecitabine
Dose 
InterruptionDose 
ReductionDose 
InterruptionDose 
Reduction
Grade 1 Any None None None None
Grade 2 First None None Delay until 
resolved to 
Grade 1 or 
lessResume 
at full 
dose
Subsequent None None Delay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,b
Grade 3 Any Delay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,bDelay until 
resolved to 
Grade 1 or 
lessReduce 
dose by 
one dose 
levela,b
Grade 4 Any Discont inue 
study drug— Discontinue 
study drug—
a:  If recovery is not achieved after 21 days of interruption , study drug should be discontinued. 
b:  Subjects who continue to experience toxicity and require a dose r eduction below the lowest dose level of 
cape citabine (500 mg/m2twice daily) or sorafenib (200 mg tablet twice daily, every other day) must discontinue study 
drug.
Occurrences should include events in Study 12444
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 132of 147
Section 4.5.3.2, Erlotinib
Old text:
4.5.3.2 Erlotinib
Erlotinib tablets are manufac tured by Schwartz Pharma Manufacturing, Inc. for OSI 
Pharmaceuticals, Inc. 
The tablet formulation consists of erlotinib and the excipients lactose monohydrate, 
hypromellose, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, 
sodium starch glycolate, sodium lauryl sulfate, and titanium dioxide.  The 25 mg, 100 mg, 
and 150 mg strengths are supplied as round white, film- coated, bi -convex tablets with no
imprint. The active compound of erlotinib is N-(3-ethynylphenyl) -6, 7- bis(2 -
methoxyet hoxy)-4- quinazolinamine and its molecular weight is 429.90 Daltons.
Supply, packaging, labeling and storage
The erlotinib tablets will be supplied in high -density, polyethylene bottles of 30 tablets each.  
The bottles will have a tamper -evident seal and a child -resistant cap.  Each bottle of
erlotinib will have a 1 -panel standard label or booklet label affixed.  For the 100 mg and 
150 mg erlotinib doses, two bottles will be further packaged into a subject pack wit h a 2 -
panel standard label or booklet label affixed.  For the 50 mg erlotinib dose, four bottles of 
erlotinib 25 mg tablets will be further packaged into a subject pack with a 2 -panel standard 
label or booklet label affixed.  One panel of the label will be permanently attached to the 
subject pack while the other portion will be a tear-off section that will be appended to the 
dispensing documentation. This label will contain the study ID, sponsor ID, contents, 
directions for use, storage requirements, batch, and investigational use statement as well a s 
spaces to record the subject number and date dispensed. The label will also include any 
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 133of 147
other text as required by local law and legislation. Each subject pack label will also have a 
unique pack number.  The lab els on the bottles within the pack will have the same pack 
number.  The labels will not contain any unblinding information. Erlotinib must be stored 
at room temperature and not above 25°C (77°F).
Once the study medication has been received, it must be stored in a dry, secure location (ie, 
locked cabinet) accessible only to authorized staff.  
The study drug must be used exclusively for the investigation specified in this protocol.  
The investigative site must acknowledge receipt of drug supplies.  Generally , 
acknowledgement for this study will be don e using the IVRS/IWRS system.  The 
confirmation of receipt sent by the IVRS/IWRS system must be printed and filed 
appropriately in the investigative site file.  Occasionally, the IVRS/IWRS may not be 
available.  The site will be instructed on using the Dispatch Order Form for 
acknowledgment in that situation.  The CRA will instruct the site on how to sign the 
Dispatch Order Form and return it to the shipping unit.
Only the investigator or a person(s) assigned will be allowed to dispense the study 
medication s to the subject.  To have complete control over the distribution and use of study 
drugs, drug accountability must be performed at every subject visit.  Empty bottles/blisters 
must be returned to the investigator along with all unused medication.  Drug acc ountability 
will be performed throughout the study.  Destruction of all unused material (ie, empty 
bottles, unused tablets, etc) must be documented and performed per standard operating 
procedures.  One copy of the destruction certificate must be kept in th e investigator’s file 
and the other copy must be sent to the Bayer representative.
New text:
None
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 134of 147
Section 4.5.3.3, Capecitabine
Old text:
4.5.3.3 Capecitabine
Sponsor -supplied capecitabine 150- mg and 500- mg tabl ets will be supplied in child-
resistant blis ter packs (wallets) of 20 tablets each.  Each blister pack of capecitabine will 
have a 2- panel standard label or booklet label affixed.  One portion of the label will be 
permanently attached to the subject pack w hile the other portion will be a tear- off se ction 
that will be appended to the dispensing documentation.  This label will contain the trial ID, 
sponsor ID, contents, directions for use, storage requirements, batch, and investigational 
use statement as well as spaces to record the subject number and date dispensed.  The label 
will also include any other text as required by local law and legislation.  The capecitabine 
must be stored in its original, immediate package at a temperature not above 30°C (86°F).  
Alternatively, capecitabine may be supplied locally according to institutional procedures or 
may be supplied by the sponsor to the site in locally available commercial packaging 
labeled for the study
New text:
Capecitabine is commercially approved for brea st cancer and readily available in many 
countries including generic sources. Subjects on treatment with both capecitabine and 
sorafenib at the end of the 12444 RESILIENCE trial who are switched to the STEP study 
will switch to commercial supply capecitabin e. In addition, subjects will continue to re ceive 
sorafenib as clinical supply.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 135of 147
Section 4.5.5, Selection of Doses in the Study
Old text:
Patients will receive sorafenib (Nexavar) 200 mg tablets and should continue receiving the 
same dose they  were receivi ng in their original trial. Patients receiving sorafenib /erlotinib or 
sorafenib/capecitabine combination should continue the same doses as in the originating 
trial.
New text:
Patients will receive sorafenib (Nexavar) 200 mg tablets and should continue rece iving the 
same dose they  were receiving in t heir original trial. Patients receiving sorafenib or 
sorafenib/capecitabine combination should continue the same doses as in the originating 
trial.
Section 4.5.6, Selection and Timing of Dose for Each Subject
Old text:
The patient should continuing receiv ing the same dose they  were receiving in the previous 
trial.  Dose increase bey ond the dose the patient is currentl y receiving is not acceptable.
Sorafenib (Nexavar) , erlotinib, and capecitabine may be decreased in the event of toxicity  
based on the Dose M odification criteria outlined in Section 4.5.2.
New text:
The patient should continuing receiving the same dose they  were receiving in the previous 
trial.  Dose increase bey ond the dose the patient is currentl y receiving is not acceptable.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 136of 147
Sorafenib (Nexav ar)and capecitabine may be decreased in the event of toxicity  based on the 
Dose Modification criteria outlined in Section 4.5.2.
Section 4.5.8, Prior and Concomitant Therapy
Old text:
Non-permissible concomitan t medication/therapies:
Anticancer chemother apy, except erlotinib and capecitabine, immunotherapy  or live
vaccines during the study.
New text:
Non-permissible concomitant medication/therapies:
Anticancer chemotherapy, except TACE and capecitabine, immunoth erapy or live
vaccines during the study.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 137of 147
Section 11.1, Study Flow Chart
Old text:
Activity Visit 1 Minimum 
Every
8 weeksEnd of 
Treatment
Demography a, bX
Pregnancy Test X
Vital signs X X X
ECOG performanceaX X X
Survival status (dead or alive, date of death or 
date of last contact, as a pplicable)X Xd
Adverse events a
All treatment related
All Grade 3 or higher regardless of 
attribution
All serious adverse eventsX
X
XX
X
XX
X
X
Laboratory evaluations a
Hematology (Hgb, RBC, W BC, 
platelets, differential)
CBC (ALT, AST, amylase, lipase)
PT-INR cX
X
XX
X
XX
X
X
Dispense/return sorafenib (and erlotinib or
capecitabine if applicable )aX X X
Reason for termination of treatment aX
Concomitant medications X X X
aRecord these data in the CRF and source documents.
bIncludes originating study number, patient number and date of first sorafenib dose in originating 
study.
cFor anticoagulated patients only
dFor patients in long term follow up, survival status is assessed at a minimum of every 3 months
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 138of 147
New text:
Activity Visit 1 Minimum 
Every
8 weeksEnd of 
Treatment
Demography a, bX
Pregnancy Test X
Vital signs X X X
ECOG performanceaX X X
Survival status (dead or alive, date of death or 
date of last contact, as applicable)X Xd
Adverse events a
All tre atment related
All Grade 3 or higher regardless of 
attribution
All serious adverse eventsX
X
XX
X
XX
X
X
Laboratory evaluations a
Hematology (Hgb, RBC, W BC, 
platelets, differential)
CBC (ALT, AST, amylase, lipase)
PT-INR cX
X
XX
X
XX
X
X
Dispense/return sorafenib (and capecitabine if 
applicable )aX X X
Reason for termination of treatment aX
Concomitant medications X X X
aRecord these data in the CRF and source documents.
bIncludes o riginating study number, patient number and date of first sorafenib dose in originating 
study.
cFor anticoagulated patients only
dFor patients in long term follow up, survival status is assessed at a minimum of every 3 months
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 139of 147
10.5 Amendment 7
Date of amend ment: 15 MAY 2018, v6.0.
10.5.1 Modification 1: Cha
nge of responsibility for Sponsor’s Medical Expert, 
Study Manager, Statistician, Global Clinical Lead and Principal 
Investigator
Description of modification to the title page:
On the title page of the protocol, Sponsor’s address was updated, Sponsor’s addr ess (US 
territory ) was added. Also , the c ontact names for the Study  Manager, Statistician and Global 
Clinical L ead were updated . In addition, the Principal I nvestigator’s contact name and 
address were updated.
Rationale:
Personnel change in study team and Principal Investigator .
List of affected section:
Section Title page –amended .
10.5.2 Modification 2: Overall survival (OS) evaluation removed from the study 
objectives
Description of modifica tion to the study plan:
The overall surviv al(OS) evaluation has been removed from the study  objectives.
Rationale:
Given that the primary  study  objective is to enable patients receiving sorafenib (Nexavar) in a 
completed Bay er/On yx sponsored clinical tria l to continue treatment, the data on OS is n ot  
being utilized for an y analy ses. Therefore, to minimize burden to patients and sites, OS data 
collection at follow up will no longer be performed and OS will be removed as a study  
objective.
List of effected s ections:
Sections 2, 4.6.1, 6.1
10.5.3 Modification 3: Safety visits
Description of modification to the study design and plan:
The p atients should be evaluated b y a stud y physician for safet y at least once every  8 weeks
and more frequently as needed. The protocol allows for a ±7 day window when scheduling 
any visit. Phy sicians can choose to continue to see the patients every  8 weeks in a face to face 
visit. At least every  other visit must be a mandatory on site visit for examination and drug 
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 140of 147
dispensing , with the other visit being either in person or as a phone call. It is at the discretion 
of the investigator based on the patient’s current condition and adverse event profile to 
determine if the next visit will be performe d on site or as a phone visit. Any scheduled phone 
visit is mandatory  and it will be at the discretion of the investigator to decide if that phone 
visit is sufficient. I f the patient needs a ph ysical examination, the visit will be performed on 
site. I f the investigator feels the patient is stable with no new safet y concerns nor new AEs in 
between visits, a phone call with labs, ECOG and review of AEs would be enough .
Rationale:
To lessen the travel burden on patients and enable better compliance at site whi le ensuring 
patient’s safet y.It is at the discretion of the Investigator and based on the patient’s current 
condition to determine if the visit will be performed on site or as a phone call.
The protocol allows f or a±7 day  window when scheduling an y visit .
List of affected sections:
Sections 4.1,4.6.3 , 11.1
10.5.4 Modification 4: Laboratory evaluations
Description of modification to the study design and plan:
The laboratory  evaluations were modified.
Rationale:
To ensure that the laboratory  evaluations were not missed.
List of affected section :
Section 4.1
10.5.5 Modification 5: Follow - up period changed
Descripti onof modification to the study objectives:
FU period was changed from until survival to until 30 day s after last dose of study  drug. 
Overall survival is removed from the objective. 
Rationale:
This would allow some sites with only  patients in survival fol low-up for years to close , and to 
minimize b urden to patients and to enable better compliance at sites.
List of affected sections:
Sections 4.6.3, 11.1
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 141of 147
10.5.6 Modification 6: Editorial changes, corrections and clarifications
Description of modificati on to the study plan / Rationale:
The minor editorial changes are not shown b y footnotes in the body  text.
Cover page added
Minor text revisions and corrections
List of affected sections:
Sections 
1, 2, 3, 4, 4.5.6, 5, 6, 7, 8, 9, 10, 11
10.6 Amendment 8
Date of amendment :26 MAY 2020, v7.0.
10.6.1
Modification 1: Change of responsibility for Sponsor’s Medical Expert, 
Study Manager, Statistician , Medical Expert, and Global Clin ical Lead
Description of modification:
Change of stud y team members on the title page of the protocol ;the Sponsor’s Medical 
Expert’s role isnow filled by  the Clinical Development L eader (CDL) , and the respecti ve 
contact information was updated
. Further , contact names for the Study  Manager, and 
Statistician were updated. In addition, the signature of the Global Clinical Lead was removed 
as this role is now filled by  the CDL.
Rationale:
The r olename and p ersonne lchange in stud y team.
List of affected section :
Section Title page–amended .
10.6.2 Modification 2: Added new eSignature text
Description of modification:
New eSignature text added.
Rationale:
New eSignature process implemented at Bay er.
List of affected section :
Section Title page –amended .
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 142of 147
10.6.3 Modification 3: Added Post-Trial Access Program
Description of modification :
For completeness a dded that , at least in theory , Sorafenib study patients can continue t o 
receive the treatment (study  drug) not only  through a subsequent clinical but also through a 
Post-Trial Access Program or any other mechanism (e.g. local access program).
Ratio nale:
To provide the investigator with information on further potentia l post-study drug suppl y
mechanisms for s orafenib that are without costs to the patients.
List of affected sections :
Sections 1.
10.6.4 Modification 4: Removal of th e instruction s for dose modifications for 
the combination of sorafenib with capecitabine and TACE
Description of modification :
In Section 4.5.2.2
,its subsections and Section 4.5.2.3 the instructions for dose modifications 
for the combination of sorafenib with capecitabine and TACE were removed.
In addition, explaining text as to why sorafenib combination therapy  sections were removed 
was added to Section 4.5.2.2 and 4.5.2.3.
Rat
ionale:
As of Amendment 8 there are no patients receiving combination therap y with capecitabine or 
TACE. The sections were removed to avoid confusion for the remaining patients none of 
whom are receiving capecitabine or TACE.
List of affected sections:
Sections 4.5.2.2, it s sub section sand 4.5.2.3 .
10.6.5 Mod ification 5: Added clar ification for continu ation on study drug
Description of modification :
Added further opt ionsthat can lead to the end of study  treatment in the STEP study These are
the transfer toa Post -Trial -Access Program, another study  or any  other mechanism (e.g. local 
access program )in accordance with local legal without coststo the patient with respect to 
sorafenib .
Rationale:
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 143of 147
To allow phy sicians to stop thestudy  treatment not on ly if the patient is no longer benefi tting 
from the treatment or the treatment becomes commerciall y available /is reimbursed, but also if 
there is one of the following option s available : a Post -Trial -Access Program, another study  or 
any other mechanism (e.g. local access program) in accordance with local legal and 
compliance rules with no cost to the patient with respect to sorafenib .
List of affected section:
Section 2 and 4.1.
10.6.6 Modification 6: Added clarification for ending the study
Description of modification :
Added o ption to end this study  when all patients have t ransi tioned or dis
continued from the 
study .
Ratio nale:
To clarify  when the STEP study  will e nd if an alternative mechanism of continued drug 
supply  is established. 
List of affected sectio n:
Section 4.1.
10.6.7 Modification 7: Added c larif ication on la st pa tient last visit date
Desc ription of modification:
Added clarification on the definition of the end of study .
Rationale:
To define under what circumstances LPLV for this study  will be achieved , which includes 
patients stopp
ing s tudy drug or being switched to receive treat ment through a n alternative 
mechanism of sor afenib supply . 
List of affected section s:
Sections 4.9.
10.6.8 Modification 8: Removed reference to Study Sites in Japan
Description of modific ation :
Removed ref erenc e regarding Japanese regul atory  requirements for Japanese study  sites.
Rationale:
There are no patients on treatment from an y Japanese study sites.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 144of 147
List of af fected sections:
Sections 4.4, 4.5.3.1, 4.6.2, 4.6.3, 5.1, 7.3.2 and7.3.6.
10.6.9 Modification 9: 
Corrected timepoint
Description of modification :
The timepoint of the performance of the analy seswas c orrected, last patient last visit was 
changed to “after the end o f the s tudy”.
Rationale:
For further clarity .
List of affected section :
Section 6.1.
10.6.10 Modification 9: Editorial changes, corrections and clarificat ions
D
escription of modification :
The minor edito
rial changes are not shown b y footnotes in the body  text. In addition to the 
changes summarized above , minor changes were made to cor rect t ypographical errors , and 
add clarit y
.
List of affected sections:
SectionsCover page of the integrated protocol, Glossary  and Abbreviations , 1, 2, 4.1, 4.2, 
4.2.2, 4.5.3.1, 10.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 145of 147
11. Appendices
11.1 Study Flow Chart
ActivityzzzzVisit 1 Minimum Every
8 weeks
(±7 days)aaaaaEnd of 
Treatment
Demographya, bX
Pregnancy Test X
Vital signs X X X
ECOG perform anceaX X X
Survival status (dead or alive, date of de ath o r 
date of last contac t, as applicable)bbbbbX Xd
Adverse eventsa
All treatment related
All Grade 3 or hig her regardless of 
attribution
All serious adverse eventsX
X
XX
X
XX
X
X
Laboratory evaluationsa
Hematology (Hgb, RBC, WBC, 
platele ts, differential)
CBC (AL T, AS T, am ylase, lipase)
PT-INRcX
X
XX
X
XX
X
X
Dispense/return sorafenib (andccccc
capecitabine if applicableddddd)aX X X
Reason for termination of treatmentaX
Concomitant medications X X X
aRecord these data in the CRF and source do cuments.
bInclude s originating study number , patient number and date of first sorafeni bdose in originating 
study.
cFor a nticoagulated patients only
dThelong term follow upperiod is until 30 days after last dose of s tudy drug.eeeee fffff
                                                
zzzz:  The text row regarding date of death was deleted in Amendment 3. See Section 10.3 , Modification 6.
aaaaaThe vis it window  has been modified by Ame ndment 7. See Section 10.5.3 , Modification 3.
bbbbb: The text row  concerning survival was added in Amendment 3. See Section 10.3, Mod ification 1.
cccccReference to erloti nib removed since none of the subj ects that transferred into this study were assigned to 
erlotinib from study 12 917. See Sectio n 10.4, Modification 2.
ddddd: Participation of subjects from the SEAR CH trial (Study 12917) or the RESI LIENCE trial (Study 12444) 
was add ed un der Amendment 3.  See Section 10.3, Modifica tion 5
eeeee:  The table f ootnote regarding assessment of su rviva l was ad ded in Amendment 3. See Section 10.3,
Modification 1.
fffffThe table footnote w as revised to change the FU period to until 30 days after last dose of study drug in 
Amendment 7. See Se ction 10.5.5 , Modi fication 5.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 146of 147
11.2 New York Heart Association Criteria
Functional Capacity
Class I:  Patients with cardiac disease but without res ulting limitation of phy sical 
activity .  Ordinary  physical activity  does not cause undue f atigue, palpitation, 
dyspnea, or angi nal pain .
Class II :  Patients with 
cardiac d isease resulting in slight limitati on of physical 
activity .  They  are comforta ble at rest.  Ordinary  physical activity  results in fatigue, 
palpitations, dy spnea, or anginal pa in.
Class III :  Patients with cardiac disease resulting in marked limita tion of p
hysical 
activity .  They  are comfort able at rest.  Less than ordinary  activity  causes fatigue, 
palpitations, dy spnea, or anginal pain.
Class IV :  Patients with cardiac disease resulting in ability  to carry  on an y physical 
activity  without discomfor t.  Symptoms of he art failure or the anginal syndrome 
may be present even at rest.  I f any physical activity  is undertaken, discomfort is 
increased.
Integrated Clinical Study Protocol Amendme nt 8
BAY 43 -9006 / 12311
26MAY 2020 Version 7.0 Page: 147of 147
11.3 ECOG Performance Status
Grade Description
0 Fully active, able to ca rry on all pre -diseases performance without 
restriction.
1 Restricted in phy sically strenuous activity but ambulatory and able t o carry 
out work of a light or sedentary nature ( eg,light housework, office work). 
2 Ambulator y and capable of all self -care but unable to carry out any work 
activities . Up and about more than 50% of waking hours. 
3 Capable of only limited self -care, confined to bed or chair more than 50% 
of waking hours. 
4 Completely disabled. Cannot carry  on any self -care. Totally confine d to 
bed or chair. 
5 Death